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Aging and diet
In the past decades, multiple factors, in particular the drastically reduced mortality rate and the 
improvement of health care, have contributed to the aging population in developed countries and in 
many developing ones. The global share of older people (aged >60 years) has increased from 9.2% 
in 1990 to 11.7% in 2013 of the world population. In the future, the elderly population is expected 
to expand further, from 841 million in 2013 to more than 2 billion in 2050 (21.1% of the world 
population) [1]. The increasing life expectancy goes hand in hand with the emergence of age-related 
chronic diseases and disabilities [2]. 
In humans, twin studies estimate that genetic differences have a modest contribution of 25% 
to lifespan variation in the population at large, underscoring environmental factors as the important 
contributor, 75% of the variation [3-6]. Since environment is a modifiable factor, it is crucial to 
understand how it affects the aging process, in order to identify healthy aging strategies. Among the 
components of environmental factors that influence aging, none is more instrumental than nutrition. 
In animal models, the most robust intervention that extends lifespan is calorie restriction (CR), a diet 
that reduces the amount of food intake by 30-40%, which will be discussed in more details in the 
coming section. In the opposite situation, the current society’s diets, which are typically energy-dense 
and high in (saturated) fat, sugars and digestible starch and low in dietary fibres and other plant food 
bioactives [7, 8], are directly associated with a worldwide outbreak of diseases  [9, 10]. The prevalence 
of these diseases, for example metabolic syndrome and non-alcoholic fatty liver disease, in general 
increases with age [11, 12].
  
Aging liver
The liver plays a key role in regulating metabolic health, which covers the metabolism of 
nutrients, xenobiotic, hormones and metabolic waste products, thereby maintaining homeostasis. 
The liver is central to these metabolisms, as much of the regulatory mechanisms are initiated in 
the liver, which then modulate metabolism activities of other organs [13]. To ensure homeostasis 
maintenance, the liver is equipped with a highly integrated and complementary network [14]. 
During aging functional and structural age-related impairments are observed in the liver, for 
example decreased liver volume, blood flow, and capacity for liver regeneration [15, 16]. Such 
changes are associated with significant impairment of many hepatic metabolic and homeostatic 
activities with implications for systemic aging and age-related diseases. Aging liver is associated 
with a physiological increase of lipid accumulation [17]. Non-alcoholic fatty liver disease (NAFLD) 
is the most common chronic liver disease worldwide, which characteristic is the accumulation 
of fat >5% in the liver [18]. NAFLD represents a spectrum of abnormalities from benign hepatic 
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steatosis, non-alcoholic steatohepatitis (NASH) to liver cirrhosis and hepatocellular carcinoma. 
The different stages of NAFLD have been associated with aging, including hepatic steatosis [17, 
19], steatohepatitis [20] and fibrosis [21, 22]. The mechanisms underlying the development of this 
complex disease are not fully understood, however NAFLD has been associated with molecular 
changes which are commonly observed during aging, e.g. reactive oxygen species formation, DNA 
damage, hepatocyte senescence and related epigenetic mechanisms [23-26]. 
Alterations in fat metabolism may lead to liver fat accumulation, i.e. increasing free fatty 
acid intake and de novo lipogenesis, decreasing fatty acid oxidation and hepatic very low 
density lipoprotein-triglyceride secretion [27]. A number of studies have highlighted the role of 
peroxisome proliferator-activated receptors α (PPARα) in NAFLD development [28-30]. PPARα 
is one of the isoform of PPAR transcription factor with the greatest affinity with fatty acid and 
the most abundant isotype in hepatocytes [31]. Due to its affinity to fatty acid, PPARα has a 
regulatory role in the adaptation to fed and fasted state. Its activation results in downstream 
transcription of genes involved in lipid metabolism, including fatty acid degradation, synthesis, 
transport, storage, lipoprotein metabolism and ketogenesis [32-34]. Moreover, PPARα regulates 
the expression of the fibroblast growth factor 21 (Fgf21) during starvation [35, 36]. In turn, Fgf21 
acts as an endocrine hormone targeting various functions including metabolic control [37]. 
Studies characterising PPARα’s role in aging has been limited, however, PPARα expression in the 
liver has been reported to decrease with age [38]. 
Calorie restriction and aging
Calorie restriction (CR), defined as a reduced energy intake without malnutrition, has been 
shown in numerous animal studies as by far the most effective approach to extend lifespan and 
prevent age-related diseases [39-41]. A 10-50% reduction in calorie intake, compared to normal ad 
libitum consumption, induces a proportionate increase in maximum lifespan that is proportionate 
to the restriction degree [42, 43]. Research on CR in humans has not been conclusive, but provides 
clues that the same beneficial metabolic adaptations that occur in model species are also observed 
in humans [42, 44]. Studies on humans voluntarily practicing long-term CR without malnutrition 
(i.e. Calorie Restriction with Optimal Nutrition society) showed advantages on cardiovascular health 
and features resembled those individuals 20 years younger on the typical Western diet [45, 46]. 
A study on muscle transcriptome of the CR practitioners also supported the expression profile 
similarity to that of the younger subjects [44].
Despite the beneficial effects of a CR diet, this dietary regimen is rigorous and therefore difficult 
to be maintained for most humans. A previous study showed that after many years of habituation 
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to a Western-style diet, the adaptation to CR for long-term is challenging [47]. Moreover, several 
serious health disadvantages of CR have been observed in humans and animal models: impairment 
of infection and wound healing, increased risk of impaired reproductive function, osteoporotic bone 
fractures, anemia and cardiac arrhythmias [48-50]. 
Alternatives to CR dietary regimen
Researchers in the nutrition and health science field continually search for a practicable and 
effective alternative to CR. Periodic CR (or even fasting), which applies CR at regular intervals in 
between periods of ad libitum food consumption has recently gained interest. This intermittent form 
of CR may improve the feasibility for people to maintain the dietary pattern. One of the difficulties 
of applying CR is impaired satiety, while the intermittent regimen allows a period when appetite 
can be satisfied. A number of dietary regimens that have been explored include alternate-day 
fasting (ADF), intermittent fasting (IF), intermittent starvation, every-other-day feeding and fasting 
mimicking diet (FMD). Studies exploring these dietary regimens have demonstrated promising 
results. Different research groups have shown that in humans and animal models ADF induces 
similar health benefits as CR, including increased lifespan and decreased risk of diabetes and 
cardiovascular disease [51-53]. Another variant, IF, has revealed greater resistance to endotoxic 
stress and improved insulin sensitivity [54]. Recently, Brandhorst et al. reported that the FMD 
extends life span in mice, reducing the incidence of cancer, boosting the immune system, reducing 
inflammatory diseases, slowing bone mineral density loss and improving the cognitive abilities in 
older mice. They extended the study to human subjects and found that this diet regimen decreases 
risk factors  for aging, diabetes, cardiovascular disease and cancer [55]. It is important to realise 
that most of these dietary restriction variants employ a more severe food restriction (e.g. 75% 
restriction in IF regimen) and the safety of the diet application has not been thoroughly examined 
[56]. Adverse effects of fasting include headache, fainting, weakness, dehydration, and hunger 
pangs. Fasting also slows the basal metabolic rate, so that the ad libitum consumption period could 
be more fattening after undergoing fasting. This implies that, the intermittent application of CR, 
instead of fasting, may provide less health risk, while still carries beneficial health outcomes. 
Phenotypic plasticity in aging
Phenotypic plasticity is the ability to alter the phenotype to adaptively match to changes in the 
environment [57]. Physiological homeostasis, which means maintaining an equilibrium/balance in 
response to a varying environment by altering physiological parameters, also represents phenotypic 
plasticity [58]. In this context, aging can be viewed as a time-dependent loss of homeostatic 
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integrity  that maintain the structure and function of adult tissues [59]. The functional decline during 
aging implies a loss of the normal function or plasticity due to internal or external environmental 
signals. In the liver, for instance, the regenerative capacity to recover from insults has been shown 
to decreases at old age [60]. 
From an evolutionary perspective, our ancient ancestors’ food supplies volatility most likely 
resulted in bouts of starvation periods. In the late Paleolithic era, during the time when humans 
existed as hunter-gatherers, cycle of feast and famine was not avoidable. This dietary pattern 
consists of oscillations in energy availability and therefore might have driven the selection of genes 
involved in the regulation of metabolism [61]. In the “thrifty genes” hypothesis, it is proposed that 
the energy availability oscillations result in natural selection of genes which favour efficient fat 
storage and use of energy. During the Paleolithic era the thrifty metabolism was likely beneficial for 
survival, but in the current times of permanent availability of foods this becomes a mismatch. From 
a metabolic perspective, chronic excessive energy loads may lead to a state of metabolic confusion, 
in which nutrient signalling pathways are constantly activated/inhibited. As a result, the gateways 
that control substrate traffic are never fully open or shut, and the continuous influx of carbon fuel 
from multiple sources and directions interferes with efficient substrate switching [62]. 
STUDY AIMS AND DESIGN
The Integrated Research on Developmental Determinants of Aging and Longevity (IDEAL) 
project aims to elucidate the role of early life conditions affecting late-life health, disease and aging. 
As a part of the IDEAL consortium, in 2011 we started a mice aging study in Wageningen University, 
aiming to investigate diet-induced phenotypic plasticity during aging. Specifically, the aim of the 
research presented in this thesis is to study the effects of various dietary interventions, including the 
novel intermittent calorie restriction (INT) diet, on shaping metabolic health and the transcriptomic 
profile of the liver during aging. We explored the effects of life-long exposure to INT diet, which 
is a weekly alternating dietary regimen between 40E% CR and ad libitum medium-fat (MF) diets. 
This diet intervention challenges the body to adapt to fluctuations of energy availability and time-
restricted feeding. We hypothesized that these continuous challenges to adapt to variations in the 
diet will offer the INT-exposed mice beneficial health effects. Three other diet groups were included 
in the study (Figure 1), which received either: 1) ad libitum control diet, 2) CR receiving 70E% of the 
food consumed by the control group, or 3) ad libitum MF diet. The dietary intervention started at the 
age of 9 weeks and ended by the last sacrifice time point at 28 months.  
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Figure 1. Study scheme of the mice aging cohort. At the age of 2 months, the mice were randomly assigned to either 
control (C), calorie restriction (CR), medium-fat (MF), or intermittent (INT) diet. The mice were culled at 4 different age 
time point: 6, 12, 24 and 28 months, which represent mature adult, middle age, old, and very old time point. The cohort 
also covered two diet switches: 1) MF to INT (MF-INT) diet switch at the age of 12 months and 2) CR to MF (CR-MF) diet 
switch at the age of 24 months. The boxes indicate the chapters that discuss the pointed diet and age groups.  
Previous mice studies on NAFLD development typically apply a high percentage of fat (45-
60E%) to resemble the Western-style diet [63]. However, NAFLD is acutely induced at young age 
and this does not represent the development in human populations, which accumulate the adverse 
effect of a Western-style diet over many years. In this study we applied a long-term exposure to a 
less extreme diet by using a fat content of 25E% medium fat, which we expect to simulate a slow 
onset of NAFLD as it was observed in the Western human population. We chose the C57BL/6J 
mouse as the animal model, since metabolic features that are altered during the course of disease 
progression mirror the human situation [64]. 
Within the cohort, we incorporated two different diet switch experiments, which aimed to study 
the phenotypic plasticity of the mice at the middle and old age: 1) a switch at 12 months from 
Diet switch 2
CR-MF
C
CR
MF
2          
INT
Age (months) 6 12          24          28          
Diet switch 1
MF-INT
Chapter 2
Chapter 3
Chapter 4
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continuous MF diet to INT diet, in order to explore INT diet as an obesity counteracting intervention, 
which was examined at the age of 24 months and 2) a switch at 24 months from continuous CR 
to ad libitum MF diet, to study the phenotypic plasticity of the life-long CR-exposed animals when 
challenged by changing environment to MF diet. 
OUTLINE OF THE THESIS
In chapter 2, we investigated whether the INT diet is able to reverse the detrimental effects 
of a MF diet on the liver and its implication on NAFLD development. We showed that the INT diet 
maintained metabolic health and reversed the adverse effects of the MF diet, thus effectively 
prevented the development of NAFLD in middle-aged mice. The long term application of the INT 
diet regimen is further investigated in chapter 3, in which the mice were examined at an old age 
of 24 months. In this chapter, we also studied the response of the animals to a diet switch from 
continuous MF-exposure to an INT diet. Hereby we wanted to explore whether the INT regimen 
can reverse the long-term effects of MF diet in middle-aged mice. The adaptation to a diet switch 
at an old age is further investigated in chapter 4. A subset of mice that had been exposed to long-
term CR for 22 months was switched to a MF diet and the responses at physiological, metabolic 
and gene expression levels were examined 4 months after the diet switch. In chapter 5, the data 
from the different dietary interventions and age time points were gathered to explore the molecular 
processes underlying the association of NAFLD and the plasma level of Fgf21, an emerging non-
invasive biomarker for NAFLD. Finally, the general discussion and conclusions are presented in 
chapter 6. 
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ABSTRACT
 
Scope: We aimed to investigate whether a novel dietary intervention consisting of an 
every-other-week calorie restricted diet could prevent non-alcoholic fatty liver disease (NAFLD) 
development induced by a medium-fat diet.
Methods and results: Nine week-old male C57BL/6J mice received either a 1) control (C), 
2) 30E% calorie restricted (CR), 3) medium-fat (MF; 25E% fat) or 4) intermittent (INT) diet, a diet 
alternating weekly between 40E% CR and an ad libitum MF diet until sacrifice at the age of 12 
months. The metabolic, morphological, and molecular features of NAFLD were examined. The INT 
diet resulted in healthy metabolic and morphological features as displayed by the continuous CR 
diet: glucose tolerant, low hepatic triglyceride content, low plasma alanine aminotransferase. In 
contrast, the C- and MF-exposed mice with high body weight developed signs of NAFLD. However, 
the gene expression profiles of INT-exposed mice differed to those of CR-exposed mice and showed 
to be more similar with those of C- and MF-exposed mice with a comparable body weight.
Conclusions: Our study reveals that the INT diet maintains metabolic health and reverses the 
adverse effects of the MF diet, thus effectively prevent the development of NAFLD in 12-month-old 
male C57BL/6J mice.
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INTRODUCTION
The modern Western-style diet and sedentary lifestyle often promote a positive energy balance, 
which has importantly contributed to the global rapid increase in the prevalence of metabolic syndrome 
in the recent decades [1-4]. Non-alcoholic fatty liver disease (NAFLD), a condition in which the liver 
excessively accumulates fat, has been considered as a hepatic manifestation of metabolic syndrome. 
Therefore, the increasing prevalence of metabolic syndrome and NAFLD becomes a major concern [5, 6] 
and implies an urgent need for a feasible and effective dietary intervention to prevent NAFLD [7].
Calorie restriction is widely known for its beneficial effects on health that is consistently 
demonstrated in various species [8-10], and these beneficial effect also include a decrease in hepatic 
triglycerides level [11, 12]. However, an issue that has been frequently raised is the adherence of 
the general population to such a strict eating pattern [13, 14], as many individuals might encounter 
difficulties on long-term adaptation to CR after many years of habituation to a Western-style diet, 
as was shown by Racette et al. [15]. Therefore, a dietary regimen with alternating applications of 
food restriction or even food abstinence and ad libitum consumption emerges as an attractive 
option. Various forms of alternating dietary intervention have been explored, such as alternate-
day fasting, intermittent fasting, intermittent starvation and every-other-day feeding. The results 
are promising, the health benefits of the different alternative regimens are similar to continuous 
exposure to calorie restriction, including improved glucose tolerance and decreased cardiovascular 
disease risk [14, 16-19]. Consequently, the application of an alternating dietary regimen as a 
preventive measurement against the development of NAFLD becomes of interest.  
In this study, we aimed to investigate whether an every-other-week restricted diet, which we 
termed as the intermittent (INT) diet, is able to reverse the detrimental effects of a Western-style 
diet on the liver and its implication on NAFLD development in the male C57BL/6J mice. In the INT 
diet we applied a medium-fat (MF; 25E% fat) ad libitum diet to represent the Western-style diet and 
a 40E% calorie restriction (CR) diet as the restricted diet, and the animal feeding was alternated in 
a weekly basis between the MF and 40E% CR. To demonstrate a progressive NAFLD development 
in the Western-style diet, we included a diet group of continuous MF diet ad libitum. In addition, 
we also included two other diet groups, an ad libitum feeding of a control diet (C) and a continuous 
30E% CR to complement the comparison to a normal and healthy diet respectively.
We demonstrated that the INT diet resulted in proper glucose tolerance, low hepatic triglyceride 
content, low plasma alanine aminotransferase, similarly to the continuous CR diet. On the other 
hand, the C- and MF-exposed mice with high body weight developed signs of NAFLD. However, 
the INT diet group did not share much similarities on the gene expression level with the CR diet 
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group. The gene expression of INT-exposed mice showed to be more comparable with those of 
C- and MF-exposed mice with a comparable body weight. Thus, the INT diet effectively prevents 
the development of NAFLD in C57BL/6J mice, it maintains healthy physiological features without 
altering the gene expression profile. 
MATERIALS AND METHODS
Ethics statement
Experiments were approved by the Local Committee for Care and Use of Laboratory Animals 
at Wageningen University (code number: drs-2010151b).
Animals and diets
Male C57BL/6J mice (age of 7 weeks) were purchased from Janvier (Cedex, France) and were 
housed in pairs of two in the light and temperature (20oC)-controlled animal facility of Wageningen 
University (12-hour light/dark cycle, light on at 04.00). The mice received standard AIN-93G diet [20] 
(Research Diet Services, Wijk bij Duurstede, The Netherlands) for 2 weeks upon arrival. 
At the start of the diet intervention the mice were 9 weeks old, housed individually and 
randomly distributed into four intervention groups: 1) Control diet (C) receiving AIN-93W diet ad 
libitum (n=89); 2) calorie restricted diet (CR) receiving AIN-93W-CR in portions containing 70E% 
of the mean energy intake (30E% reduced energy intake) of the group of the control mice were 
provided each day at 15.30 (n=117); 3) medium fat diet (MF; 25E% fat) receiving AIN-93W-MF ad 
libitum (n=127); and (4) intermittent diet (INT) receiving alternating one week AIN-93W-MF ad 
libitum followed by one week 60E% based on the mean energy intake (40E% reduced energy intake) 
of the mice on the AIN-93W diet (n=155). AIN-93W is a variant of AIN-93M (maintenance of adult 
mice), which slightly differs on the fat source. The 10E% fat content in AIN-93M solely comes from 
soybean oil, while the fat source of AIN-93W is a mix of 6E% fat soybean oil and 4E% palm oil, 
in order to balance saturated and unsaturated fat composition. AIN-93W-CR contained increased 
concentration of vitamins and minerals content in order to feed these mice the same concentrations 
of micronutrients as the mice receiving AIN-93W diet and avoid malnutrition. Complete diet 
composition is listed in Supplementary Table 1 (Research Diet Services, Wijk bij Duurstede, The 
Netherlands). All mice were provided with ad libitum access to water. 
Body weight of all mice was recorded every two weeks. To represent a weekly body weight 
development, we weighed a smaller sample of mice of each intervention group every other week 
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(20-24 mice). Food intake of 20 mice of each intervention group was measured every three months, 
comprising one week measurement for the C, CR and MF-fed mice and two weeks measurement 
for the INT fed mice. Portion sizes of the mice on the CR and INT were adjusted at the beginning of 
the study and at the age of 6 months based on food intake of C mice. 
At the age of 12 months, 14 mice of each intervention group were sacrificed between 14.00-
17.00 on 5 consecutive days (the remaining mice stayed in the experiment to allow an investigation 
at older ages). To analyse an adaptive capacity of peroxisome proliferator-activated receptor alpha 
(PPARα), 7 mice in each intervention group were treated with a PPARα agonist, while the rest of 
the animals were mock-treated. Prior to sacrifice each mouse was first fasted for 4 hours after 
which they received an intragastric gavage of either solvent (0.5% carboxymethyl cellulose) or 
PPARα agonist Wy-14,643 dispersed in solvent (160 mg Wy-14,643/kg body weight), then fasted 
again for another 6 hours. All 14 mice of each diet group were included in metabolic parameter 
measurements to allow more optimal statistical analyses, but only 7 mock-treated animals were 
included in molecular analysis, since the treatment with the PPARα agonist would affect the gene 
expression levels. The PPARα adaptive capacity analysis will be covered in a separate publication. 
INT mice were sacrificed in their ad libitum MF feeding week. 
After sedation with a mixture of isoflurane (1.5%), nitrous oxide (70%) and oxygen (30%), blood 
samples were collected by cardiac puncture, then followed by neck dislocation. The epidydimal 
white adipose tissue (WAT) and liver were weighed and were subsequently snap-frozen and stored 
at -80oC until further molecular/biochemical analysis. For histological analysis, the livers were fixed 
in 4% paraformaldehyde.
Oral glucose tolerance test
The mice sacrificed at the age of 12 month were all subjected to an oral glucose tolerance test 
(OGTT) two weeks prior to sacrifice. In the OGTT, the mice were fasted for 6 hours, then received 1.5 
mg glucose per gram body weight via an oral gavage. Subsequently, blood glucose was measured 
15, 30, 45, 60, 90 and 150 minutes following the glucose load using Accu-Check blood glucose 
meters (Roche Diagnostics, Almere, The Netherlands).
RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen, Breda, The Netherlands) according 
to the manufacturer’s instructions. The RNA was treated with DNAse and purified on columns 
using the RNeasy microkit (Qiagen, Venlo, The Netherlands). RNA concentration was measured 
on a NanoDrop ND-1000 UV–vis spectrophotometer (Isogen, Maarsen, The Netherlands) and 
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RNA integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies, Amsterdam, The 
Netherlands) with 6000 Nano Chips according to the manufacturer’s instructions. RNA was judged as 
suitable only if samples showed intact bands of 18S and 28S ribosomal RNA subunits, displayed no 
chromosomal peaks or RNA degradation products, and had a RNA integrity number (RIN) above 8.0.
Microarray hybridization and analysis
To reveal the liver transcriptomic profile of the four different diets, whole-genome gene 
expression was analysed by microarray analysis. This analysis included 7 mock-treated animals 
from each C, MF and INT diet groups, and 6 animals from the CR diet group. One hundred nanogram 
of RNA was used for Whole Transcript cDNA synthesis (Affymetrix, Santa Clara, CA, USA). 
Hybridization, washing and scanning of Affymetrix GeneChip Mouse Gene 1.1 ST arrays were carried 
out according to standard Affymetrix protocols. Arrays were normalized using the Robust Multi-
array Average method [21, 22]. Probe sets were defined according to Dai et al. [23]. In this method 
probes are assigned to unique gene identifiers, in this case Entrez IDs. The probes on the Gene 1.1 
ST arrays represent 21,225 Entrez IDs. For the analysis, only genes having intensity value of >20 
on at least 5 array were taken into account, which resulted in 14,758 genes. Array data have been 
submitted to the Gene Expression Omnibus, with accession number GSE61233. The hierarchical 
clustering plot depicting gene expression profile similarity was constructed by using Multiple 
Experiment Viewer [24] and the accompanying body weight heatmap was prepared in Excel. 
cDNA synthesis and real-time quantitative PCR
Real-time quantitative PCR (Q-PCR) was used to quantify gene expression changes for 
a selection of genes on all individual samples, as described previously [25]. For each individual 
sample, single-stranded complementary DNA (cDNA) was synthesized from 1 μg of total RNA using 
the First Strand cDNA Synthesis Kit (Thermo Scientific, Landsmeer, The Netherlands) following the 
supplier’s protocol. Primer sequences were retrieved from the online PrimerBank database [26], 
or otherwise designed using the Primer3 program [27] and the sequences of the primers used are 
listed in Supplementary Table 2. Primers were tested for specificity by BLAST analysis. Q-PCR 
was performed using SensiMix SYBR No-ROX kit (Bioline, Alphen aan den Rijn, The Netherlands) 
and CFX384 thermal cycler (Bio-Rad, Veenendaal, The Netherlands). The following thermal cycling 
conditions were used: 2 min at 94°C, followed by 40 cycles of 94°C for 15 s and 60°C for 45 s. Q-PCR 
reactions were performed in duplicate and all samples were normalized to 18S expression.
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Histology
5 mm paraffin-embedded sections were cut and mounted on Superfrost microscope slides. The 
sections were de-waxed in xylene and rehydrated in a series of graded alcohols. After staining with 
Meyer’s hematoxylin-eosine (H-E) or fast green FCF/Sirius red F3B staining sections were mounted 
with DePex mounting medium (Gurr, BDH, Poole, Dorset, UK). 
Hepatic triglyceride content determination
Liver homogenates of 5%w/v were prepared in buffer containing 250 mM sucrose, 1 mM EDTA, 
10 mM Tris-HCl (pH 7.5). Liver triglyceride content was determined using the Triglyceride Liquicolor 
Monoreagent from Instruchemie (Delfzijl, The Netherlands) according to the manufacturer’s 
instruction.   
Plasma measurement
Plasma concentration of ALT and AST were measured with commercially available kits from 
Instruchemie (Delfzijl, the Netherlands) following the protocol optimized by Stienstra et al. [28]. 
Plasma insulin level was measured using kit from ALPCO Diagnostics (Salem, NH, USA) according 
to the manufacturer’s instruction. 
Statistical analysis 
Data analysis was performed with GraphPad Prism version 5.04 (GraphPad Software, San 
Diego, USA), using one-way ANOVA followed by Tukey post-test analysis or Kruskal-Wallis 
test followed by a Dunn’s post-test for not normally-distributed data. Correlation analysis was 
performed using Pearson correlation. P <0.05 was considered significant. 
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RESULTS 
Modest body, liver and WAT weight gain in mice exposed to an 
intermittent diet
To determine the physiological features of mice after exposure to an INT diet regimen, various 
parameters were measured. Adaptation to the high/low energy intake was observed in the weekly 
body weight measurements of the INT-fed mice, showing fluctuations in mean body weight related 
to the diet received in the preceding week (Fig. 1A). After the ad libitum feeding week body weight 
of the INT mice was lower than that of C and MF groups, while after the calorie restricted week their 
body weight remained higher than that of the mice in the CR group. Strong heterogeneity in body 
weight of mice in the C and MF diet groups was observed, which was reflected by the large error 
bars, in contrast to the mice within the CR and INT groups where the variation was very low. 
Body weight gain in C- and MF-fed mice included a significant increase in adiposity measured 
by the amount of white adipose tissue present in WAT, compared to the CR- and INT-fed mice 
(P <0.001, Fig. 1B). Similarly, the WAT-to-body weight ratio also showed a significant increase 
in C and MF (P <0.001). Liver weights of the INT-fed mice were nearly as low as that of the CR 
mice and differed significantly from the liver weights of the C and MF groups (P <0.05 and <0.001, 
respectively, Fig. 1C). Interestingly, while the liver-to-body weight ratio of the C, CR and MF groups 
were comparable, a slight but significant decrease was found for the INT-fed mice compared to CR 
and MF exposed mice (P <0.05). Overall, a strong correlation between liver and body weight was 
observed (r = 0.83) and also between liver and WAT weight (r = 0.82). 
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Figure 1. Beneficial effects of an INT diet regimen on body, WAT and liver weight, food intake and glucose 
tolerance. (A) Weekly measurement of body weight. (B) WAT weight and the ratio to the body weight. (C) Liver weight, 
ratio to body weight, and liver weight correlation with body and WAT weight. (D) Energy intake measurement at 12 
months old of age, daily (left) and weekly (right). (E) Glucose clearance measured by an oral glucose tolerance test. (F) 
Fasting plasma insulin levels. Error bars reflect standard deviation (SD). *) P <0.05; **) P <0.01; ***) P <0.001 vs the INT 
group.
Eating behaviour and total energy intake in mice exposed to the 
intermittent diet
As anticipated, the switch between high/low food availability strongly affected the eating 
behaviour of INT-exposed mice. The daily energy intake measurement revealed hyperphagia during 
the first few days of the ad libitum feeding week (Fig. 1D), compensating the 40% energy reduction 
in the restricted feeding week, followed by a gradual decrease in food intake. As a result, the actual 
total energy intake of INT-fed mice was 87.9% of the mean intake of the C-fed mice (Supplementary 
Table 3A). Furthermore, since the INT-fed mice received the MF diet during the week they were fed 
ad libitum, overall these mice consumed more fat, 20.5% of the total energy intake, compared to 9% 
in the C group (Supplementary Table 3B).
A B
C
***
***
***
ED F
***
***
*
*** * * r = 0.83P-value < 0.0001
**
***
Body w eight (g)
Li
ve
r w
ei
gh
t (
g)
20 30 40 50
0.5
1.0
1.5
2.0
2.5
C
CR
MF
ID
r = 0.82
P-value < 0.0001
***
***
***
***
Age (w eeks)
Bo
dy
 w
ei
gh
t (
g)
10 20 30 40 50
10
20
30
40
50 C
CR
MF
INT
 W
A
T 
w
ei
gh
t  
(g
)
C CR MF INT
0.0
0.5
1.0
1.5
2.0
Re
la
tiv
e 
W
A
T 
w
ei
gh
t  
(%
)
C CR MF INT
0
1
2
3
4
5
Li
ve
r w
ei
gh
t (
g)
C CR MF INT
0.0
0.5
1.0
1.5
2.0
2.5
Re
la
tiv
e 
liv
er
 w
ei
gh
t  
(%
)
C CR MF INT
0
1
2
3
4
5
6
WAT w eight (g)
Li
ve
r w
ei
gh
t (
g)
0.0 0.5 1.0 1.5 2.0
0.5
1.0
1.5
2.0
2.5
C
CR
MF
INT
kc
al
/d
ay
/m
ou
se
Da
y 1
Da
y 2
Da
y 3
Da
y 4
Da
y 5
-7
0
2
4
6
8
10
C
CR
MF
INT-CR w eek
INT-MF w eek Time  (min)
Bl
oo
d 
gl
uc
os
e 
le
ve
l (
m
m
ol
/L
)
0 50 100 150
5
10
15
20
25
30 C
CR
MF
INT
Pl
as
m
a 
in
su
lin
 le
ve
l (
ng
/m
l)
C CR MF INT
0
1
2
3
kc
al
/ w
ee
k/
 m
ou
se
C CR MF INT
0
20
40
60
80
100
120
Carbohydrate
Protein
Fat
Intermittent  d iet  protects  the  l i ver  f rom NAFLD development  in  middle-aged mice
22
2
Tolerance to glucose was maintained in mice exposed to intermittent diet
To establish the effects of the different diets on glucose metabolism, an oral glucose tolerance 
test (OGTT) was carried out in the mice 2 weeks prior to sacrifice. The maximal glucose level of 
INT-exposed mice was lower and returned more rapidly to the basal fasting level than that of the C 
and MF groups (P <0.01, Fig.1E), though not to the extent as observed in the CR group. Similarly, 
the area under the curve (AUC) of INT diet group was significantly lower than C and MF groups 
(P <0.001, Supplementary Fig. 1), but not as low as the AUC of CR diet group. Furthermore, 
averaged fasting plasma insulin level was lower in INT-fed mice compared to mice that received the 
C and MF diets (Fig. 1F), although this effect did not reach statistical significance (P >0.05) due to 
the large inter-individual variation between the mice in the different intervention groups.
Intermittent diet protected the liver from developing the biochemical 
and histological marks of NAFLD 
Next, we evaluated the effects of the dietary interventions on various biochemical and 
morphological features related to the development of NAFLD. Fatty liver development was 
examined by quantification of the hepatic triglyceride (TG) content. A very low TG content in mice 
exposed to the CR and INT diets was observed (Fig. 2A). Mice fed the C or MF diet showed hepatic 
TG deposition with a large inter-individual difference, of which most of the animals exceed the 
diagnosis level of NAFLD, >5-10% (or 50-100 mg TG/ g liver) [29]. The level of TG content strongly 
correlated with body weight (r = 0.83, Fig. 2B) and liver weight (r = 0.91, Supplementary Fig. 2A). 
To determine whether hepatic function was affected due to exposure to the different diets, serum 
levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), two well-established 
markers of liver injury/damage, were measured. Interestingly, the lowest ALT and AST levels were 
detected in the INT group (P <0.05, Fig. 2C and 2D). In C- and MF-fed mice we found that the elevated 
level of the ALT was correlated with increasing hepatic TG levels (Supplementary Fig. 2B). 
Histological analysis was carried out to examine whether the different diets induced 
morphological changes in the liver. Haematoxylin-eosin (H-E) staining of liver sections of C- and 
MF-fed mice with high body weights (the highest tertile of bodyweight), of which elevated hepatic TG 
levels were measured, revealed fat accumulation with development of macro- and microvesicular 
lipid droplets (Fig. 2E). On the other hand, animals with the low body weights (the lowest tertile of 
body weight) of the C and MF groups displayed normal liver morphology, similar to animals of the 
CR and INT intervention groups with both low and high body weight. To assess the progression of 
hepatic fibrosis, we performed a collagen Sirius-red staining (Fig. 2F). The results obtained showed 
that the high body weight-animals of the C and MF groups developed collagen scarring, indicating the 
presence of hepatic fibrosis in these mice, while this effect was not observed in CR and INT-fed mice. 
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Figure 2. Hepatic TG, plasma ALT and AST and liver histology indicated NAFLD development in C- and MF-
fed mice, but not in mice exposed to CR and INT. (A) Hepatic TG content. (B) Correlation between hepatic TG and 
body weight. (C) Plasma ALT. (D) Plasma AST. Error bars reflect SD. *) P <0.05; **) P <0.01; ***) P <0.001 vs. INT group. 
(E) H-E staining and (F) FCF Green and Sirius Red staining of liver section of animals with the high and low body weight 
(original magnification 200x). 
Gene expression profiles reflected the body weight similarity 
amongst the C, MF and INT groups, but not for the CR group
To obtain an overview of the molecular profiles induced by the different dietary interventions, 
a microarray analysis was carried out on the livers of the mice of all four intervention groups. An 
unsupervised clustering analysis was performed and a dendrogram plot of the gene expression 
profile similarity is depicted in Figure 3A. The clustering analysis was performed on all genes, 
but due to space limitation the plot is represented by the top 250 most variable genes based 
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on interquartile range. The dendrogram is complemented by a heatmap of the body weight, 
representing each animal. Three major clusters were observed: 1) a cluster of all animals in the CR 
diet group, 2) a cluster consists of the C and MF animals that mostly containing a high body weight, 
and 3) a cluster consists of animals with moderate body weight from the C, MF and mostly INT 
diet group. The clustering and sub-clustering patterns of the second and third clusters suggested 
that the gene expression profile of the C, MF and INT diet groups is strongly correlated with body 
weight similarity. Interestingly, the gene expression profile of the CR-exposed mice was distinct 
from those of the mice exposed to the INT diet, despite the fact that the physiological, biochemical 
and morphological features of the mice in the CR and INT diet groups, e.g. hepatic TG content, were 
similar. 
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Figure 3. INT-fed mice displayed a similar gene expression profile to C- and MF-exposed mice with 
similar body weights. (A) A hierarchical clustering plot depicting the liver gene expression profiles similarity of the 
different diet regimens. The color band under the plot represents the body weight of individual mice in a white-to-red 
color scale (white = low values, red = high values). Q-PCR analysis on all animals of all dietary intervention groups 
shows differential expression of genes involved in (B) lipid droplet formation, (C) inflammatory and fibrosis, and (D) 
macrophage/monocyte recruitment. No statistical difference was found for gene expressions in INT-fed mice compared 
to the other intervention groups. Error bars represent SD.
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Expression of genes associated with lipid droplet formation were 
increased with increasing body weight
To examine NAFLD development in INT-fed animals at a molecular level in more detail, 
we analysed the expression of genes involved in lipid droplet formation, which are known to be 
highly correlated with the severity of NAFLD [30-32]. Q-PCR analysis was performed on all mice 
of all four intervention groups for cell death-inducing DFFA-like effector A (Cidea) and C (Cidec), 
monoacylglycerol O-acyltransferase 1 (Mogat1) and fibroblast growth factor 21 (Fgf21) (Fig. 3B). 
The expression level of microarray and Q-PCR analysis showed to correspond to each other. 
Mean expressions levels of the INT-fed mice for all four genes were lower than that of the C 
and MF groups. However, the observed differences did not reach statistical significance, most likely 
due to the large inter-individual difference in expression levels observed in the C- and MF-fed mice, 
which was similar to the observed physiological features. Comparison of gene expression and 
body weight revealed significant positive correlations (r = 0.63-0.74) for all four genes (Fig. 3B and 
Supplementary Fig. 3A). These results suggest that increased body weight might promote lipid 
droplet formation leading to NAFLD, while the INT regimen maintained a moderate body weight 
and low expression of genes involved in lipid droplet formation. 
High body weight is essential but not sufficient for NASH pathogenesis 
The effects of different diets on hepatic inflammation and fibrosis were assessed by Q-PCR 
analysis of four genes: serum amyloid A 2 (Saa2), lipocalin 2 (Lcn2), metallothionein (Mt2) and 
tissue inhibitor of metalloproteinase 1 (Timp1). The results presented in Fig. 3C revealed low 
expression levels of all four genes in all diet groups, except for a few animals in the C and MF 
groups which consistently showed elevated expression levels.  Plotting of the gene expression 
levels versus body weight revealed that elevated expression levels of the inflammatory/fibrosis-
related genes were exhibited by the C- and MF-exposed animals with the highest body weight (Fig. 
3C and Supplementary Fig. 3B), in which the positive correlations were considered significant (P 
<0.001-0.0102). However, not all animals with high body weight showed elevated gene expression 
of the markers for inflammation and fibrosis, which was indicated by a weaker body weight-gene 
expression correlation compared with the lipid droplet formation genes (r = 0.48-0.59). 
In addition, expression levels of previously established macrophage/monocyte marker 
genes linked to NASH pathogenesis [28], including monocyte chemoattractant protein 1 (Mcp1), 
macrophage inflammatory protein 1α (Mip1α), cell surface glycoprotein F4/80 (F4/80+) and CD68 
antigen (Cd68), were analysed. Expression levels of these macrophage/monocyte markers were 
generally low in all diet groups and an elevated level was only observed for a few animals in the 
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MF group (Fig. 3D and Supplementary Fig. 3C). It should be noted that elevated expression of 
inflammation and fibrosis genes was consistently found in the same animals having the highest body 
weight, explaining the weak correlations between the expression levels of monocyte/macrophage 
markers gene and body weight (r = 0.39-0.49). 
Taken together, these results indicate that hepatic inflammation and macrophage/
monocyte infiltration occur in only a few animals with high body weight mainly in the MF group. 
However, since not all mice having a high body weight showed these elevated gene expression 
levels of these markers, body weight is not necessarily an indicator of hepatic inflammation 
or infiltration. 
DISCUSSION
In this study, we showed that a weekly alternating diet consisting of 40E% CR and ad libitum 
feeding of a MF (25E%) diet prevented development of NAFLD/NASH, which was induced by life-
long exposure to a MF diet and even the low-fat control diet. INT-fed mice maintained glucose 
tolerant, showed normal insulin levels and low plasma ALT and AST levels. Furthermore, they 
did not exhibit signs of hepatic steatosis and fibrosis, indicated by the hepatic triglyceride levels 
and morphology observations. Interestingly, all metabolic parameters measured were improved 
in INT-fed mice and were found to be highly similar to the results obtained from mice that have 
been continuously exposed to a CR diet. Likewise, the INT and CR intervention groups exhibited no 
sign of hepatic lipid accumulation, inflammation or macrophage/monocyte infiltration at the gene 
expression level.
Studies examining the effects of an increased dietary fat content on NAFLD development 
typically apply a high percentage of fat (40-60E%) to resemble the Western-style diet [33]. Hepatic 
steatosis is then acutely induced and developed at young age (3-4 months) [33]. However, the 
prevalence of NAFLD has been shown to increase with advancing age and this indicates that the 
adverse effect of Western diet accumulates over many years [34-37]. Therefore, in this study we 
applied a long-term exposure to a less extreme diet by using a fat content of 25E%, which we 
expect to simulate a slow onset of NAFLD developed at middle-age time point by the consumption 
of MF diet. We demonstrated that the long-term exposure of male C57BL/6J mice to a MF diet until 
the age of 12 months resulted in pronounced weight gain, impaired glucose clearance, elevated 
insulin levels and an increase in plasma ALT levels. Hepatic steatosis and fibrosis were observed 
in some but not all mice which had the highest body weight. Together our results reveal that 1) 
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long-term exposure to a MF diet seriously impairs metabolic homeostasis and is a risk factor for 
NAFLD development, and 2) applying every-other-week 40E% CR largely reversed the adverse 
health effects induced by the MF diet in 12-month-old mice.
Health-promoting effects of a CR diet have been commonly recognized, but compliance to 
such a diet is challenging for most individuals [15], and therefore an INT diet is explored as the 
alternative. Our results indicated that the adverse health effects of a MF diet could be reversed 
by applying every-other-week CR, however, it should be noticed that most metabolic parameters 
measured showed slightly better outcomes in the continuous CR-fed mice compared to the INT 
group. This result suggests that the INT regimen does not fully bestow all beneficial metabolic 
improvements of the CR diet. Only plasma ALT revealed significantly lower levels in INT-fed 
mice compared to mice that have received the CR diet. ALT is a transaminase enzyme and it 
has previously been shown that CR induces hepatic gluconeogenesis, accompanied by increased 
transamination activity as the first step in amino acid catabolism, resulting in elevated plasma 
ALT level [38]. In addition, it should be noted that, although the outcomes of the INT diet regimen 
are novel as it discovers a remarkable improvement on liver parameters compared to a MF diet, 
we cannot exclude that the health benefits observed are (partially) due to lower body weights, in 
addition to the alternating of the diets. 
We found that, despite the similarity in energy intake between C and MF diet group, the 
animals that received a higher fat content in their diet developed a higher body weight. This has 
been observed in more studies [25, 39] and possibly results from the lower energy requirement to 
store excess energy from fat than from carbohydrate, due to the additional conversion of glucose to 
fatty acids. However, our results demonstrate that body weight gain and not the type of the diet, is 
a stronger predictor of hepatic steatosis development, e.g. liver mass, hepatic TG accumulation and 
expression of genes associated with lipid droplet formation. Then, the development hepatic fibrosis 
and inflammation seemed to be triggered by additional factor(s) in addition to body weight, as not 
all animals with the highest body weight developed fibrosis or inflammation, supporting the role 
of the “second hit” required in the development of NASH as first proposed by Day and James [40].  
Substantial inter-individual variation in all analysed features was observed between mice of 
the C and MF groups. Heterogeneity in the response to diets is a previously reported characteristic 
of C57BL/6J mice [41, 42]. We previously also showed that, upon exposure to a low-fat or high-
fat diet, low or high responders could be distinguished in both intervention groups. The low and 
high responders revealed differences in food intake, body-weight gain, adiposity, a broad range of 
plasma markers, and liver features [30]. A number of possible mechanisms behind the observed 
variation in C57BL/6J mice have been proposed, such as copy number variations in the mouse 
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genome and epigenetic features, but the exact underlying cause is not known yet [42, 43]. 
The results obtained in this study showed that in all four intervention groups both WAT and 
liver weight correlate, as expected, with body weight. However, the ratio of WAT- and liver-to-body 
weight in INT-exposed mice revealed an intriguing weight distribution. While relative WAT weight 
was higher than that of CR-fed mice, relative liver weight was significantly lower, suggesting a 
potential beneficial health effect for the liver of the INT compared to the CR diet. When more energy 
is consumed than needed for daily energy expenditure, the excess is in first instance stored in WAT, 
which has the capacity to expand in order to store the surplus of lipids and to prevent ectopic fat 
deposition. However, there is a limit to the lipidstorage capacity of WAT and when this is exceeded, 
spill-over is suggested to occur resulting in fat storage in organs, such as heart, pancreas, skeletal 
muscle and liver [44]. When fat accumulation in the liver exceeds the threshold of 50-100 mg TG/ g 
liver, this results in liver steatosis (Fig. 4A). Thus, the fact that the relative WAT weight was much 
higher than the relative liver weight in INT-fed mice suggests that energy excess consumed during 
the ad libitum MF week is primarily stored in WAT, but the energy deficiency during the CR week 
is compensated by releasing fat from the liver, instead of fat utilisation from WAT (as illustrated in 
Fig. 4B). This hypothesis is supported by a previous finding showing a rapid liver fat clearance (up 
to 29.6% decrease of liver TG content) occurring after 48 hours of CR in humans [11]. Although the 
exact mechanism of the rapid liver fat extraction is unknown, this is an intriguing feature of the INT 
regimen that might contribute notably to NAFLD prevention by the INT diet. 
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Figure 4. Proposed models for how the fat storage is distributed in WAT and liver. (A) Excess fat is initially stored 
in WAT, which may expand until a certain threshold. If the lipid-storage capacity is reached, ectopic fat deposition starts 
to occur in various organs, such as liver. (B) During the ad libitum feeding week, the excess energy is mainly stored 
in WAT, but the compensation of deficit energy during the restricted feeding week might be mobilized predominantly 
from the liver fat storage. This proposed mechanism of an alternating diet may prevent hepatic steatosis development.
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Remarkably, our results revealed that, while the metabolic profile of INT-fed mice 
was comparable to that induced by the CR diet, the INT- and CR-fed mice showed different 
transcriptomic profiles. As the INT-fed mice were sacrificed during their ad libitum MF feeding 
week, gene expressions patterns observed were most likely regulated to adapt to the ad libitum 
feeding condition to maintain homeostasis. This suggests that the transcriptome is a more flexible 
phenotype, and more closely resembles the ad libitum-fed groups. Unfortunately, due to the limited 
number of animals in this study, we were not able to assess the liver transcriptomics of INT mice 
during their restricted feeding week. 
In conclusion, the results obtained in this study show that a weekly alternating INT diet varying 
between 40E% CR and ad libitum MF feeding prevents NAFLD development. Mice exposed to the 
INT diet retain healthy physiological features as displayed by continuous exposure to CR, while the 
gene expression profile was shown to be dissimilar with CR, but more similar to that of C- and MF-
fed mice with comparable body weight.
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SUPPLEMENTARY TABLES
Supplementary Table 1. Composition of the experimental diet. The CR diet was adjusted for 
the vitamins and minerals amount to ensure a homologous intake between both groups.
Supplementary Table 2. List of primer sequence used in Q-PCR analysis
 AIN-93W AIN-93W-CR AIN-93W-MF 
Energy (kcal/g) 3.85 3.77 4.25 
Energy from fat (%) 9 10 25 
Energy from protein (%) 15 15 13 
Energy from carbohydrates (%) 76 75 61 
Mineral mix AIN-93M (g%) 35 50 35 
Vitamin mix AIN-93M (g%) 10 14 10 
Choline bitartrate (g%) 2.5 3.5 2.5 
 
Gene name Forward primer (5’ → 3’) Reverse primer (5’ → 3’) 
Cidea TGACATTCATGGGATTGCAGAC GGCCAGTTGTGATGACTAAGAC 
Cidec ATGGACTACGCCATGAAGTCT CGGTGCTAACACGACAGGG 
Mogat1 TCCCGTTGTTCCGAGAATATCT TGCTCAGCACATGAGACAAAC 
Fgf21 GTGTCAAAGCCTCTAGGTTTCTT GGTACACATTGTAACCGTCCTC 
Saa2 GCGAGCCTACACTGACATGA TTTTCTCAGCAGCCCAGACT 
Lcn2 TGGAAGAACCAAGGAGCTGT GGTGGGGACAGAGAAGATGA 
Mt2 GCCTGCAAATGCAAACAATGC AGCTGCACTTGTCGGAAGC 
Timp1 GCAACTCGGACCTGGTCATAA CGGCCCGTGATGAGAAACT 
Mcp1 CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG 
Mip1α CCTCTGTCACCTGCTCAACA GTAGACTCACATGGCGCTGA 
F4/80+ CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
Cd68 CCAATTCAGGGTGGAAGAAA CTCGGGCTCTGATGTAGGTC 
18s CGGCTACCACATCCAAGGA CCAATTACAGGGCCTCGAAA 
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Supplementary Table 3A. Relative energy intake of different diets
Supplementary Table 3B. Nutrient intake of the different diets
 Control CR MF INT 
Energy intake 
(kcal/week) 
103.29.4 60.81.1 116.912.0 90.78.1 
Relative energy 
intake (%) 
100 58.9 113.3 87.9 
 
Nutrients Control CR MF INT 
Carbohydrate Kcal 78.67.7 45.60.8 67.49.0 59.34.9 
% 76.0 75.0 61.6 65.9 
Protein Kcal  15.51.5 9.10.2 14.41.9 12.31.0 
% 15.0 15.0 13.1 13.7 
Fat Kcal 9.30.9 6.10.1 27.63.7 18.42.0 
% 9.0 10.0 25.3 20.5 
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SUPPLEMENTARY FIGURES
Supplementary Figure 1. The area under the curve (AUC) of oral glucose tolerance test (OGTT) of INT diet group 
significantly lower than the C and MF diet groups, but not to the extent of CR diet group. 
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Supplementary Figure 2. (A) A correlation between liver TG content and liver weight. (B) A correlation between 
plasma ALT and AST level to the liver TG content
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Supplementary Figure 3. A correlation between body weight and expression of genes involved in (A) lipid droplet 
formation, (B) hepatic inflammation and fibrosis genes, (C) macrophage/monocyte infiltration genes.  
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Intermittent  ca lor ie  restr ict ion  largely  counteracts  the  adverse 
health  ef fects  of  a  medium-fat  d iet  in  ag ing  C57BL/6J mice
ABSTRACT
Calorie restriction (CR), without malnutrition, has been shown to extend life and health span 
in model species. For most humans, a life-long CR diet is too arduous to adhere to and poses 
adverse side effects. The aim of this study was to explore whether weekly intermittent CR can 
reverse the adverse short- and long-term effects of a medium-fat (MF) diet in aging mice. For this 
purpose we have exposed C57BL/6J mice to an intermittent (INT) diet, alternating weekly between 
CR and ad libitum feeding of a MF diet. This weekly intermittent CR significantly counteracted the 
adverse effects of the MF diet on mortality, body weight and a wide range of liver health markers 
in 24-month-old mice. Transcriptome analysis of the liver revealed that hepatic gene expression 
profiles of INT-exposed animals were much more comparable to CR than to MF-exposed mice. 
At 12 months of age, a subgroup of MF-exposed mice was transferred to the INT diet. Of the 2815 
genes displaying differential expression between the INT- and MF-exposed mice, 1510 genes 
changed to the INT-expression profile during the 12 months after the diet switch. However, a small 
subset of 148 genes were identified that were consistently changed by the MF diet during the first 
phase of life. Our results suggest that MF-induced deregulated PXR activity persistently affects lipid 
and xenobiotic metabolism in the liver of the old diet switch mice. In conclusion, weekly intermittent 
CR largely, but not completely, reversed the short- and long-term effects caused by a MF diet.
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ABSTRACT
The beneficial health effects of a calorie restricted (CR) diet, avoiding malnutrition, can 
be appreciated from two perspectives. First, in our obesogenic society where about half of the 
population is overweight or obese [1], maintaining a reduced energy intake is the best nutritional 
strategy to achieve and maintain weight loss [2, 3]. Since obesity causes a wide range of serious 
chronic diseases, the negative energy balance induced by a CR diet will result in weight loss and 
persuade, concomitantly, health promoting effects. Secondly, CR has been acknowledged as the 
most successful approach to increase longevity in a wide range of species [4]. Apart from life-span, 
reduced food intake also increases health-span. Here, the health-promoting effect is not achieved by 
counteracting obesity-related disorders but by ameliorating a wide range of aging-related diseases 
[5, 6]. It is worth mentioning, however, that these obesity- and age related disorders fundamentally 
overlap. 
In order to achieve longevity, the application of a CR diet requires life-long adherence to a 
very strict dietary regimen. Severe food restriction is very arduous and too difficult to practice and 
to sustain for most individuals. Importantly, long-term exposure to a CR diet might also cause 
substantial side effects like amenorrhoea, osteoporosis, decreased fertility and libido, impaired 
wound healing and increased susceptibility to infections [7-10]. Health-promoting effects have been 
reported by different variants of the CR diet, practising intermittent energy restriction [11-13]. By 
applying repetitive cycles of fasting/CR and eating, the negative side effects of CR are thought to be 
circumvented. Moreover, an intermittent CR regimen is more feasible to hold on to. Importantly, 
increasing evidence points out that the beneficial health effects of (intermittent) CR are not solely 
caused by reduced body weight [14, 15]. Timing and limitation of meal frequency affect the circadian 
rhythm and might induce a repetitive challenge that most likely will contribute to the health 
promoting effects [16-18]. 
One of most frequently affected organs in obese individuals is the liver, which is recognized 
to be the most important metabolic organ and supporting nearly every other organ in the body. 
Obesity induces a spectrum of abnormalities in the liver called non-alcoholic fatty liver disease 
(NAFLD), which is currently the most common chronic liver disease in developed countries. NAFLD 
is seen in 20-40% of the general adult population, but incidence in severe obese adult individuals 
is much higher (70-90%) [19]. The mildest form of NAFLD is simple hepatic steatosis (HS) and is 
characterized by intrahepatic accumulation of lipids alone. In around 47% of the affected individuals 
this benign hepatic lipid accumulations evolves into non-alcoholic steatohepatitis (NASH) 
characterized by inflammatory infiltration of the liver and low-level fibrosis [20]. Between 10 to 29% 
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of the individuals with NASH develop advanced fibrosis, cirrhosis and ultimately, hepatocellular 
carcinoma (HCC) [21, 22]. This progressive disease development is characterized by increasing 
severity and predisposition to mortality. It has been reported that both the prevalence of NAFLD 
as well as progression into more severe forms of NAFLD in the general population increase with 
age [23-25]. The early stages of NAFLD are considered to feature a benign, non-progressive and 
reversible disease [19]. Management of HS and NASH is mainly focused on treatment of obesity 
by introducing lifestyle modifications including increased exercise and decreased calorie intake. 
Although there is strong evidence that the early stages of NAFLD caused by an obesogenic diet 
are reversible, it is currently not clear whether all detrimental effects are completely restored after 
long-term exposure to such a diet. 
In this study we explored the effects of intermittent calorie restriction (INT) regimen on NAFLD 
development during aging by applying a relatively robust form of the INT diet in male C57BL/6J 
mice. By alternating weekly between a 40E% calorie restricted control diet and an ad libitum 
medium-fat (MF) diet, the mice were challenged to adapt to differences in 1) energy intake, 2) 
macronutrient composition of the diet and 3) constant food exposure versus an one-portion-a-day 
feeding pattern. The effects of this challenging diet on overall body health were explored. In addition, 
we examined the biochemical, morphological and molecular effects this diet caused in the liver of 
24-month-old mice. The obesity-counteracting effects of this diet were identified by introducing a 
diet switch in life-long MF exposed mice at the age of 12 months to the INT diet. In 24-month-old 
mice we examined into what extent the adverse health effects caused by the MF diet are reversible 
on whole-body as well as on liver health. Life-long exposure to a low-fat control diet (C), MF or a 
continuous CR diet (30% calorie reduction) were included as normal, unhealthy and healthy aging 
controls, respectively.
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RESULTS
Intermittent calorie restriction protected against the detrimental 
effects of a medium-fat diet
To explore the effects of weekly intermittent CR a panel of different physiological markers were 
measured. Body weight was recorded weekly during the study and showed, as expected, that the 
MF-exposed mice gained the highest body weight while the lowest body weight was observed for 
the CR-fed animals (Figure 1A). Bodyweight of the INT-fed mice displayed a constantly fluctuating 
pattern, dependent on the diet the mice received in the preceding week. DEXA scan analysis showed 
that, in line with the bodyweight, the percentages of fat (f) and lean (l) body mass of the INT-exposed 
mice (l: 68.3%, f: 31.7%) were in between those of the CR- (l: 78.9%, f: 20.1%) and C-fed mice (l: 64.4%, 
f: 35.6%) (Figure 1B). Food intake recordings presented in Figure 1C show that, during the entire 
study, of all intervention groups the INT-exposed mice have the highest energy intake during the ad 
libitum feeding week and the lowest during their CR-restricted week. Combining the intake values of 
the CR and ad libitum MF weeks at 24 month of age revealed that the mean energy intake of the INT-
fed mice was slightly lower than the amount of calories consumed by C-fed mice and substantially 
higher than that consumed by the CR-exposed mice (Figure 1D). Furthermore, it is important to note 
that this figure also reveals that, although the INT-exposed mice consume less kcal/week than the 
control mice, their fat intake is higher. Consequently, INT-exposed mice were challenged by fluctuating 
amount of calories, but also by a difference in macronutrient composition of the consumed diet. We 
have recently shown that 12-month-old mice exposed to the INT diet demonstrate hyperphagia during 
the first few days of the ad libitum feeding week [26]. This increased eating pattern at the first days 
after the diet switch still occurred at old age (Supplemental Figure S1A). 
Daily activity recorded at the age of 23 months revealed that the INT-exposed animals were 
significantly more active than the C- and MF-exposed mice and similarly active to the life-long CR-
exposed animals (Figure 1E). Although this increased activity pattern in the INT-exposed mice 
was found in both the CR and the ad libitum MF feeding week, the timing of the activity differed (see 
Supplemental Figure S1B). During the MF-week the burst of activity was observed at the moment 
that the light was switched off. During the CR-week the activity increased when the food was provided, 
30 minutes before the light was switched off similar to the pattern found for the life-long CR exposed 
mice. Mortality rates of the 4 intervention groups, presented in Figure 1F, show the highest survival 
in CR-fed animals. The survival rate of this intervention group was significantly higher than that of the 
C-fed (p=0.001) and MF-fed (p<0.001) mice. The survival rate of the INT-exposed mice was lower than 
that of the CR-fed mice, but still significantly enhanced (p=0.04) compared to the MF-exposed mice.
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Figure 1. Intermittent CR strongly increases life span and health span. (A) Weekly bodyweight measurements 
show a fluctuating body weight of the INT-exposed mice dependent on the diet the mice received in the preceding week 
and a mean body weight in between that of the C- and CR-exposed animals. (B) INT-exposed mice display an increase in 
lean body mass but not to the same extent as found in the CR-fed animals. (C) During the whole study the highest food 
intake was found for the ad libitum fed mice from the INT group while the during the CR week this intervention group 
had the lowest food intake. (D) Mean energy intake of the INT-fed mice is slightly lower compared to the MF-exposed 
animals and significantly higher compared to the CR-fed mice. (E) Mean daily activity levels in the INT-fed mice were 
highly similar to the CR-exposed animals and differ significantly from the MF-exposed mice. (F) Weekly intermittent CR 
causes a significant increase in survival compared to the MF-exposed mice but not to the same extent as found for the 
CR-fed animals. (G) An OGTT test showed that glucose clearance in the INT-exposed mice is similar to CR-fed mice. (H) 
Fasting insulin levels of the INF-fed mice were in between the levels found in the MF and CR-exposed mice. (I) eWAT 
weight of the INT-exposed animals was significantly lower compared to the MF-fed mice but significantly higher than 
found for the CR-exposed mice. 
An oral glucose tolerance test (OGTT), carried out 2 weeks prior to sacrifice, revealed that 
glucose clearance in the INT-fed mice was strongly improved compared to the MF-exposed mice 
and almost similar to the CR-fed mice (Figure 1G). In addition, fasting insulin levels in the INT-
exposed mice showed a tendency to decrease compared to the MF-exposed mice, although this 
effect was not significant (Figure 1H). No significant changes between the intervention groups was 
found for plasma free fatty acid (FFA), triglyceride (TG), plasminogen activator inhibitor 1 (PAI-1) and 
resistin (Supplemental Figure S1C). Weight of the epididymal white adipose tissue (eWAT) in the 
INT-exposed mice was found to be significantly decreased compared to the MF-exposed mice and 
significantly increased compared to the CR intervention group (Figure 1I).  A similar effect was found 
for kidney weight but not for heart, lung, spleen and pancreas weight (Supplemental Figure S1D).
Taken together, intermittent CR significantly improved the overall health compared to the MF-
fed mice, indicating a protection against the detrimental effects of a MF diet. However, the beneficial 
effects were not as pronounced as induced by the continuous CR exposure. 
A B C D
E F
Fa
sti
ng
 in
su
lin
 (n
g/
m
L)
C
M
F
IN
T CR
0
1
2
3
4
5 nsns
eW
AT
 w
ei
gh
t (
g)
C
M
F
IN
T CR
0
1
2
*****
G H I
C
M
F
IN
T-
CR
IN
T-
M
F CR
0
2
4
6
8
10
M
ea
n 
ac
tiv
it/
24
 h
 (c
ou
nt
s*
10
00
)
Age (weeks)
Su
rv
iv
al
 (%
)
52 65 78 91 104
50
75
100
C
CR
MF
INT
***
*
Age (month)
Fo
od
 in
ta
ke
 (k
ca
l/w
ee
k)
3 4 6 8 10 12 14 16 18 20 22 24
40
80
120
160
200 C
CR
MF
INT - MF week
INT - CR week
45
3
Life-long weekly intermittent calorie restriction reduced most but 
not all detrimental effects caused by a MF diet in the liver
To evaluate the effects of life-long INT feeding on the liver, a panel of different markers were 
examined in 24-month-old mice. Liver weight in the INT-fed mice was significantly lower compared 
to the MF-exposed mice and did not differ significantly from the CR-fed mice (Figure 2A). A significant 
decrease in the intrahepatic triglyceride (IHTG) levels was found in the INT-fed mice compared to 
the MF-exposed mice, but the levels were significantly higher compared to the CR-exposed mice 
(Figure 2B). Histological analysis of the livers of the mice from the different intervention groups 
confirmed the results of the IHTG measurements (Supplemental Figure S2A and B). Moreover, 
intermittent CR caused significant improvement of plasma alanine aminotransferase (ALT) levels, a 
well-established marker of liver injury/damage compared to the mice exposed to the MF diet (Figure 
2C). In addition, histological scoring of inflammatory aggregates (Figure 2D) and quantification of 
liver fibrosis by measuring 4-hydroxyproline levels (Figure 2E) showed significant improvement 
of liver health of the INT-fed mice compared to the MF-exposed mice. These last three markers 
represent the more advanced stages of NAFLD and revealed no significant differences between the 
INT- and CR-exposed mice. 
In summary, despite the fact that INT-fed animals had been exposed to the MF diet for half of 
their life, apart from displaying slight accumulation of liver triglycerides, they performed equally 
well as CR-exposed mice for all other NAFLD markers tested.
Figure 2. Intermittent CR counteracts the adverse health effects of the MF diet on the liver. The adverse effects 
caused by a MF diet on (A) liver weight, (B) IHTG, (C) ALT, (D) inflammation histology and (E) 4-hydroxyproline levels 
were significantly counteracted by intermittent CR. 
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Gene expression profiles of 24-month-old INT-fed mice were more 
similar to CR than to MF-exposed animals
Next, we studied the differences in hepatic gene expression patterns of the INT-exposed mice 
in comparison to the CR and MF intervention groups. For this purpose, microarray (MA) analysis 
was applied on RNA isolated of the livers from the mice. As shown in Figure 3A, the number of 
significantly (p<0.01) differentially expressed genes between INT- and CR-exposed mice was most 
abundant in 6-month-old mice and decreased during aging. In contrast, the difference between INT- 
and MF-exposed animals increased with age and the highest number of differentially expressed 
genes was found at the oldest time point. At the age of 24 months, in total 569 genes were found 
to be differential expressed between INT- and CR-fed mice while 2815 genes displayed differential 
expression between INT- and MF-exposed animals. Principal Component Analysis (PCA) of the 
top-1000 most variable genes in the 24-month-old animals, showed higher similarity between the 
INT and the CR-fed animals than between the INT- and MF-exposed mice (Figure 3B). Ingenuity 
pathway analysis (IPA) revealed that the differentially expressed genes in the two comparisons are 
related to different “Diseases and disorders”. Genes related to “Neurological disease, cancer and 
hereditary disorders” were found to be differentially expressed between INT- and CR-exposed mice 
(Table 1). Differential gene expression between INT- and MF-exposed mice was found to include 
genes involved in “Immunological, endocrine and gastrointestinal diseases” (representing mostly 
diabetes-related genes) (Table 1). In addition, in the top canonical pathways RXR activation was the 
major difference between INT- and CR-fed mice while immune pathway related genes dominate the 
difference between INT- and MF-exposed animals. Furthermore, IPA revealed that for hepatoxicity-
related processes, differential gene expression between INT and CR diet groups pointed towards 
differences in fat and bilirubin metabolism while differential gene expression between INT and MF-
exposed mice were involved in the advanced stages of NAFLD-related processes including fibrosis 
and cirrhosis (Table 1). This result confirms the biochemical data presented in Figure 2.
In conclusion, these results indicate that in 24-month-old mice, gene expression profiles 
obtained from the liver of INT-exposed mice are distinct from the MF-fed mice and resemble more 
the molecular features of CR-exposed animals. This result indicates that weekly intermittent CR 
evidently alters gene expression profiles induced by the MF diet at old age.
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Figure 3. Gene expression in the liver of 24-months-old INT-exposed mice is more similar to that of CR than 
MF-fed animals. (A) The number of genes significantly differentially expression between INT and CR-exposed mice 
decreases during aging while this number increase during aging between the INT and MF-exposed intervention groups. 
(B) The PCA plot generated from the top-1000 most variable genes revealed that the expression profiles of the INT-fed 
animals is more similar to the CR than to the MF-exposed animals. 
Table 1. Functional differences in the differentially regulated genes
A
B
INT-7
INT-3
INT-15
INT-5
INT-13
INT-1
INT-11
CR-3
CR-1
CR-5
CR-13
CR-7
CR-9
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MF-13
MF-3
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 24M INT vs CR 24M INT vs MF 
  Category p-value Category p-value 
Diseases 
and 
disorders 
  
Neurological disease 2.81E-5 – 2.54E-2 Immunological disease 2.66E-41 – 5.26E-9 
Cancer 3.30E-5 – 2.54E-2 Endocrine systems 
disorders 
6.01E-39 – 5.60E-29 
Hereditary disorders 3.92E-5 – 2.54E-2 Gastrointestinal disease 6.01E-39 – 7.43E-9 
Top 
canonical 
pathways 
  
LPS/IL-1 mediated inh. 
of RXR function 
8.87E-07 iCOS-iCOSL signalling T 
helper cells                                    
3.78E-12 
PCR/RXR activation 7.00E-06 Role of NFAT in immune 
response   reg. 
4.43E-12 
TR/RXR activation 5.87E-05 IL-8 signalling 8.47E-12 
Hepa-
toxicity 
  
Liver cholestasis 8.50E-5 – 1.86E-2 Liver cirrhosis 5.97E-10 – 2.35E-1 
Liver steatosis 2.14E-4 – 1.43E-1 Liver hyperplasia 1.63E-9 – 6.09E-1 
Liver hyperbilirubinemia 1.18E-3 – 5.02E-2 Liver fibrosis 5.23E-7 – 4.86E-1 
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Phenotypic plasticity observed in the MF/INT diet switch group 
In the final part of our analysis we explored the plasticity of the long-term effects induced 
by the MF diet. For this purpose, a subset of 12-month-old mice was transferred from the MF to 
the INT diet (MF/INT diet switch group). The mice of the diet switch group received the INT diet till 
sacrifice at the age of 24 months. As shown in Figure 4A, the results of the OGTT analysis revealed 
that glucose metabolism of the mice in the diet switch group was similar to that of the life-long 
INT-exposed mice. Furthermore, survival of the diet switch group markedly increased compared 
to the life-long MF-exposed animals, although this effect did not reach the level of significance 
(Figure 4B). Compared with the life-long MF-exposed mice body weight decreased significantly 
in the diet switch mice (Figure 4C). A reduction in eWAT (Figure 4D) and liver (Figure 4E) weight 
was observed but both adaptations were not significant. Analysis of a panel of liver health markers 
(Figure 4F) revealed no change in IHTG levels after the diet switch and a marked but not significant 
decrease in plasma ALT, lymphocyte infiltration and 4-hydroxyproline levels  (Figure 4G-I) in the 
MF/INT diet switch mice compared to the life-long MF-exposed animals.
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Figure 4. Effects of exposure to a MF diet are partially reversed after transferring the mice to the INT diet 
for the last 12 months of their life. Strong adaptation to the INT diet in the MF/INT diet switch group was found by 
measuring (A) glucose clearance (B) survival and  (C) body weight. The decrease in (D) eWAT weight, (E) liver weight, 
(F) IHTG levels, (G) liver inflammatory aggregates, (H) plasma ALT and (I) 4-hydroxyproline levels after the diet switch 
were not significant.
Molecular adaptations and irreversible changes in the liver of the 
MF/INT diet switch group
As shown in Figure 3A, microarray analysis revealed that at the age of 24 months 2815 genes 
displayed significant differentially expression between INT- and MF-exposed mice. We compared the 
expression levels of these 2815 genes between the diet switch group with either the life-long MF- 
or INT-exposed animals, respectively (for an overview see Supplemental Figure S3A). Expression 
levels of 1510 genes were found to be similar in the MF/INT and the life-long INT-exposed animals 
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and distinct from the MF-exposed animals (MF/INT vs INT p>0.01; MF/INT vs MF p<0.01). This result 
indicated that expression levels of these 1510 genes adapted to the INT diet the mice had received 
during the last 12 months of their life. Expression levels of a second subset of 1157 genes did not 
differ significantly from either the MF or from the INT-fed animals (MF/INT vs INT p>0.01; MF/INT 
vs MF p>0.01). Interestingly, expression of a relative small subset of 148 genes differed significantly 
between the MF/INT diet switch and the INT-exposed mice, but not from the MF-exposed mice (MF/
INT vs INT p<0.01; MF/INT vs MF p>0.01). This result implies that the differential expression induced 
by the MF diet of these 148 genes did not adjust to the INT diet during the last 12 months of life, thus 
indicating an irreversibility of the MF-induced effects. The heatmap of the hierarchical clustering of 
this selection of 148 genes presented in Figure 5A shows clustering of the INT-exposed mice and a 
distinct expression profile compared to mice of the MF and MF/INT intervention groups. IPA applied 
to compare the canonical pathways of the 148 irreversible (Supplemental Table S1) and the 1510 
reversible genes, revealed that these subsets of genes represented distinct canonical pathways. 
The 148 consistently altered genes were found to affect RXR-mediated processes and xenobiotic 
metabolism signalling (Figure 5B). In contrast, the 1510 adaptive genes were found to be involved 
in a variety of immune response and inflammation-related pathways and in hepatic fibrosis/stellate 
cell activation (Figure 5C). IPA was applied to obtain insight into the mechanisms regulating the 
expression of the 148 consistently altered genes and found that PXR was the strongest regulator of 
this selection of genes (Supplemental Table S2).
In Figure 5D expression profiles of Hsd3b5, Cd36 and Pparγ are shown, representing 3 
examples of genes of the subset of 148 consistently altered genes (other examples are presented 
in Supplemental Figure S3B). Interestingly, for most of the genes displaying consistently changes 
induced by the MF diet, significantly different expression between the INT and MF-exposed mice 
starts at a young age (6 or 12 months). Figure 5E presents the expression levels of Cyp2u1, Lpl and 
Clec10a, showing that the mean expression levels in the MF/INT-exposed animals differs strongly 
from the life-long MF-exposed mice. For these genes of which the expression levels adapted to 
the INT diet, no marked changes were found between young MF- and INT-exposed animals (other 
examples are presented in Supplemental Figure S3C). By analysing the age-related effect of the 
148 consistently altered genes in more detail we found that 43% of these genes showed a MF-
induced change in gene expression at young age (6 or 12 months) while this was found for only 9% 
of the 1510 adaptive genes.
In conclusion, differential expression regulation of irreversible genes might have an onset 
earlier in life than the genes of which the expression levels adapt to the INT diet.
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Figure 5.  A small fraction of the MF-induced genes during the first 12 months of life are consistently altered. 
(A) A heatmap of the 148 consistently altered genes show a different expression profile between the INT compared to 
the MF and MF/INT diet switch mice. IPA analysis of the (B) 148 consistently changed genes and the (C) 1510 adaptable 
genes reveal that they present different functional categories. (D) MA profiles of 3 examples of irreversible genes and 
(E) genes that adapt to the INT diet after the diet switch.
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DISCUSSION
In this study we examined the effects of life-long intermittent CR in aging mice. We applied 
a relatively robust variant of this dietary intervention and exposed the mice thereby to multiple 
challenges. This concept was inspired by the hypothesis that life and health-span extending effects 
are not necessarily derived from the energy reduction only, but that intermittent exposure to 
challenges might have an additional health-promoting effect [16-18]. During the experiment the 
INT-fed mice weekly lose or gain ~15% of their bodyweight, illustrating the constant adaptation 
of their body to the alternating energy availability. Furthermore, since the composition of the diet 
also differed between the weeks, the gastrointestinal tract as well as metabolic organs, e.g. the 
liver, were challenged to handle variations in carbohydrate and fat content. The third challenge was 
the food exposure time. During the CR week one portion of food was offered 30 minutes prior to 
the initiation of the dark-phase and the mice consumed the whole portion (almost all) at once. In 
contrast, during the MF-week the mice had continuous access to food. The results we present 
show that, although the mean energy intake of the INT-exposed over a two week time interval 
mice was only marginally (7%) reduced compared to the MF-exposed mice, the 24-month-old mice 
display 1) a significant decrease in body weight, 2) a better fat/lean body mass ratio, 3) an improved 
glucose metabolism and 4) an increased survival. However, it should be noted that, apart from 
glucose metabolism, life-long CR-exposed mice performed better on all features compared to the 
INT intervention group. 
It is important to take into consideration that, in addition to energy intake reduction and 
exposure to various challenges, the daily activity of the INT-exposed mice appeared to differ 
significantly from the MF-exposed mice. We have previously reported increased daily activity in 
life-long CR-exposed mice in this cohort [27] in line with what has been reported earlier [6]. Since 
exercise is an important factor regulating health, this feature might very likely contribute to the 
health improving effects induced by the INT and CR diet. Intriguingly, no difference was found in the 
daily activity of the INT-exposed mice between the energy restricted and ad libitum feeding week. 
This suggests that the increased activity can be seen as a habit more than a response to the lack of 
availability of food [27].
The effects of the INT diet were analysed in more detail in the liver, a central organ in the 
regulation of metabolic health. NAFLD frequently occurs in obese individuals and is recognized as 
the hepatic manifestation of metabolic syndrome. In the 24-month-old MF-exposed mice, increased 
IHTG, liver inflammation, liver 4-hydroxyproline levels and increased plasma ALT levels suggest the 
presence of advanced stages of NAFLD. Life-long exposure to the CR diet fully protected against 
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NAFLD development. INT-fed mice display normal plasma ALT levels, no liver inflammation and no 
liver fibrosis. These mice, however, display mild steatosis with IHTG levels significantly lower than 
the MF-exposed mice. This result differs from what we previously have observed in 12-month-old 
mice where the INT diet improved liver health even beyond the effect achieved by the CR diet [26]. The 
results we present here indicate that, at the long run, an INT diet protects the liver for the advanced 
stages of NAFLD. However, this INT diet does not fully prevent MF-induced lipid accumulation. Gene 
expression profiles generated from the liver of the 24-month-old INT-exposed mice revealed that 
gene expression in these animals appeared to be more similar to the CR than to the MF-exposed 
mice, underscoring the beneficial effects of the INT diet on metabolic health. Functional analysis 
of the differentially expressed genes further confirmed that intermittent CR affects pathways 
involved in liver fibrosis and cirrhosis and the advanced stages of NAFLD. Taken together, strong 
improvement in total body and liver health was caused by regular short term exposure to a CR diet. 
The INT diet almost completely counteracts the effects of the MF diet, which these mice consumed 
for half of their life. However, despite of the additional challenges these mice have been exposed to 
the effects did not reach the standards achieved by a life-long CR diet.
CR interventions are often applied to achieve weight loss in overweight and obese subjects. In 
the second part of our study we explored into what extent, the molecular effects induced by a MF 
diet in the liver during the first 12 months of life, can be reversed by exposure to the INT diet during 
the second 12 months of life. Microarray analysis showed significant differential expression of 2815 
genes between 24-month-old MF and INT intervention groups. Analysis of the gene expression levels 
in the MF/INT diet switch group revealed that the majority of these 2815 differentially expressed 
genes partially (1157 genes) or fully (1510 genes) adopted to the INT expression profile. IPA analysis 
revealed that the subset of 1510 reversible genes represent predominantly inflammation pathways. 
Similarly, a decrease in plasma ALT levels and liver lymphocyte aggregates and fibrosis was 
observed in the diet switch mice, although these effects were not significant. Expression levels of 
a relative small subset of genes (148), however, appeared consistently changed by exposure to the 
MF diet during the first 12 months of life. IPA showed that this subset of 148 genes encompasses a 
large number of genes involved lipid and xenobiotic metabolic processes. The observation that PXR 
(or NR1I2) was the strongest predicted upstream regulator suggests a connection between these 
two functions. PXR is a ligand-activated nuclear receptor that, upon activation, forms a heterodimer 
with RXR. This complex is not only activated by exogenous toxins but has also been shown to 
responds to endobiotics like bile acids and steroid hormones [28]. Previous studies have shown that 
PXR activation in mice induces fatty acids uptake via up-regulation of Cd36  which is also one of the 
148 consistently regulated genes. Additionally, other genes involved in lipid metabolism including 
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Pparγ, Cidea and Cidec are consistently up-regulated in the MF/INT diet switch mice. With respect 
to the PXR target genes involved in xenobiotic metabolism it should be noted that a large number 
of genes are consistently upregulated by the MF diet including Gstm1, Gstm5, Fmo1, Fmo2, Fmo3, 
Abcc3, Cyp3a5, etc., indicating strongly enhanced xenobiotic and/or endobiotic metabolism in both 
the MF-exposed and the diet switch mice. Taken together these results suggest that, after a strong 
weight loss, robust reductions in the advanced stages of NAFLD can be achieved but that hepatic 
steatosis might not be fully reversible at old age.
In conclusion, our data indicate that intermittent CR offers significant health improving effects 
and largely counteracts the effects of a MF diet, but does not reach the health- and life span 
improving effects of a CR diet. Although the number of consistent molecular changes induced by a 
MF diet is small, they might have potentially important adverse effects on health.
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EXPERIMENTAL PROCEDURES
Ethics statement
The institutional and national guidelines for the care and use of animals were followed and the 
Local Committee for Care and Use of Laboratory Animals at Wageningen University approved the 
experiment (code number: drs-2010151b).
Animals and diets
Male C57BL/6J mice (age of 7 weeks) were purchased from Janvier (Cedex, France) and were 
housed in pairs of two in the light and temperature (20oC)-controlled animal facility of Wageningen 
University (12-hour light/dark cycle, light on at 04.00). The mice received standard AIN-93G 
(Research Diet Services, Wijk bij Duurstede, The Netherlands) for 2 weeks upon arrival. 
At the start of the diet intervention the mice were 9 weeks old, housed individually and 
randomly distributed into four intervention groups: 1) Control diet (C) receiving AIN-93W diet ad 
libitum (n=89); 2) calorie restricted diet (CR) receiving AIN-93W-CR in portions containing 70E% of 
the mean energy intake of the group of the control mice were provided each day at 15.30 (n=117); 
3) medium fat diet (MF) receiving AIN-93W-MF ad libitum (n=127); and (4) intermittent diet (INT) 
receiving alternating one week AIN-93W-MF ad libitum followed by one week 60E% of control diet 
based on the mean energy intake of the mice on the AIN-93W diet (n=155). AIN-93W-CR contained 
increased concentration of vitamins and minerals content in order to feed these mice the same 
concentrations of micronutrients as the mice receiving AIN-93W diet and avoid malnutrition. 
Complete diet composition is listed in Supplementary Table S3 (Research Diet Services, Wijk bij 
Duurstede, The Netherlands). All mice were provided with ad libitum access to water. 
Body weight of all mice was recorded every two weeks. To represent a weekly body weight 
development, we weighed a smaller sample of mice of each intervention group every other week 
(20-24 mice). Food intake of 20 mice of each intervention group was measured every two months, 
comprising one week measurement for the C, CR and MF-fed mice and two weeks measurement 
for the INT-fed mice. Portion sizes of the mice on the CR and INT were adjusted at the beginning 
of the study and at the age of 6, 12 and 18 months based on food intake of C mice. At the age of 
6, 12 and 24 months, 12-16 mice of each intervention group were sacrificed between 14.00-17.00 
on 5 consecutive days (the remaining mice stayed in the experiment and were sacrificed at older 
ages). INT mice were sacrificed in their ad libitum MF feeding week. Similar to what we performed 
in the previous study [26], prior to sacrifice each mouse was first fasted for 4 hours after which 
they received an intragastric gavage of either solvent (0.5% carboxymethyl cellulose) or Wy-14,643 
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dispersed in solvent (160 mg Wy-14,643/kg body weight), then fasted again for another 6 hours. in 
each dietary intervention group. In each diet group, the mice were paired according to bodyweight 
at sacrifice, so that mock and Wy-14,643 treatment were provided to mice with similar body 
weight. Only mock-treated animals were included in the molecular analysis, since the Wy-14,643 
treatment have an immediate effect on the gene expression levels. The purpose of this treatment 
is to examine PPARα adaptive capacity analysis, which will be covered in a separate publication. 
After sedation with a mixture of isoflurane (1.5%), nitrous oxide (70%) and oxygen (30%), blood 
samples were collected by cardiac puncture, then followed by neck dislocation. Weight of various 
organs was measured and subsequently organs/tissues were snap-frozen and stored at -80oC until 
further molecular/biochemical analysis. For histological analysis, organs/tissues were fixed in 4% 
paraformaldehyde.
Daily activity measurement
At 23 months of age, a subset of mice were housed in new cages to monitor physical activity 
continuously as previously described [27, 29]. First mice were allowed to acclimatise for 3 days; 
followed by monitoring the activities of again 3 days. The results shown were averaged to dampen the 
day-to-day variability (n=3 per group). Activity sensors (dual technology detector DUO 240, Visonic; 
adapted by R. Visser, NIN, Amsterdam, The Netherlands) were mounted above the cages and data 
were analysed with MED-PC® IV software for data collection (MED associates, St Albans, VT, USA). 
Activity was expressed in counts per 30 min (both for the total 24 h period, the dark period (active 
period) and the light period (inactive period)). Activity was calculated for each mouse separately. 
Statistical analyses were performed using SPSS 19.0 (SPSS Benelux, Gorinchem, the Netherlands) 
and differences were considered significant at a P-value below 0.05. Statistical analyses were 
performed on total daily activity data by use of a mixed model with post hoc LSD testing.
DEXA scan body composition analysis
Body composition was measured by Dual Energy X-ray Absorptiometry (DEXA) scan, using 
a PIXImus imager (GE Lunar, Madison, WI, USA). The scan produced data concerning lean mass, 
fat mass and bone mineral density. During the measurements the animals were under general 
anaesthesia (isoflurane/N2O/O2).
Oral glucose tolerance test
The mice sacrificed at the age of 23 months were all subjected to an oral glucose tolerance test 
(OGTT) two weeks prior to sacrifice. In the OGTT, the mice were fasted for 6 hours, then received 1.5 
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mg glucose per gram body weight via an oral gavage. Subsequently, blood glucose was measured 
15, 30, 45, 60, 90 and 150 minutes following the glucose load using Accu-Check blood glucose 
meters (Roche Diagnostics, Almere, The Netherlands).
RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen Breda, The Netherlands) according to 
the manufacturer’s instructions. The RNA was treated with DNAse and purified on columns using 
the RNAeasy microkit (Qiagen, Venlo, the Netherlands). RNA concentration was measured on a 
NanoDrop ND-1000 UV–vis spectrophotometer (Isogen, Maarssen, The Netherlands) and RNA 
integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies, Amsterdam, The 
Netherlands) with 6000 Nano Chips according to the manufacturer’s instructions. RNA was judged 
as suitable only if samples showed intact bands of 18S and 28S ribosomal RNA subunits, displayed 
no chromosomal peaks or RNA degradation products, and had a RNA integrity number (RIN) above 
8.0.
Microarray hybridization and analysis
100 ng of purified RNA was used for the preparation of labelled cDNA, applying the Ambion 
Whole Transcript (WT) Expression kit (Life Technologies, Carlsbad, USA) in combination with 
the Affymetrix GeneChip WT Terminal Labelling kit (Affymetrix, Santa Clara, USA). All samples 
were hybridized at one time point to Affymetrix GeneChip Mouse Gene 1.1 ST arrays according 
to standard Affymetrix protocols. Microarray analysis was performed in MADMAX, a pipeline for 
statistical analysis of microarray data. Arrays were normalized using the Robust Multiarray Average 
[30, 31]. Probe sets were defined according to Dai et al.[32]. In this method probes are assigned to 
unique gene identifiers, in this case Entrez IDs. The probes on the Gene 1.1 ST arrays represent 
21,225 Entrez IDs. Array data will be submitted to the Gene Expression Omnibus after acceptance 
of the manuscript.
Bioinformatic analysis
Of the 21,225 defined genes covered by the MA, only genes with an intensity value of ≥20 on 
at least 5 arrays, represented by at least 7 probes per gene on the array and an interquartile range 
(IQR) ≥0.1 were selected for further analysis and not annotated were removed. The top-1000 most 
variable genes were used for Principle Component Analysis (PCA) using MultiExperimentViewer 
version 4.8.1 [33, 34]. Signal log2 ratios, which represent fold changes (FC), and related significances 
of change were calculated from the mean signal intensities and differences between diet groups 
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was analyzed  using intensity based-moderated t-statistics (IBMT) implementing empirical Bayes 
correction [35]. Resulting 2log ratios and p-values were applied for further descriptive bioinformatic 
analysis of the data. Ingenuity Pathway Analysis (IPA, Ingenuity® Systems, www.ingenuity.com) 
was used to explore the canonical pathways affected by the 148 reversibly and 1510 consistently 
changed genes. Comparison of the expression patterns of the 148 irreversible changed genes 
in the MF, INT and MF/INT diet switch groups was carried out by generating a heat map using 
MultiExperimentViewer, version 4.8.1  [33, 34].
Histopathology
Formalin-fixed and paraffin-embedded cross-sections (5µm) of the  liver lobe was stained 
with haematoxylin and eosin. Hepatic inflammation was assessed by counting the number of 
inflammatory foci at a 100× magnification (view size 3.1 mm2), in five non-overlapping fields.
Hepatic triglyceride and 4-hydroxyproline measurement
Liver triglycerides were determined in 5% liver homogenates prepared in buffer containing 
250 mM sucrose, 1 mM EDTA, 10 mM Tris-HCl (pH 7.5), using the triglyceride Liquicolor 
Monoreagent (Instruchemie, Delfzijl, The Netherlands). 4-hydroxyproline content was determined 
spectrophotometrically in liver hydrolysates as previously described in Hillebrandt et al. [36].
Plasma measurement
Plasma insulin, resistin and PAI-1 levels were measured using a Mouse Adipokine (MADKMAG-
71K) kit, according to the manufacturer’s instructions. Plasma concentration of ALT was measured 
with commercially available kits from Instruchemie (Delfzijl, the Netherlands). Plasma insulin level 
was measured using a Mouse Adipokine (MADKMAG-71K) kit, according to the manufacturer’s 
instructions. Plasma triglyceride and free fatty acid were measured using Liquicolor (Instruchemie, 
Wiesbaden, Germany) and NEFA-C kit (Wako, Neuss, Germany), respectively. Both assays were 
performed according to manufacturer’s instructions.
Statistical analysis 
Except for the gene expression, data were analysed with GraphPad Prism 5.04 applying 1-way 
ANOVA followed by a Tukey post-test analysis. Statistical significance for the survival of groups was 
established by the log-rank analysis of Kaplan-Meier plots.
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SUPPLEMENTARY TABLES
Supplementary Table S1. 148 genes displaying differential expression between MF and INT-
exposed mice revealing that do not adapt to the INT diet in the MF/INT diet switch group
 MF vs INT MF/INT vs MF MF/INT vs INT 
Symbol FC p-value  FC p-value  FC p-value  
Hsd3b5 -25.23 1.09E-06 1.87 3.09E-01 -13.47 9.31E-05 
Serpina4-ps1 -7.24 5.08E-06 1.64 2.26E-01 -4.42 6.43E-04 
Susd4 -4.08 2.06E-06 1.69 5.91E-02 -2.41 2.69E-03 
Gpr110 -3.39 2.05E-04 1.20 5.70E-01 -2.84 1.88E-03 
C4a -3.09 1.93E-07 1.60 2.02E-02 -1.93 1.88E-03 
Slc22a28 -2.84 6.23E-05 1.34 2.36E-01 -2.12 4.36E-03 
Cyp7b1 -2.32 5.17E-05 1.24 2.76E-01 -1.87 2.86E-03 
Sult5a1 -2.32 1.39E-07 1.33 5.48E-02 -1.74 3.94E-04 
Grm8 -2.25 2.69E-07 1.31 6.68E-02 -1.72 4.88E-04 
Mup21 -2.17 1.27E-03 1.07 7.60E-01 -2.02 4.32E-03 
Slc22a7 -2.15 9.34E-04 1.07 7.59E-01 -2.00 3.29E-03 
Serpine2 -2.01 6.47E-05 1.20 2.79E-01 -1.68 3.34E-03 
Cabyr -1.95 3.23E-03 -1.01 9.73E-01 -1.97 3.90E-03 
Olfr541 -1.95 3.66E-07 1.31 2.91E-02 -1.49 1.91E-03 
Adh6-ps1 -1.79 1.57E-03 1.10 5.86E-01 -1.62 9.98E-03 
Cyp21a1 -1.78 2.29E-03 1.07 6.96E-01 -1.65 9.16E-03 
Lama3 -1.72 4.77E-07 1.12 2.72E-01 -1.54 6.14E-05 
Ttc39c -1.63 7.15E-05 1.03 8.25E-01 -1.59 2.44E-04 
Lrrc16a -1.62 3.16E-03 1.02 9.23E-01 -1.59 5.51E-03 
Igfbp2 -1.58 6.43E-04 1.07 5.90E-01 -1.47 4.62E-03 
Pcolce2 -1.55 3.77E-04 1.01 9.38E-01 -1.54 7.18E-04 
Tspan33 -1.55 5.51E-05 1.11 3.00E-01 -1.39 2.56E-03 
Slco2a1 -1.52 1.91E-04 1.11 3.39E-01 -1.37 5.50E-03 
C8b -1.51 1.14E-03 -1.05 7.10E-01 -1.58 4.98E-04 
Hes6 -1.49 1.51E-03 1.04 7.50E-01 -1.44 5.23E-03 
Slc30a3 -1.47 2.16E-05 1.13 1.53E-01 -1.30 3.91E-03 
Alas2 -1.46 6.49E-05 1.05 6.09E-01 -1.39 5.80E-04 
Ccbl1 -1.45 1.24E-04 1.04 6.82E-01 -1.39 7.44E-04 
Ppp1r9a -1.43 2.26E-03 1.01 9.13E-01 -1.41 4.19E-03 
Rd3 -1.41 3.06E-06 1.13 7.93E-02 -1.25 2.40E-03 
Adrb3 -1.40 6.21E-03 -1.01 9.51E-01 -1.41 6.76E-03 
Gm4981 -1.39 4.91E-04 1.02 8.42E-01 -1.36 1.34E-03 
Cyp2c44 -1.37 4.20E-04 1.05 5.92E-01 -1.31 3.18E-03 
Gm3934 -1.36 1.22E-03 -1.03 7.89E-01 -1.40 7.42E-04 
Tle6 -1.36 1.80E-04 1.04 6.08E-01 -1.30 1.43E-03 
Gstp1 -1.35 3.94E-04 -1.02 8.46E-01 -1.38 3.09E-04 
Serpina11 -1.35 5.26E-04 -1.04 6.58E-01 -1.40 1.79E-04 
Dnase1 -1.32 1.78E-05 1.06 3.45E-01 -1.25 7.69E-04 
Irf6 -1.31 2.58E-03 -1.01 9.34E-01 -1.32 2.73E-03 
Gcat -1.30 1.36E-04 1.08 2.78E-01 -1.21 6.01E-03 
Srgap3 -1.30 3.18E-03 -1.01 8.93E-01 -1.31 2.87E-03 
Tiaf2 -1.29 4.44E-04 1.05 5.24E-01 -1.23 4.45E-03 
Tdrkh -1.28 1.75E-03 -1.01 8.52E-01 -1.30 1.37E-03 
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 MF vs INT MF/INT vs MF MF/INT vs INT 
Symbol FC p-value  FC p-value  FC p-value  
Apom -1.27 1.33E-03 -1.05 5.23E-01 -1.32 2.41E-04 
Cbs -1.25 1.36E-03 -1.02 7.58E-01 -1.28 7.31E-04 
Tnik -1.24 6.80E-03 -1.03 7.19E-01 -1.28 3.19E-03 
Smarcd2 -1.23 1.19E-04 1.06 2.41E-01 -1.16 6.92E-03 
Cwf19l1 -1.23 2.37E-04 1.04 4.55E-01 -1.18 3.60E-03 
D830014E11Rik -1.23 3.16E-03 -1.02 8.15E-01 -1.25 2.13E-03 
Slc19a2 -1.22 2.86E-03 -1.05 4.66E-01 -1.28 4.07E-04 
Gm10766 -1.21 5.27E-03 1.00 9.87E-01 -1.21 7.14E-03 
Gabrd -1.21 1.48E-03 1.03 5.89E-01 -1.18 9.38E-03 
Bmp2 -1.21 2.32E-03 1.02 7.50E-01 -1.19 7.63E-03 
Kdr -1.21 1.20E-04 1.06 2.47E-01 -1.15 6.68E-03 
Apobec2 -1.21 5.21E-03 -1.01 8.73E-01 -1.22 4.33E-03 
Gcn1l1 -1.21 2.82E-05 1.07 1.18E-01 -1.13 6.97E-03 
Porcn -1.20 6.41E-03 -1.02 7.89E-01 -1.23 3.91E-03 
Scarf1 -1.20 4.33E-03 -1.02 6.94E-01 -1.23 1.82E-03 
Tmem63a -1.20 1.09E-03 1.01 8.25E-01 -1.18 2.95E-03 
Ppp1r1a -1.19 9.66E-05 1.04 3.31E-01 -1.14 3.33E-03 
Gtf2h4 -1.19 5.31E-04 1.03 5.03E-01 -1.15 5.67E-03 
Sun2 -1.18 1.79E-03 -1.05 3.47E-01 -1.24 1.20E-04 
Exoc3l -1.18 3.91E-03 -1.01 8.31E-01 -1.19 2.80E-03 
Adcy4 -1.18 6.82E-03 -1.00 9.87E-01 -1.18 8.34E-03 
Fgf8 -1.18 3.17E-03 1.01 8.23E-01 -1.16 7.82E-03 
Repin1 -1.17 1.17E-03 -1.05 3.50E-01 -1.22 7.63E-05 
Rbfa -1.17 5.50E-04 1.03 4.72E-01 -1.13 6.68E-03 
Pskh1 -1.16 4.82E-05 1.03 3.75E-01 -1.13 1.47E-03 
Sil1 -1.15 4.17E-04 1.03 5.19E-01 -1.12 4.32E-03 
Nelfe -1.15 6.65E-03 -1.02 6.40E-01 -1.18 2.28E-03 
Skiv2l -1.14 8.84E-05 1.04 1.92E-01 -1.09 7.93E-03 
Os9 -1.13 3.93E-04 -1.01 8.47E-01 -1.14 3.10E-04 
Irf3 -1.13 8.83E-04 1.02 5.53E-01 -1.11 7.01E-03 
Arid1b -1.09 8.59E-03 -1.02 5.27E-01 -1.11 1.83E-03 
Angptl3 1.13 4.33E-04 -1.02 6.52E-01 1.11 2.54E-03 
Arf4 1.16 2.75E-03 -1.01 8.89E-01 1.15 5.47E-03 
Fmo1 1.16 7.29E-03 1.04 4.84E-01 1.20 1.24E-03 
Gbe1 1.16 8.50E-03 1.01 8.80E-01 1.17 7.17E-03 
Tcn2 1.17 5.55E-04 -1.03 4.66E-01 1.14 6.91E-03 
Gstm1 1.18 2.70E-03 -1.01 9.14E-01 1.17 4.91E-03 
Kif18a 1.18 9.76E-03 1.03 6.92E-01 1.22 4.18E-03 
Setd8 1.19 8.54E-03 1.03 6.01E-01 1.23 2.52E-03 
Bche 1.20 3.15E-03 1.04 5.10E-01 1.25 5.69E-04 
Rny3 1.20 4.18E-04 -1.02 7.21E-01 1.18 1.87E-03 
Megf9 1.21 7.00E-03 1.01 9.01E-01 1.22 6.38E-03 
Slc16a7 1.22 5.75E-03 1.10 1.71E-01 1.34 1.03E-04 
Supplementary Table S1. (Continued)
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 MF vs INT MF/INT vs MF MF/INT vs INT 
Symbol FC p-value  FC p-value  FC p-value  
Cdk6 1.22 3.29E-03 1.04 5.98E-01 1.27 9.03E-04 
Fut8 1.22 1.43E-03 1.03 5.79E-01 1.27 3.44E-04 
Fkbp1a 1.23 3.86E-03 -1.01 8.68E-01 1.21 8.01E-03 
Prdx3 1.24 6.93E-06 -1.08 1.10E-01 1.16 2.77E-03 
Syce2 1.25 1.88E-03 1.01 8.61E-01 1.26 1.52E-03 
Tmc6 1.25 2.67E-04 -1.03 6.42E-01 1.22 1.74E-03 
Slc9a6 1.26 7.12E-04 -1.04 5.54E-01 1.21 5.83E-03 
Cers6 1.29 8.61E-03 1.09 3.57E-01 1.41 7.48E-04 
Impact 1.30 2.09E-05 -1.11 8.78E-02 1.18 8.39E-03 
Abcc3 1.30 7.03E-03 1.01 9.14E-01 1.32 6.69E-03 
Ugt8a 1.31 5.34E-04 -1.03 7.22E-01 1.28 2.31E-03 
Acer2 1.32 1.15E-03 -1.04 6.70E-01 1.27 5.53E-03 
Osgin2 1.35 7.76E-04 -1.00 9.91E-01 1.35 1.15E-03 
Rtn4 1.38 4.64E-04 -1.06 5.12E-01 1.30 4.87E-03 
Vwf 1.38 3.00E-07 -1.11 6.72E-02 1.24 5.27E-04 
Dzip1l 1.38 2.97E-07 -1.15 1.64E-02 1.20 3.21E-03 
Nebl 1.41 1.60E-03 -1.01 9.31E-01 1.40 2.85E-03 
Cyp3a59 1.42 6.10E-03 1.14 2.94E-01 1.61 3.31E-04 
Vldlr 1.43 9.94E-03 1.12 3.98E-01 1.60 1.12E-03 
Selp 1.43 6.54E-05 -1.05 5.54E-01 1.36 7.55E-04 
Fam19a2 1.44 2.19E-04 1.01 8.82E-01 1.46 2.04E-04 
C1qtnf7 1.45 2.20E-05 -1.15 1.04E-01 1.27 7.00E-03 
Spa17 1.45 1.17E-05 -1.17 5.64E-02 1.24 9.71E-03 
Zfp521 1.46 1.17E-06 -1.19 1.56E-02 1.22 8.54E-03 
Aebp1 1.48 3.40E-05 -1.14 1.41E-01 1.29 6.22E-03 
Prelid2 1.51 1.77E-03 1.06 6.39E-01 1.61 5.73E-04 
Tm4sf4 1.53 7.81E-05 -1.12 2.67E-01 1.36 4.20E-03 
Plagl1 1.54 8.44E-06 -1.19 5.81E-02 1.29 7.48E-03 
Gstm2 1.54 6.56E-05 -1.15 1.67E-01 1.34 7.83E-03 
Gas6 1.55 5.19E-03 1.09 5.84E-01 1.69 1.37E-03 
Glod5 1.56 5.29E-05 -1.13 2.57E-01 1.38 3.31E-03 
Cyp3a11 1.58 3.49E-08 -1.11 1.79E-01 1.43 1.61E-05 
Rsph4a 1.59 6.85E-03 1.46 2.60E-02 2.31 5.14E-06 
Nqo1 1.60 5.57E-03 1.03 8.63E-01 1.64 4.45E-03 
Gm10872 1.65 2.15E-03 1.02 9.24E-01 1.68 2.21E-03 
Abcb1a 1.69 5.06E-05 1.00 9.96E-01 1.69 8.15E-05 
Chil1 1.71 2.13E-03 1.02 9.03E-01 1.74 2.02E-03 
Pparg 1.76 5.08E-04 -1.07 6.61E-01 1.64 2.82E-03 
Tmem45b 1.90 1.64E-03 1.10 6.26E-01 2.10 4.98E-04 
Cyp2c39 1.96 1.35E-04 1.08 6.50E-01 2.11 4.35E-05 
Corin 1.96 1.68E-05 -1.16 3.14E-01 1.69 8.90E-04 
Cd36 2.03 9.12E-04 1.02 9.38E-01 2.06 1.02E-03 
Tceal8 2.03 1.12E-06 -1.22 1.38E-01 1.66 4.69E-04 
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 MF vs INT MF/INT vs MF MF/INT vs INT 
Symbol FC p-value  FC p-value  FC p-value  
Plin4 2.04 2.03E-03 -1.04 8.46E-01 1.95 4.83E-03 
Mbnl3 2.08 4.70E-06 -1.15 3.67E-01 1.82 2.18E-04 
Rcan2 2.16 5.36E-06 -1.07 6.66E-01 2.01 4.76E-05 
Lgals1 2.21 8.17E-05 -1.12 5.68E-01 1.98 8.59E-04 
Fam83a 2.41 3.88E-07 -1.39 4.34E-02 1.74 1.19E-03 
Ttc39a 2.41 6.03E-08 -1.27 1.15E-01 1.91 6.02E-05 
Fmo2 2.43 8.24E-07 -1.19 3.03E-01 2.04 7.69E-05 
Orm3 2.47 4.08E-03 1.23 4.99E-01 3.03 7.11E-04 
S100a11 2.70 1.25E-04 -1.31 2.73E-01 2.05 5.80E-03 
Gprc5b 2.78 1.77E-05 -1.06 8.03E-01 2.63 7.43E-05 
Themis 2.91 4.06E-05 -1.22 4.28E-01 2.39 9.49E-04 
Cyp2a22 3.00 1.31E-03 1.24 5.23E-01 3.70 2.37E-04 
Cidec 3.85 2.00E-04 -1.32 4.22E-01 2.91 3.70E-03 
Fmo3 4.22 2.19E-07 -1.60 6.74E-02 2.63 4.11E-04 
B430212C06Rik 4.41 4.85E-07 1.09 7.62E-01 4.78 2.95E-07 
Cidea 5.08 2.57E-05 1.39 3.73E-01 7.04 1.52E-06 
Cyp2b13 9.81 1.16E-10 1.06 8.48E-01 10.41 1.45E-10 
 
Supplementary Table S1. (Continued)
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Supplementary Table S2. Upstream regulators of the 148 MF-consistent genes with a 
p-value of overlap <0.001 and an activation score >2.00 or repression score <-2.00
Supplementary Table S3. Composition of the experimental diet. The CR diet was adjusted for the 
vitamins and minerals amount to ensure a homologous intake between both groups.
Upstream 
Regulator 
Exp. 
Fold 
Change 
Molecule Type Predicted 
Activation 
State 
Activation 
z-score 
p-value of 
overlap 
PXR   ligand-dependent 
nuclear receptor 
Activated 3.20 2.28E-13 
Ncoa-PXR-Rxra   complex Activated 2.00 4.50E-06 
PXR ligand-PXR-
Retinoic acid-RXRα 
  complex Activated 2.20 4.58E-06 
MED13   transcription 
regulator 
Inhibited -2.00 8.38E-06 
NFE2L2   transcription 
regulator 
Activated 2.80 2.83E-05 
PPARG 1.76 ligand-dependent 
nuclear receptor 
Activated 2.60 4.00E-04 
mir-223   microRNA Activated 2.00 9.24E-04 
 
 AIN-93W AIN-93W-CR AIN-93W-MF 
Energy (kcal/g) 3.85 3.77 4.25 
Energy from fat (%) 9 10 25 
Energy from protein (%) 15 15 13 
Energy from carbohydrates (%) 76 75 61 
Mineral mix AIN-93M (g%) 35 50 35 
Vitamin mix AIN-93M (g%) 10 14 10 
Choline bitartrate (g%) 2.5 3.5 2.5 
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SUPPLEMENTARY FIGURES
Supplemental Figure S1. Comparison of the phenotypic and biochemical features of the C, MF, INT and CR-exposed 
animals. (A) Food intake for ±20 mice per intervention group were measured during one week. For the INT and the 
MF/INT groups food intake during the ad libitum MF week and during 40E% CR week are presented. (B) Actogram 
presenting the  mean daily activity of mice from the different intervention groups recorded during 3 consecutive days. 
(C) Plasma insulin, Resistin and PAI-1 levels were measured using a Mouse Adipokine (MADKMAG-71K), according 
to the manufacturer’s instructions. (D) Weight of the indicated organs was measured when the mice were sacrificed.
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Supplemental Figure S2. Liver histology. (A) Formalin-fixed and paraffin-embedded cross-sections (5µm) of the 
liver lobe was stained with haematoxylin and eosin (H&E). The results of 4 representative examples of the different 
intervention groups show hepatic steatosis in mice of the C and MF groups and also, but to a lesser extent, in the 
INT-exposed mice. No lipid accumulation was detected in the life-long CR-exposed animals. (B) Samples were scored 
blindly by a board-certified pathologist using an adapted grading method for human NASH (Liang et al. 2014). Briefly, a 
H&E stained liver cross-section per mouse was examined and the level of steatosis was determined relative to the total 
liver area analysed (expressed as a percentage).
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Supplemental Figure S3. (A) Schematic overview of the different gene groups revealing full (1510 genes) or partial 
(1157) adaptation to the INT diet and a subset of 148 genes of which the expression levels remained similar to the 
life-long exposed MF mice. (B) 8 examples of mice representing the 148 irreversible genes. (C) 8 examples of genes 
representing the 1510 adaptable genes.  
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ABSTRACT 
Calorie restriction (CR) is a dietary regimen that supports healthy aging. In this study we 
investigated the systemic and liver-specific responses caused by a diet switch to a medium-fat (MF) 
diet in 24-month-old life-long, CR-exposed mice. Nine-week-old C57BL/6J mice were exposed 
either to a control, CR or MF diet. At the age of 24 months, a subset of mice of the CR group was 
transferred to ad libitum MF feeding (CR-MF). The mice were sacrificed at the age of 28 months, then 
biochemical and molecular analyses were performed. Our results showed that, despite the long-
term exposure to CR regimen, mice in the CR-MF group displayed hyperphagia, rapid weight gain, 
and hepatic steatosis. However, no hepatic fibrosis/injury or alteration in CR-improved survival was 
observed in the diet switch group. The liver transcriptomic profile of CR-MF group largely shifted to 
a profile similar to the MF-fed animals but leaving ~22% of the 1578 differentially regulated genes 
between the CR and MF diet groups comparable with the expression of the life-long CR group. 
Therefore, although the diet switch was performed at an old age, the CR-MF-exposed mice showed 
plasticity in coping with the challenge of a MF diet without developing severe liver pathologies.
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INTRODUCTION 
Aging has been described as an important risk factor for most chronic diseases, largely due 
to the impaired capacity to maintain homeostasis and resilience against environmental stress or 
damage at old age. For the liver, aging has been associated with an increasing risk to develop non-
alcoholic fatty disease (NAFLD) [1-5]. NALFD covers a spectrum of liver diseases ranging from 
simple steatosis to non-alcoholic steatozhepatitis (NASH), fibrosis and cirrhosis. While hepatic 
steatosis is considered to be benign, NASH is the more severe condition that is characterized 
by inflammation and possibly, fibrosis. Aging has been linked to NAFLD development through 
a number of commonly shared molecular mechanisms associated with both the NAFLD/NASH 
development and hallmarks of aging, e.g. reactive oxygen species formation, DNA damage and 
hepatocyte senescence [6, 7]. Aging and NAFLD are also intertwined with the modern obesogenic 
environment. The prevalence of obesity has been shown to increase at older age [8]. Commonly 
observed consequences of obesity are elevated plasma insulin and free fatty acid levels. Due to 
these changes, free fatty acid uptake and triglyceride production in the liver increase, leading to 
the development of NAFLD [9]. 
Calorie restriction (CR), a diet regimen of reduced energy intake without malnutrition, has been 
shown in numerous animal studies as by far the most effective approach to extend lifespan and 
to prevent age-related and metabolic diseases [10-12]. Research on CR in humans has not been 
conclusive, but provides clues that beneficial metabolic adaptations observed in model species also 
occur in humans [13, 14]. The application of CR has been reported to be beneficial for liver health, by 
improving insulin sensitivity and reducing triglyceride accumulation in the liver [15-19]. 
The beneficial effects of CR are known to be induced immediately after the start of the 
application [20-23]. However, data concerning the response of long-term calorie-restricted 
subjects to ad libitum feeding, in particular the liver-specific responses at metabolic and 
transcriptomic level, are still limited. Among the few mice studies investigating the reversibility 
of CR-induced changes [20, 24-27], there are only two studies investigating the CR effects on 
liver physiology and transcriptome. Giller and co-workers showed that the effects of 6-month CR 
completely diminish within 2 weeks of control diet feeding in C57BL/6JRj mice [27]. Furthermore, 
Dhahbi and colleagues reported that in 34-month-old B6C3F1 mice exposed to a CR diet for 21 
months, 90% of the CR-induced changes in gene expression in the liver disappear within 8 week 
of control diet feeding [20]. 
In the present study we exposed C57BL/6J mice to 30E% CR from young (9 weeks) till old (24 
month) age. Between 24 and 28 months of age we exposed a subset of mice in the CR group to an 
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ad libitum medium-fat (MF) diet, thereby generating a CR-MF diet switch group. In the sacrificed 
28-month old mice, we investigated the systemic and liver-specific responses to the diet switch at 
a physiological, metabolic and molecular level. In our study we explored both the plasticity of the 
mice at old age and the persistency of the effects caused by a life-long CR diet.
RESULTS 
Switching from a CR to MF diet at old age caused increasing body 
adiposity without affecting survival 
Nine-week-old C57BL/6J mice were randomly divided over 3 intervention groups and exposed to 
a control (C), calorie restriction (CR) or medium-fat (MF) diet. At the age of 24 months we replaced the 
diet of a subset of the CR intervention group by ad libitum exposure to the MF diet (CR-MF diet switch) 
(Fig. 1A). All mice were sacrificed at the age of 28 months. Figure 1B shows that, at the time point of 
the diet switch, the body weights of the C and MF-exposed mice were substantially higher than that of 
the CR-exposed mice. Following the transfer to the MF diet, the body weight of the CR mice dramatically 
increased (Fig. 1B), reaching a new plateau at 27 months of age. At the moment of sacrifice, the body 
weight of the CR-MF diet switch group was significantly higher than that of the life-long CR-fed mice, 
comparable to that of the C group, but still significantly lower than that of the MF-exposed mice. 
Food intake was recorded bi-monthly and revealed that, transferring mice from the CR intervention 
group to ad libitum MF feeding, resulted in severe hyperphagia. Food intake of the CR-MF group at the 
age of 26 months was even slightly higher than that of the life-long MF intervention group (Fig. 1C). 
However, at the age of 28 months, when the body weight gain was stabilized at a new plateau, food 
intake of the CR-MF mice decreased to similar amounts as consumed by the C intervention group. 
Weight measurement of the epididymal white adipose tissue (eWAT) and liver revealed 
significant increases in the CR-MF group compared with the life-long CR-exposed mice (Fig. 1D). 
However, after normalization to body weight, a significant increase was observed in the CR-MF group 
only in relative eWAT weight, while no significant difference was found for the relative liver weight 
(Fig. 1E). In accordance with the eWAT weight, the plasma levels of leptin, one of the regulators of 
energy intake and fat storage secreted by adipose tissue, were found to be significantly higher in 
the CR-MF compared to the CR group (Fig. 1F). Correlation analysis revealed a significant positive 
correlation between eWAT weight and plasma leptin level (Fig. 1G; r = 0.7003, p <0.0001). 
Since CR is known to protect against aging-related low grade systemic inflammation, which 
is also called inflammaging [28], a panel of 16 inflammatory markers, including interferon gamma 
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(IFNγ), tumor necrosis factor (TNF), interleukin-1α (IL-1α ), IL-1β, IL-2, IL-6, IL-7, IL-10, IL-15, 
chemokine (C-C motif) ligand 2 (CCL2 or MCP1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), 
chemokine (C-X-C) motif ligand 1 (CXCL1 or KC), CXCL9 (MIG) and CXCL10 (IP-10), was measured 
in plasma to characterize the inflammation status following the exposure to MF diet. The PCA plot 
presented in Figure 1H revealed that the plasma inflammatory profile of the CR-MF switched 
animals had shifted into the direction of the C-fed mice.
The survival rate recorded between 24 and 28 months revealed that mortality of the CR-MF 
diet switch group was equivalent to the life-long CR-exposed mice and strongly different from the 
C and MF intervention groups (Fig. 1I). Therefore, despite the changes in whole body adiposity, 
the improved survival gained in the CR period was successfully maintained during the four months 
exposure to the MF diet.
Figure 1. Physiological changes during the CR-MF diet switch. (A) Experimental design. (B) Body weight 
development from 24 to 28 month of age following the diet switch. (C) Food intake measurement at 24, 26 and 28 
month. (D) eWAT and liver weight. (E) Relative weight of eWAT and liver to the body weight. (F) Plasma leptin. Statistical 
significance was assessed by 1-way ANOVA followed by Tukey post-test analysis. (G) Correlation between eWAT weight 
and plasma leptin level, analyzed by applying Pearson’s correlation. (H) PCA of 16 plasma inflammatory cytokines. 
(I) Kaplan-Meier survival curve, statistical difference was assessed by log rank analysis. Error bars reflect standard 
deviation (SD). *p <0.05; **p <0.01; ***p <0.001.
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The liver transcriptome of the CR-MF diet switch mice strongly 
shifted to the MF profile 
To investigate the diet switch effect on the liver transcriptome of the animals in the CR-MF diet 
group, a microarray analysis was performed. A principal component analysis (PCA) was carried 
out, using the C diet group as the reference. The results presented in Figure 2A show a remarkable 
shift in the transcriptome profile of the CR-MF diet switch group from the CR towards the MF-
exposed mice. Notably, the inter-individual variability in the MF diet group and in particular the 
CR-MF group, was much higher than in the CR group. 
Although a pronounced switch in the transcriptomic profile of the CR-MF-exposed animals 
from the life-long CR group was detected, the diet switch did not result in a complete overlap 
with the expression profile of the MF-exposed group. To investigate which genes in the CR-MF 
expression profile remained similarly expressed with that of the life-long CR-exposed mice, we 
applied the following gene screening (see Fig. 2B). We first identified the differentially expressed 
genes between the life-long CR and MF groups (p<0.01), which resulted in a list of 1578 genes. Then, 
to determine which of these 1578 genes remained comparable to the CR-exposed mice after the 
CR-MF switch and significantly different to those of the MF diet group, we screened for the genes 1) 
displaying no differential expression between the CR-MF and CR groups (p≥0.05) and 2) displaying 
significant (p<0.01) difference in expression between the CR-MF and MF intervention groups. The 
direction of the fold change was also checked to confirm that the CR-MF and CR groups show the 
same direction of change in comparison to the MF group. A subset of 354 “CR- associated genes” 
were identified, exhibiting similar expression in the CR and CR-MF groups. Figure 2C visualizes the 
expression levels of the 354 CR-associated genes in the individual CR-, CR-MF- and MF-exposed 
mice. Overall, we showed that, following the CR-MF diet switch, 354 genes remained similarly 
expressed with the life-long CR exposed mice (~22% of the 1578 genes), while the majority (~78% 
of the 1578 genes) adapted to the MF expression profile. 
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Figure 2. Liver transcriptomic profile of the CR-MF diet switch largely altered toward the direction of the 
life-long MF diet group. (A) PCA plot for individual animals showing the CR-MF animals shifted to the cluster of 
MF diet group. (B) Analysis scheme for investigating the status of the CR-differentially expressed genes after CR-MF 
diet switch. A smaller proportion of differentially expressed genes remained similar to the expression of the life-long 
CR, while most of the genes shifted towards the profile of MF’s. (C) Heatmap comparing the expression of 354 CR-
associated genes in the CR, CR-MF and MF diet groups. (D) The fraction of the CR-associated and not CR-associated 
genes in the top 10 differentially regulated pathways between the life-long CR and MF diet groups. 
Functional characterization of the CR-associated genes in the liver
Ingenuity Pathway Analysis (IPA) was applied to explore which canonical pathways were 
represented by the 1578 genes displaying differential expression between the CR and MF intervention 
groups. The 10 most significantly different canonical pathways listed in Supplementary Table S1 
revealed highly significant regulation of various pathways commonly acknowledged to be affected 
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by CR, including mitochondrial dysfunction, oxidative phosphorylation and apoptosis signaling. 
Next, we assigned the gene members in each pathway as a CR-associated or MF-adapted gene, 
according to the above explained criteria. The results presented in Figure 2D show that the 
pathways containing a relative high percentage of CR-associated genes were found to be related to 
disease progression, e.g. sphingosine-1-phosphate signaling, apoptosis, hepatic fibrosis / hepatic 
stellate cell activation. Meanwhile, oxidative phosphorylation and mitochondrial dysfunction, both 
of which are pathways related to energy utilization, only contained a small fraction of the CR-
associated genes (4% and 6%, respectively). This suggests that, following the CR-MF diet switch, 
pathways related to energy utilization largely adapted to the expression profile of the MF diet group. 
In addition, these results suggest that the CR-associated genes in the CR-MF diet switch group 
are not confined to a specific pathway. We extended the analysis to CR-regulated key metabolic 
pathways, which are known to be energy/nutrient sensing-dependent [29]. PCA performed on 
AMPK, PI3K/AKT and insulin-IGF (Supplementary Fig. S1) signaling’s gene sets revealed that the 
expression profile of the CR-MF diet switch mice again strongly shifted from the CR profile toward 
the life-long MF cluster. 
Identification of upstream regulators of the CR-associated genes in 
the liver
Next, by applying IPA, we searched for predicted upstream regulators of the 354 CR-associated 
genes. The results presented in Table 1 show the top 10 predicted up-stream regulators revealing 
highly significant p-values (10-10-10-3). We observed that the regulators related to hepatic fibrosis 
including transforming growth factor β1 (Tgf-β1), interleukin-1β (IL1β) and hypoxia-inducible factor 
1-α (HIF-1α) were inhibited (activation z-score < -2.000). Two of these regulators, IL1β and HIF-
1α, are also related to inflammation. Furthermore, Acyl-CoA oxidase 1 (Acox1), which has been 
previously linked to NAFLD for its role in lipid metabolism [30], was predicted to be activated. Acox1 
activity represents fat oxidation, which helps to prevent the accumulation of fat in the liver. 
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Table 1. Upstream regulators of the 354 CR-associated genes
Development of hepatic steatosis, but no hepatic fibrosis/injury, in 
the CR-MF diet switch group
Next we explored the CR-MF diet switch effect on NAFLD development in more detail. 
Measurement of plasma markers revealed that the plasma insulin levels increased in the CR-MF 
mice in response to the diet switch, but did not reach the levels of the life-long MF-exposed animals 
(Fig. 3A). The plasma alanine transaminase (ALT) level, a marker for liver injury, was markedly 
elevated only in the life-long MF diet group but not in any of the other intervention groups (Fig. 
3B). The measurement of hepatic steatosis, which is represented by intrahepatic triglyceride (IHTG) 
content, revealed that after the diet switch the level of fat accumulation in the liver of the CR-MF 
diet group significantly increased to a level comparable to the life-long MF-exposed mice (Fig. 3C). 
The measurement of liver hydroxyproline content, a marker for hepatic fibrosis, showed elevated 
levels in the life-long MF-exposed animals, but not in the CR-MF group (Fig. 3D). To summarize, 
the 4 months exposure to MF diet resulted in elevated insulin and IHTG levels, but did not induce the 
progression of NALFD to liver fibrosis and injury.
Top 10 upstream 
regulator 
Target genes 
(n) 
Predicted 
activation 
state 
Activation      
z-score 
p-value 
ACOX1 17 Activated 3.153 1.32 x 10-10 
TGFB1 59 Inhibited -3.581 1.40 x 10-9 
AHR 19 Activated 2.523 1.04 x 10-6 
IL1B 32 Inhibited -2.774 3.82 x 10-6 
COMMD1 5 Activated 2.236 1.56 x 10-5 
Alpha catenin 10 Activated 2.618 1.94 x 10-5 
BTNL2 8 Inhibited -2.121 2.61 x 10-5 
HIF1A 16 Inhibited -2.140 2.04 x 10-4 
ERK 11 Inhibited -2.121 9.71 x 10-4 
CD44 9 Inhibited -2.449 1.06 x 10-3 
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Figure 3. The CR-MF diet switch group demonstrated elevated insulin and IHTG levels, but comparable plasma ALT 
and liver hydroxyproline compared to the CR group. (A) Fasting plasma insulin level. (B) Plasma ALT. (C) Intrahepatic 
triglyceride (IHTG) content. (D) Liver hydroxyproline content. Statistical significance was assessed by 1-way ANOVA followed 
by Tukey post-test analysis. Error bars reflect SD. *p <0.05; **p <0.01; ***p <0.001.
CR-MF diet switch shifted plasma N-glycomics profile without 
altering the gene expression level of Fut8, one of the major 
glycosyltransferases
Previous studies have shown that plasma N-glycosylation profiles are associated with 
chronic liver diseases [31]. The results presented in Figure 4A show that all three major N-glycan 
structures previously identified [32], bigalactosylated, biantennary glycan (NA2), agalactosylated, 
core-α-1,6-fucosylated biantennary glycan (NGA2F) and bigalactosylated, core-α-1,6-fucosylated 
biantennary glycan (NA2F), were significantly different between the life-long CR and MF diet groups. 
The levels of NA2, NGA2F and NA2F in the CR-MF diet group were in between those of the CR- and 
MF-fed animals, but did not differ significantly from either of the two intervention groups. Previous 
research has shown that expression and activity of α-1,6-fucosyltransferase (Fut8) in the liver was 
strongly associated with the plasma profiles of the three N-glycan structures (27). In our study, Fut8 
expression differed significantly between CR and MF-exposed mice (Fig. 4B). However, Fut8 was 
one of the 354 CR-associated genes of which the expression did not alter in response to the diet 
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switch. Interestingly, expression of another N-glycan processing enzyme called ST8 α-N-acetyl-
neuraminide α-2,8-sialyltransferase 4 (St8sia4) also differed significantly between CR and MF-
exposed mice, but expression of this gene was also affected in the CR-MF diet switch group (Fig. 
4C). It can be speculated that the increased expression of other N-glycan modifying factors, such 
as St8sia4 might be responsible for the increased glycosylation in the CR-MF diet switch group. 
Thus, despite that in the CR-MF group the hepatic expression of modifying enzyme Fut8 did not 
alter, a slight shift in the plasma N-glycomics profile in the plasma was detected after the 4 months 
exposure to MF diet. St8sia4 might be responsible for the plasma glycosylation shift. 
Figure 4. Plasma N-glycosylation profile and expression levels of glycosylation modifying genes Fut8 and 
St8sia4. (A) Plasma levels of three N-glycans, NGA2F (peak 1), NA2 (peak 5), and NA2F (peak 6) had shifted following 
the CR-MF diet switch. Statistical significance was assessed by 1-way ANOVA followed by Tukey post-test analysis. (B) 
The expression levels of CR-associated gene Fut8 in the CR-MF diet switch group remained similar to those of CR and 
significantly differed from the expression levels of MF’s. (C) Following the diet switch, gene expression levels of St8sia4 
in the CR-MF group increased. Statistical difference for the gene expression data was determined by intensity-based 
moderated t-statistic (IBMT) p-value. Error bars denote 5 and 95 percentiles. *p <0.05; **p <0.01; ***p <0.001.  
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The discrepancy between physiological feature and related gene 
expression level following the CR-MF diet switch was also found for 
hepatic steatosis development and Cd36 expression 
In addition to the Fut8 liver expression and plasma glycosylation profile, the lipid metabolism 
gene expression in the CR-MF diet switch group also did not follow the anticipated patterns. While 
IHTG levels were significantly increased in the CR-MF diet switch group, cluster of differentiation 
36 (Cd36), a key fatty acid transporter in the development of hepatic steatosis [33, 34], did not 
follow the same pattern. Cd36 displayed significantly different expression between the CR and MF 
intervention groups but its expression did not adapt to the MF diet after the diet switch (Fig. 5A). 
Also for this gene we could identify an alternative for fatty acid uptake, caveolin 1 (Cav1), which has 
been reported as contributors to fatty acid uptake [35]. Indeed, we found that the expression level of 
Cav1 was elevated in the CR-MF diet group (Fig. 5B), implying that, while the Cd36 expression was 
repressed, there was an alternative for fatty acid uptake.
Differentially methylated enhancer region was found in the intergenic 
region adjacent to Cd36
Since Cd36 plays an important role in the development of NAFLD, the mechanism behind 
its gene repression in the CR-MF diet switch is of biological interest. A possible mechanism 
underlying the Cd36 repression is by altering the DNA methylation of regions of the gene involved 
in transcription regulation. To explore this possibility, we analyzed the DNA methylation level of a 
promoter and enhancer region of Cd36. Promoter and weak enhancer regions were obtained from 
the mouse ChromHMM track [36, 37] and identified to be present in the gene body and a distant 
upstream region, respectively (Fig. 5C; for detailed chromosomal position refer to Supplementary 
Fig. S2). As shown in Figure 5D, we did not find a significant difference for the methylation level 
in the promoter region. However, the methylation levels of all 4 CpG sites analyzed in the enhancer 
region were significantly higher in the MF diet group compared to the levels in CR group (Fig. 5E). 
Interestingly, although the methylation levels of CR-MF diet switch group were slightly increased 
compared to the life-long CR mice, the methylation percentage of each of the CpGs was markedly 
lower compared to the life-long MF-exposed animals. 
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Figure 5.  The gene expression levels of fatty acid uptake-related genes Cd36 and Cav1, and DNA methylation 
levels of Cd36. (A) The gene expression levels of CR-associated gene Cd36. (B) The gene expression levels of Cav1. 
Statistical significance of the gene expression data was determined by IBMT p-value. (C) The location of promoter 
and enhancer region upstream of Cd36. Error bars denote 5 and 95 percentiles. (D) DNA methylation levels of CR, 
CR-MF and MF in the promoter region. (E) DNA methylation levels in the intergenic enhancer region. Differences on 
methylation levels were analyzed by using two-way ANOVA followed by post-hoc Bonferroni test. Error bars represent 
SD. *p <0.05; **p <0.01; ***p <0.001.  
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DISCUSSION 
In this study we aimed to investigate the systemic and liver-specific responses of 24-month-
old, life-long CR-exposed mice to 4 months of MF intervention. Our data revealed that in the diet 
switch group most of the CR-related features shifted to the MF profile: 1) whole body adiposity, 
2) hepatic steatosis, 3) global transcriptome and 4) CR-specific molecular features including IGF-
1/insulin signaling, oxidative phosphorylation and AMPK signaling. These results show that the 
CR-MF-exposed animals have great plasticity in coping with the challenge of the MF diet. We also 
show that a number of CR-related features was maintained in the CR-MF group: 1) the prevention 
of hepatic fibrosis and injury, 2) the improved survival and 3) the expression levels of a subset of 
CR-related genes that were not altered by 4 months exposure to the MF diet.
Even after a long-term exposure to the CR diet until an old age of 24 months, the mice were 
not adapted to the low energy intake and displayed extreme hyperphagia. The life-long CR-exposed 
mice in our ageing cohort demonstrated their anticipation to receiving their daily food allotment 
by a burst in their activity level just prior to the regularly scheduled feeding [38]. The hyperphagic 
response is an indicator that hunger persists even after a long-term CR [39] and is maintained 
until body weight reaches the level of the ad libitum-fed animals [25]. Subsequently, hyperphagia 
is followed by a dramatic weight gain, adipose tissue expansion and hepatic steatosis. Metabolism 
has a thrifty “catch-up fat” characteristic, in which metabolic processes have evolved to be efficient 
in storing excessive energy once an energy supply is available [40]. Our experiment indicates that a 
life-long application of the CR regimen is not able to acclimatize the mice to low energy intake and 
to resist the thriftiness, when the food availability is no longer restricted. 
Following the CR-MF diet switch, the beneficial effects of a CR diet on the liver transcriptomic 
profile changed dramatically, confirming the results of previous investigations [20, 27]. This could be 
explained by the dependence of a number of CR-mediated pathways (e.g. oxidative phosphorylation, 
AMPK signaling) on energy depletion/stress [41, 42]. Despite the pronounced alteration of the 
transcriptomic profile, in our study we found a set of 354 CR-associated genes, which expression 
remained to be comparable with the expression levels of the life-long CR intervention group. This 
finding differs from the results of other studies [20, 27]. Possible explanations for this difference 
include the experimental settings, such as the varying length of exposure to CR, severity of calorie 
reduction, diet type, mouse strain, and age at observation. 
One of the most intriguing findings in the current study emerged when we investigated to what 
extent the CR-associated genes are linked to their related phenotypes. Previous studies on Fut8 
hepatic expression and plasma glycosylation profile shows the modulation of Fut8 expression and 
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NGA2F, NA2 and NA2F plasma levels during aging and chronic liver diseases [31, 32]. Expression of 
this gene did not alter during the 4 months exposure to MF diet, but a slight shift in the fucosylated 
N-glycan levels, NGA2F and NA2F, in the plasma was observed. We hypothesized that St8sia4, 
which is also involved in N-glycan processing, might be responsible for the increased glycosylation 
in the CR-MF diet switch group. Another possibility is the presence of other fucosyltransferases, 
such as Fut2 and Fut3 in the gut [43], which leads to plasma glycosylation profile modification by 
multiple tissues.
Another intriguing discrepancy in gene expression and physiological outcome is the 
hepatic expression of Cd36, a fatty acid transport gene the overexpression of which increases 
susceptibility to accumulate liver fat [34, 44]. The deletion of this gene has previously been shown 
to cause resistance to diet-induced hepatic steatosis [45]. In our study we found that, despite of 
the development of hepatic steatosis, the expression of Cd36 in the CR-MF group remains low, 
comparable to the expression levels in the life-long CR diet group. The role of fatty acid transport 
was seemingly compensated by an increased expression of Cav1. This demonstrates that, after life-
long exposure to a CR diet, the system is still plastic and can adapt to a MF diet, but that alternative 
genes might be used when a certain function needs to be carried out. 
Furthermore, we found that the methylation status of the far upstream enhancer (~40 kbp 
from the transcription start site), but not of the promoter region of the Cd36 was affected by the 
MF diet. Although this observation implies that changes in DNA methylation might be responsible 
for the altered expression levels of the Cd36 our results remain inconclusive. First of all, the 
methylation levels of the CR-MF diet switch group are in between those of the CR and MF groups, 
while the expression levels remain similar to those of the life-long CR-exposed mice. Secondly, 
in the MF intervention group both gene expression and methylation levels of the enhancer region 
of Cd36 were significantly increased, compared to the CR-fed mice.  Decreased CD36 expression 
together with decreased DNA methylation has recently been shown in response to a hypocaloric 
diet-induced weight loss in female subjects [46]. Similar to what we observed, this study showed 
that gene expression and DNA methylation levels are positively associated, contrary to the current 
notion that increased methylation leads to transcription repression. However, the results presented 
in the study show differential methylation region close to the transcription start site, while in our 
study methylation of the enhancer was altered. Further studies are required to unravel the relation 
between gene expression and DNA methylation for the Cd36 gene.
To conclude, despite the long-term exposure to the CR regimen, the CR-MF diet switch group 
was not accustomed to this strict regimen and developed hyperphagia causing weight gain and 
hepatic steatosis. The liver transcriptomic profile of CR-MF group largely shifted to a profile similar 
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to the MF-fed animals, leaving only ~22% of the 1578 differentially regulated genes between the CR 
and MF diet groups comparable with the expression of the life-long CR group. As illustrated by the 
analysis of the expression of Cav1 and Cd36 expression and their relation with hepatic steatosis, 
the liver has a robust metabolic network that includes multiple regulators contributing its plasticity 
in coping with the challenge of MF diet. Therefore, although the diet switch was performed at an 
old age, the CR-MF-exposed mice showed plasticity in adapting to the MF diet without developing 
severe liver pathologies, which likely contributes to the maintenance of the CR-improved survival. 
87
4
MATERIAL AND METHODS
Ethics statement
The institutional and national guidelines for the care and use of animals were followed and the 
Local Committee for Care and Use of Laboratory Animals at Wageningen University approved the 
experiment (code number: drs-2010151b).
Animals and diets
Male C57BL/6J mice were purchased from Janvier (Cedex, France) at 7 weeks of age and allowed 
to acclimate for 2 weeks, receiving standard AIN-93G (Research Diet Services, Wijk bij Duurstede, 
The Netherlands) upon arrival. In the light and temperature (20oC)-controlled animal facility of 
Wageningen University (12-hour light/dark cycle, light on at 04.00), they were housed in pairs during 
the acclimatization period, but were individually housed after the dietary intervention started.
At the start of the diet intervention the mice were 9 weeks old and randomly distributed into three 
intervention groups: 1) Control diet receiving AIN-93W diet ad libitum  (n=89); 2) CR diet receiving 
AIN-93W-CR in portions containing 70E% of the mean energy intake of the group of the control mice 
were provided each day at 15.30 (n=117); 3) medium fat diet (MF) receiving AIN-93W-MF ad libitum 
(n=127). AIN-93W-CR contained increased concentration of vitamins and minerals content in order 
to feed these mice the same concentrations of micronutrients as the mice receiving AIN-93W diet 
and avoid malnutrition. Complete diet composition is listed in Supplementary Table S2 (Research 
Diet Services, Wijk bij Duurstede, The Netherlands). All mice were provided with ad libitum access 
to water. The long-term dietary invention was continued until a sacrifice at the age of 28 month, but 
in addition to the three diet groups, at 24 month the animals in the CR diet group were randomly 
assigned either to remain on the CR diet (n=30) or undergo a diet switch to the MF diet (n=32). This 
resulted in a group of 25-32 animals in each group at 24 month. Anticipating that the animals would 
not be used to ad libitum feeding after exposure to CR for a long term, the food intake was increased 
gradually, by addition of 10%E per week. Therefore, it took 3 weeks for the animals to be allowed 
to have MF ad libitum. Body weight of all mice was recorded weekly. Food intake of 20 mice of each 
intervention group was measured every two months. Portion sizes of the mice on the CR were based 
on the mean food intake of the C-exposed mice measured during a time span of 7 days. 
At the age of 28 months, 8-11 mice of each intervention group were sacrificed between 14.00 and 
17.00 on 3 consecutive weeks. Prior to sacrifice each mouse was first fasted for 4 hours after which 
they received an intragastric gavage of 0.5% carboxymethyl cellulose (CMC), then fasted again for 
another 6 hours. For the CR and CR-MF groups, there were additional 9 and 8 animals, respectively, 
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and they were treated with an addition of Wy-14643 substance in their 0.5% CMC intragastric gavage. 
Since Wy-14643 treatment gives an effect on gene expression level, these animals were not included 
in the transcriptomic analysis, but they were included in the phenotypical measurements. After 
sedation with a mixture of isoflurane (1.5%), nitrous oxide (70%) and oxygen (30%), blood samples 
were collected by cardiac puncture, then followed by neck dislocation. Weight of various organs was 
measured and subsequently snap-frozen and stored at -80oC until further molecular/biochemical 
analysis. 
Hepatic triglyceride and hydroxyproline content determination
Liver triglycerides were determined in 5% liver homogenates prepared in buffer containing 250 
mM sucrose, 1 mM EDTA, 10 mM Tris-HCl (pH 7.5), using the triglyceride Liquicolor Monoreagent 
(Instruchemie, Delfzijl, The Netherlands). Hydroxyproline analysis was performed as previously 
described in Hillebrandt et al. [47].  
Plasma measurement
Plasma concentration of ALT was measured with commercially available kits from Instruchemie 
(Delfzijl, the Netherlands). Plasma insulin, IL-6 and CCL2 levels were measured using a Mouse 
Adipokine (MADKMAG-71K) kit, while plasma IFNγ, TNF, IL-1α, IL-1β, IL-2, IL-7, IL-10, IL-15, 
CCL3, CCL4, CCL5, CXCL1, CXCL9 and CXCL10 from Mouse Cytokine (MCYTMAG-13K) kit (Millipore, 
Billerica, MA, USA), according to the manufacturer’s instructions. 
RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen, Breda, The Netherlands), according 
to manufacturer’s instructions. The RNA was treated with DNAse and purified on columns using 
the RNeasy microkit (Qiagen, Venlo, The Netherlands). RNA concentration was measured on a 
NanoDrop ND-1000 UV–vis spectrophotometer (Isogen, Maarsen, The Netherlands) and RNA 
integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies, Amsterdam, The 
Netherlands) with 6000 Nano Chips, according to manufacturer’s instructions. RNA was judged as 
suitable only if samples showed intact bands of 18S and 28S ribosomal RNA subunits, displayed no 
chromosomal peaks or RNA degradation products and had a RNA integrity number (RIN) above 8.0.
Microarray hybridization
Hybridization, washing and scanning of Affymetrix GeneChip Mouse Gene 1.1 ST arrays were 
performed according to standard Affymetrix protocols. Microarray analysis was performed in 
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MADMAX, a pipeline for statistical analysis of microarray data [48]. Arrays were normalized using 
the Robust Multiarray Average method [49, 50]. Probe sets were defined according to Dai et al. [51]. 
In this method probes are assigned to unique gene identifiers, in this case Entrez IDs. The probes 
on the Gene 1.1 ST arrays represent 21,225 Entrez IDs. For the analysis, only genes having 1) an 
inter-quartile range of >0.1 and 2) an intensity value of >20 on at least five arrays were taken into 
account, which resulted in 15,417 genes in the dataset. Array data will be submitted to the Gene 
Expression Omnibus. 
For the microarray data analysis, differentially expressed probe sets were identified by using 
linear models (library limma) and the intensity-based moderated t-statistic (IBMT) method was 
applied [52, 53]. Resulting log2 intensities and p-values were used for further descriptive bioinformatic 
analysis of the data. Heatmap and PCA plots were constructed by using MultiExperiment Viewer 
version 4.8.1 [54] and factomineR package in R, respectively. Pathway analysis was performed in 
Ingenuity Pathway Analysis (IPA; Ingenuity® Systems).
Plasma glycomics analysis
N-glycans on the plasma glycoproteins were analyzed by using DNA Sequencer-Aided, 
Fluorophore-Assisted Carbohydrate Electrophoresis (DSA-FACE) technology. The same DSA-FACE 
protocol used in [55, 56] for the analysis of the human plasma N-glycome was applied for the 
mouse plasma. Shortly, 2 μl of total plasma was incubated for 5 min at 95°C with 2 μl of 5% SDS 
in 10 mM NH4HCO3. The N-glycans on the plasma glycoproteins were enzymatically released with 
33 Units of PNG-ase F (New England Biolabs,Ipswich, MA, USA) in 3 μl of 3.33% NP-40 and 10 mM 
NH4HCO3, pH 8.3 and incubated for 3 h at 37°C. The released N-glycans were desialylated with 2 
mU of Neuraminidase of Arthrobacter ureafaciens (Roche Diagnostics GmbH, Mannheim, Germany) 
in 5mM NH4Ac, pH 5, incubating for 3 h at 37°C. Subsequently, 2 μl of the desialylated N-glycans 
in 5 μl of water were dried completely at 60°C for 1 h. After that, 2 μl of a labeling solution (1:1 
mixture of 20 mM of fluorophore 8-amino-1,3,6-pyrenetrisulfonic acid (APTS) (Life Technologies, 
Carlsbad, CA, USA) in 1.2 M citric acid and 1 M NaCNBH3 in DMSO) were added per sample and 
incubated overnight at 37°C. The reaction was stopped with 150 μl of water to each well. This 
solution was diluted 1:2.5 in water and 2 μl of this solution were added to 8 μl of D-Formammide 
for the sequencing analysis in a DNA-sequencer ABI-PRISM 3730xl (Applied Biosystem, Foster 
City, CA, USA). The electopherogram of the mouse plasma N-glycans profile contained several 
peaks that were structurally characterized by overlapping their migration positions with those 
previously measured in the human plasma profile. Five major glycan peaks had the same migration 
positions of the well-known human N-glycan structures (Supplementary Fig. S3), in particular, 
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peak 1 (NGA2F, an agalactosylated core-α-1,6-fucosylated, biantennary N-glycan), peak 3 
(NG1A2F, a mono-galactosylated core-α-1,6-fucosylated, biantennary N-glycan), peak 5 (NA2, a 
bigalactosylated, biantennary N-glycan), peak 6 (NA2F, a bigalactosylated, core-α-1,6-fucosylated 
biantennary N-glycan) and peak 9 (NA3, a triantennary, trigalactosylated N-glycan). The heights 
of these peaks, that represent the relative concentrations of the N-glycan structures, were 
quantified and normalized to the total signal intensity by using Peak Scanner software (Applied 
Biosystem,Foster City, CA, USA).
DNA isolation from the liver tissue
Genomic DNA was isolated from the liver by using the classical proteinase K digestion and 
phenol:chloroform extraction. The DNA was treated with RNase and eluted in RNase and DNase free 
distilled water. DNA purity and quantity were checked spectrophotometrically with NanoDrop ND-
1000 (NanoDrop Technologies, Wilmington, USA) and fluorometrically with Qubit DNA (Invitrogen, 
Oregon, USA). 
Bisulfite conversion and DNA methylation analysis
Bisulfite conversion and DNA methylation analysis by means of pyrosequencing were adapted 
from a previous study [57]. For each sample, 1000 ng of genomic DNA was bisulfite-treated using 
the EZ-96 DNA Methylation™ Kit (Zymo Research, Irvine, CA, USA) and eluted in 60 μl of TE. DNA 
methylation analysis was performed using PyroMark™ pyrosequencing technology (Biotage AB, 
Uppsala, Sweden). Primers were designed using PyroMark software, and the sequences of the 
primers used are listed in Supplementary Table S3. The PCR reactions were performed in a total 
volume of 45 μl, and the volume of bisulfite-treated genomic DNA used was 4 μl. PyroMark PCR 
Master Mix and CoralLoad Concentrate were used according to the manufacturer’s instructions, and 
0.2 μM of each primer (Qiagen, Venlo, The Netherlands) was used. The following thermal cycling 
conditions were applied: 15 min at 95°C, followed by 45 cycles of 94°C for 30 s, tempX (gene-
specific, see Supplementary Table S3) for 30 s, and 72°C for 40 s, followed by a final elongation 
step at 72°C for 10 min. The PCR product (35 μl) was bound to Streptavidin Sepharose HP beads (GE 
Healthcare, Uppsala, Sweden) and purified and made single-stranded using the Pyrosequencing 
Vacuum Prep Tool according to the manufacturer’s instructions (Qiagen, Venlo, The Netherlands). 
Sequencing primers (for sequences, see Supplementary Table S3) were annealed to the purified 
single-stranded PCR product, and pyrosequencing was performed using the Q24 Pyrosequencing 
System (Qiagen, Venlo, The Netherlands). CpG methylation was analyzed with the provided software.
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Statistical analysis 
Statistical analysis, except for the microarray gene expression data, were analyzed with 
GraphPad Prism 5.04. Differences between dietary interventions were analyzed using 1-way 
ANOVA followed by Tukey post-test analysis. The alteration of DNA methylation levels in a specific 
region was evaluated with two-way ANOVA followed by Bonferroni post-test analysis. Results 
represented in bar graphs are shown as means ± standard deviation. For results plotted in box-and-
whisker plots, the box extends from 25th to 75th percentiles with a line at median value, while the 
whiskers denote 5 and 95 percentiles. Points below and above the whiskers are drawn as individual 
dots. Pearson’s correlation was used to determine the relationship between variables. Statistical 
significance for the survival of groups was established by the log-rank analysis of Kaplan-Meier 
plots. 
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SUPPLEMENTARY TABLES
Supplementary Table S1. 10 most significantly different canonical pathways between the life-long 
CR and MF intervention groups
Supplementary Table S2. Composition of the experimental diet. The CR diet was adjusted for 
the vitamins and minerals amount to ensure a homologous intake between both groups.
Supplementary Table S3. Pyrosequencing primers details of Cd36 promoter and enhancer region
Top 10 canonical pathways CR vs MF p-value 
Mitochondrial dysfunction 9.56 x 10-9 
Oxidative phosphorylation 1.04 x 10-8 
Apoptosis signaling 3.25 x 10-7 
Production of NO and ROS in macrophages 2.75 x 10-5 
IL-4 signalling 3.12 x 10-5 
MSP-RON signalling pathway 3.72 x 10-5 
Rac signalling 5.82 x 10-5 
TNFR1 signalling 7.31 x 10-5  
Sphingosine-1-phosphate signalling 1.12 x 10-4 
Tumoricidal function of hepatic natural killer cells 1.14 x 10-4 
 
 AIN-93W AIN-93W-CR AIN-93W-MF 
Energy (kcal/g) 3.85 3.77 4.25 
Energy from fat (%) 9 10 25 
Energy from protein (%) 15 15 13 
Energy from carbohydrates (%) 76 75 61 
Mineral mix AIN-93M (g%) 35 50 35 
Vitamin mix AIN-93M (g%) 10 14 10 
Choline bitartrate (g%) 2.5 3.5 2.5 
 
Gene Chromosomal 
position 
Primer sequence (5‘ to 3’) Annealing 
temp (oC) 
Amplicon 
size (bp) 
Cd36 
promoter 
ch5:17341776-
17341855 
FP: AAGTTTATAAGGGTTTATTTTTGGTGAAG 
RP: ACTCCAACATCTAAAATAACAATTACAAT 
SP: GTTTTTATTTAAGTAAGTTAGAGG 
57.8 205  
Cd36 
enhancer 
ch5:17435129-
17435227 
FP: TTGTTGTGTTAGGGAAATATTAATGAT 
RP: ATAACTCCAACACCAACCACAATAA 
SP: AGGGTAGTTATTTTAGTTAAGTTAG 
58.6 265  
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SUPPLEMENTARY FIGURES
Supplementary Figure S1. PCA plots of gene sets revealing the shift of the gene expression profile following 
the CR-MF diet switch. (A) PCA of genes in the AMPK signalling. (B) PI3K/AKT signalling. (C) Insulin-IGF signalling. 
The expression values of all three dietary interventions were normalized to the C group.
Supplementary Figure S2. Chromosomal position of regions analysed for differential DNA methylation level 
within and upstream of Cd36 gene. Epigenetic features ChromHMM, H3K4me1 and H3K27ac were obtained from 
the mouse ENCODE database and visualized in integrative genomics viewer (IGV, Broad Institute). The red and yellow 
colors in ChromHMM track represent promoter and weak enhancer regions, respectively. The regions selected for DNA 
methylation analysis by pyrosequencing are marked with boxes. 
A B C
Refseq genes
H3K4me1
H3K27ac
ChromHMM
Cd36 promoter Cd36 enhancer
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Supplementary Figure S3. Comparison of glycan migration position in mouse and human samples. Five major 
glycan peaks had the same migration positions of the well-known human N-glycan structures, i.e. peak 1 (NGA2F, 
an agalactosylated core-α-1,6-fucosylated, biantennary N-glycan), peak 3 (NG1A2F, a mono-galactosylated core-
α-1,6-fucosylated, biantennary N-glycan), peak 5 (NA2, a bigalactosylated, biantennary N-glycan), peak 6 (NA2F, a 
bigalactosylated, core-α-1,6-fucosylated biantennary N-glycan) and peak 9 (NA3, a triantennary, trigalactosylated 
N-glycan).  
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Fibroblast growth factor 21 
reflects liver fat accumulation 
and dysregulation of signalling 
pathways in the liver 
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ABSTRACT 
Fibroblast growth factor 21 (Fgf21) has emerged as a potential plasma marker to diagnose 
non-alcoholic fatty liver disease (NAFLD). To study the molecular processes underlying the 
association of plasma Fgf21 with NAFLD, we explored the liver transcriptome data of a mild NAFLD 
model of aging C57BL/6J mice at 12, 24, and 28 months of age. The plasma Fgf21 level significantly 
correlated with intrahepatic triglyceride content. At the molecular level, elevated plasma Fgf21 
levels were associated with dysregulated metabolic and cancer-related pathways. The up-
regulated Fgf21 levels in NAFLD were implied to be a protective response against the NAFLD-
induced adverse effects, e.g. lipotoxicity, oxidative stress and endoplasmic reticulum stress. An 
in vivo PPARα challenge demonstrated the dysregulation of PPARα signalling in the presence of 
NAFLD, which resulted in a stochastically increasing hepatic expression of Fgf21. Notably, elevated 
plasma Fgf21 was associated with declining expression of Klb, Fgf21’s crucial co-receptor, which 
suggests a resistance to Fgf21. Therefore, although liver fat accumulation is a benign stage of 
NAFLD, the elevated plasma Fgf21 likely indicated vulnerability to metabolic stressors that may 
contribute towards progression to end-stage NAFLD. In conclusion, plasma levels of Fgf21 reflect 
liver fat accumulation and dysregulation of metabolic pathways in the liver.
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) has been recognised as a hepatic manifestation of 
metabolic syndrome. NAFLD covers a spectrum of liver injuries ranging from fat accumulation in the 
liver (steatosis) to the more severe condition of steatohepatitis (NASH). Considering that NAFLD is 
currently the most common liver disorder, prevalence of which has been reported to be 20-40% in the 
US [1, 2], the population would benefit from a diagnosis from the early stage of NAFLD. Intervention 
via as simple a method as weight management through diet and exercise is the most effective way 
leading to reduced liver fat, NASH remission, and also reduction of fibrosis [3]. However, at present 
a population-based screening tool for NAFLD is still lacking. Serum screening of liver enzymes and 
a liver ultrasound technique have been employed in screenings and clinical studies [4], but these 
procedures are, for different reasons, suboptimal. A number of studies have pointed out that the 
blood-screening test of the commonly analysed liver enzymes, including alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl-transpeptidase 
(γ-GT) and albumin, poorly diagnose NAFLD [5-8]. The ultrasound technique has better accuracy 
than the blood screening test, but is also suboptimal due to the low sensitivity of this method [9]. 
Magnetic resonance imaging and spectroscopy has a higher sensitivity, but this technique requires 
specific and expensive instruments, which limits its measurement availability. Diagnosis on liver 
biopsies is the most accurate way to determine the presence of NAFLD, but this procedure is highly 
invasive and not suitable for population-based screening. Hence, new accurate and non-invasive 
measures are required for the diagnosis of NAFLD.
Recently, fibroblast growth factor 21 (FGF21 (Fgf21 in mice)) has emerged as a potential 
diagnostic marker for NAFLD. Serum FGF21 is found to be elevated in NAFLD patients, as compared 
to healthy subjects, and correlates with hepatic fat content and the degree of liver steatosis [4, 10-
12]. Moreover, the performance of FGF21 has been examined in a 3-year prospective study in China 
and high serum FGF21 was found to be a determinant of NAFLD, showing an area under curve 
of receiver operating characteristic (AUROC) of 0.816 [13]. Serum FGF21 has also been reported 
to increase the accuracy of non-alcoholic steatohepatitis (NASH) diagnosis using cytokeratin-18 
fragment (CK-18) [14]. Therefore, plasma/serum FGF21 seems a promising diagnostic marker for 
an accurate and non-invasive diagnosis of NAFLD.
FGF21 has multiple metabolic functions, regulating energy homeostasis, glucose-lipid 
metabolism and insulin sensitivity [15]. However, it is currently unclear which metabolic functions 
of FGF21 underlie the association of plasma FGF21 level and NAFLD. In the present study, we aim 
to identify the putative molecular mechanisms that underlie the association of plasma FGF21 level 
with NAFLD. A complicating factor for a human study in this field is that the accurate assessment of 
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NAFLD would require liver biopsies from healthy subjects, which is ethically undesirable. Therefore, 
we employed a cohort of aging mice to investigate the association between NAFLD, which was 
determined by IHTG level, and plasma Fgf21. The use of a cohort of aging mice, which consists of four 
different age time points, enables us to investigate whether plasma Fgf21 can act as a biomarker at 
different age time points. NAFLD has been reported in subjects of all ages, but particularly in middle 
to old age (40-65 years old in human) [16], which indicates that NAFLD develops over many years. 
To create a mice cohort that simulates the slow onset of NAFLD, we included a medium-fat diet 
(MF; 25E% from fat) as a diet that induces the development of NAFLD. The energy contribution from 
fat in this diet group is considered mild, compared to other NAFLD-inducing dietary interventions 
that commonly acutely stimulate NAFLD pathologies within several weeks of feeding by applying 
a high-fat diet (45E% from fat) [17, 18]. In addition to the MF diet, we introduced a normal diet 
(10E% from fat) as the control (C) group and a calorie restriction diet (CR; 30E% reduced feeding 
compared to control group) as a diet regimen that prevents NAFLD. Then, we investigated whether 
the use of plasma Fgf21 as marker for NAFLD in our mice cohort is comparable to what has 
previously been reported for humans. We next searched for the biological processes underlying the 
association of plasma Fgf21 with NAFLD by performing microarray analysis on liver mRNA by using 
two approaches. First, we searched for pathways and upstream regulators associated with plasma 
Fgf21 by performing a gene co-expression network analysis using weighted gene co-expression 
network analysis (WGCNA) [19]. In the second approach, we investigated the major transcriptional 
difference in NAFLD by performing gene set enrichment analysis (GSEA), and then determining the 
relevance of Fgf21 in the NAFLD-related pathways. To further investigate PPARα signalling as one 
of the dysregulated pathways, we examined the PPARα response to its agonist at gene expression 
level. Since we found that some of the mice of 6 months of age displayed a high level of plasma 
Fgf21 in the absence of elevated IHTG levels, we also explored the microarray data to search for 
the functions of the genes associated with the elevated Fgf21 plasma level without accumulation 
of IHTG. 
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MATERIALS AND METHODS
Ethics statement
The animal experiment was approved by the Local Committee for Care and Use of Laboratory 
Animals at Wageningen University (code number: drs-2010151b) and performed in accordance with 
the institutional and national guidelines for the care and use of animals. 
Mice aging study 
The mice aging study was a part of the IDEAL mice aging cohort that has been described in 
detail previously [20, 21]. Briefly, male C57BL/6J mice (age of 7 weeks) were purchased from Janvier 
(Cedex, France) and were housed in pairs of two in the light and temperature (20oC)-controlled 
animal facility of Wageningen University (12-hour light/dark cycle, light on at 04.00). The mice were 
acclimated for 2 weeks, receiving standard AIN-93G (Research Diet Services, Wijk bij Duurstede, 
The Netherlands) upon arrival. All mice were provided with ad libitum access to water. The study 
design is presented in Supplementary Figure S1. The diet intervention started at the age of 9 
weeks. The mice were housed individually and randomly distributed into three intervention groups: 
1) control diet (C, 10E% fat, n=89) receiving AIN-93W diet ad libitum; 2) calorie restricted diet (CR, 
n=117) receiving AIN-93W-CR in portions containing 70E% of the mean energy intake compared to 
the mice on the control diet; 3) medium fat diet (MF, 25E% fat, n=127) receiving AIN-93W-MF ad 
libitum. AIN-93W-CR contains an increased concentration of vitamins and minerals in order to feed 
these mice the same concentrations of micronutrients as the mice receiving the AIN-93W diet and 
avoid malnutrition. Portion sizes for the mice on the CR were based on food intake of mice on the 
control diet and adjusted every 6 months. The rations were provided each day at 15.30, 30 minutes 
before the light was switched off. The complete diet compositions are listed in Supplementary 
Table S1 (Research Diet Services, Wijk bij Duurstede, The Netherlands). 
The mice were culled at the age of 6, 12, 24 and 28 months. At each sacrifice, 12-18 mice of 
each intervention group were sacrificed between 14.00-17.00 on consecutive days (the remaining 
mice stayed in the experiment and were evaluated at older ages). Mice were paired per dietary 
intervention group according to body weight at sacrifice, so that mock and Wy-14,643 (Wy) treatment 
were provided to mice with similar body weight. Prior to sacrifice each mouse was first fasted for 
4 hours, after which they received an intragastric gavage of either solvent (0.5% carboxymethyl 
cellulose) or Wy dispersed in solvent (160 mg Wy/kg body weight) and were fasted again for another 
6 hours. Body weight, liver weight, IHTG and 4-hydroxyproline were measured in both the mock- 
and Wy-treated animals. Plasma Fgf21 and liver microarray analysis were performed for mock-
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treated animals only, as Wy substance is a PPARα agonist potentially affecting Fgf21 expression. 
At the sacrifice, the mice were sedated with a mixture of isoflurane (1.5%) in nitrous oxide (70%) 
and oxygen (30%). Blood samples were collected by cardiac puncture, which was followed by neck 
dislocation. Weight of various organs was measured and, subsequently, organs/tissues were snap-
frozen and stored at -80oC until further molecular/biochemical analysis. 
Measurement of hepatic steatosis and fibrosis
Intrahepatic triglyceride (IHTG) content was determined in 5% liver homogenates prepared in buffer 
containing 250 mM sucrose, 1 mM EDTA, 10 mM Tris-HCl (pH 7.5), using the triglyceride Liquicolor 
Monoreagent (Instruchemie, Delfzijl, The Netherlands), according to manufacturer’s instruction. The IHTG 
level was applied as the diagnosis standard of NAFLD using the 5% or 50 mg TG per gram liver criterion 
from Kleiner’s scoring [22]. Liver fibrosis is represented by 4-hydroxyproline content measurement in 
the liver. The 4-hydroxyproline analysis was performed as previously described in Hillebrandt et al. [23]. 
Measurement of plasma Fgf21 level and other plasma markers
The plasma Fgf21 concentration was determined using Rat/Mouse FGF-21 ELISA kits 
(Milipore, cat #EZRMFGF21-26K), according to the manufacturer’s instructions. Plasma insulin was 
measured using a Mouse Adipokine (MADKMAG-71K) kit (Millipore, Billerica, MA, USA), according 
to the manufacturer’s instructions. The cytokeratin-18 plasma concentration was measured using 
Mouse Cytokeratin 18-M30 ELISA kit (Cusabio, Hubei, China).
RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen, Breda, The Netherlands), according 
to the manufacturer’s instructions. The RNA was treated with DNAse and purified on columns 
using the RNeasy microkit (Qiagen, Venlo, The Netherlands). RNA concentration was measured 
on a NanoDrop ND-1000 UV–vis spectrophotometer (Isogen, Maarsen, The Netherlands) and RNA 
integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies, Amsterdam, The 
Netherlands) with 6000 Nano Chips, according to the manufacturer’s instructions. RNA was judged 
as suitable only if samples showed intact bands of 18S and 28S ribosomal RNA subunits, displayed 
no chromosomal peaks or RNA degradation products and had a RNA integrity number (RIN) above 
8.0.
Microarray hybridization
Hybridization, washing and scanning of Affymetrix GeneChip Mouse Gene 1.1 ST arrays were 
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performed according to standard Affymetrix protocols as described previously [20, 24]. Microarray 
analysis was performed in MADMAX, a pipeline for statistical analysis of microarray data [25]. 
Arrays were normalized using the Robust Multiarray Average method [26, 27]. Probe sets were 
defined according to Dai et al. [28]. In this method probes are assigned to unique gene identifiers, 
in this case Entrez IDs. The probes on the Gene 1.1 ST arrays represent 21,225 Entrez IDs. For the 
analysis, only genes having 1) an inter-quartile range of >0.1 and 2) an intensity value of >20 on at 
least five arrays were taken into account, which resulted in 15,885 genes in the dataset. Array data 
have been submitted to the Gene Expression Omnibus, with accession number GSE84495.
cDNA synthesis and real-time quantitative PCR
The microarray data was validated by real-time quantitative PCR (Q-PCR). For each individual 
sample, single-stranded complementary DNA was synthesized from 1 μg of total RNA using the First 
Strand cDNA Synthesis kit (Thermo Scientific, Landsmeer, The Netherlands), following the supplier’s 
protocol. Q-PCR was performed using SensiMix SYBR No-ROX kit (Bioline, Alphen aan de Rijn, The 
Netherlands) and a CFX384 thermal cycler (Bio-Rad, Veenendaal, The Netherlands). The following 
thermal cycling conditions were used: 2 min at 94°C, followed by 40 cycles of 94°C for 15 s and 60°C 
for 45 s. PCR reactions to validate Fgf21 expression were performed in duplicate and all samples 
were normalized to Rplp0 expression. Primer sequences were retrieved from the online PrimerBank 
database [29] and the sequences of the primers used are listed in Supplementary Table S2. 
Statistical analysis 
Data were analysed with GraphPad Prism 5.04. The data was expressed as mean ± standard 
error mean. Comparison between two groups was performed using student t-test, whereas 
comparison between 3 or more groups was performed using ANOVA. Correlation between two 
parameters was presented as Pearson correlation coefficient (r) and p-value. A p-value of <0.05 
was considered significant. The receiver operating characteristic (ROC) curve analysis was carried 
out and the area under the ROC curves (AUROCs) were calculated to represent their performance 
to predict NAFLD. Optimal cut-off points were calculated for sensitivity and specificity reference 
(Youden Index).  
Hepatic transcriptomics data analysis
For the microarray data analysis, differentially expressed probe sets were identified by 
using linear models (library limma) and the intensity-based moderated t-statistic (IBMT) method 
was applied [30, 31]. Resulting log2 intensities and p-values were used for further descriptive 
106
5
Fgf21  ref lects  l i ver  fat  accumulat ion  and  dysregulat ion  of  s ignal l ing  pathways  in  the  l i ver
bioinformatic analysis of the data. Gene set enrichment analysis (GSEA; http://www.broad.mit.edu/
gsea/) was performed in MADMAX. Gene sets with a false discovery rate (FDR) q-value of <0.01 
were considered significantly enriched. 
Gene co-expression networks (modules) were constructed using the blockwiseModules 
R function in Weighted Gene Co-expression Network Analysis (WGCNA) [19]. WGCNA uses a 
network distance coupled with hierarchical clustering and dynamic tree cutting to define modules 
as branches of a cluster tree. Gene modules, which summarize the main patterns of variation, are 
defined in an unbiased fashion and denoted by colors. The first principal component represents the 
summary of the module and is referred to as the module eigengene (ME). MEs were then related 
to plasma Fgf21 level and other NAFLD-related traits. This approach avoids the multiple testing 
from thousands of individual transcripts to only a number of modules. To explore the functional 
pathways and predicted upstream regulators of the gene modules, Ingenuity pathway analysis (IPA; 
Ingenuity® Systems) was used.
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RESULTS 
Control and medium-fat diet groups developed NAFLD at middle and 
old age
The dietary interventions exerted pronounced effects on the mice’s body and liver weight, as 
shown in Figure 1A and B, respectively. During aging, the MF-exposed animals gained the highest 
body and liver weight, while the CR-fed animals were the leanest. The weight gain was accompanied 
by an increase in IHTG content (Fig. 1C). While the CR-fed animals only showed a modest increase 
over time, the C- and MF-fed animals displayed an elevated IHTG level starting at middle-age, i.e. at 
12 months. Liver fibrosis, which was represented by the measurement of 4-hydroxyproline (4-HP) 
content in the liver (Fig. 1D), showed to increase at old age (24 and 28 month) in the MF diet group. 
The IHTG level was applied as the diagnosis standard of hepatic steatosis using the 5% or 
50 mg TG per gram liver criterion from Kleiner’s scoring [22]. The prevalence of hepatic steatosis 
development in the cohort is depicted in Figure 1E. At the age of 6 months, none of the mice in any 
of the diet groups developed hepatic steatosis, indicating a healthy liver condition at young/mature 
adult age. Hepatic steatosis development became visible in 12-month old mice exposed to C and 
MF diets, reaching up to 85.7% in the MF diet group. At the 24-month time point, the prevalence 
of hepatic steatosis increased considerably in the control group. At this age over 80% in the C and 
MF diet groups displayed steatosis (Fig. 1E) but at the age of 28 months, a slight decrease of 
prevalence was observed.
Since a criterion of 4-HP level for hepatic fibrosis diagnosis has not been clearly defined, we 
adapted the level of 4-HP that was reported by Fuchs et al. to be associated with extensive portal 
fibrosis (equivalent with Ishak fibrosis scoring stage 2-3) [32]. A level of >0.200 μg of 4-HP per mg 
liver was applied as an indication of liver fibrosis. Increasing prevalence of hepatic fibrosis was 
only pronounced in the MF intervention group at 24 and 28 months of age (Fig. 1F). These results 
showed that hepatic steatosis occurred in both the C and MF intervention groups at the middle-age 
time point, while hepatic fibrosis in particularly developed in the MF diet group at an old age. On 
the other hand, the CR-fed animals were protected from developing hepatic steatosis and fibrosis.
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Figure 1. Physiological changes induced by the different dietary interventions at the age of 6, 12, 24, and 28 
months. Body weight (A), liver weight (B) and IHTG content (C) dramatically increased over time, except for the CR-fed 
animals which stayed lean. Significance (p-value) of age, diet and interaction were evaluated using two-way ANOVA. 
Error bars represent s.e.m. Prevalence of hepatic steatosis (E) and fibrosis (F) in the mice aging cohort at different age 
time points.
Plasma Fgf21 reflected the hepatic fat accumulation at middle and 
old age, but not at mature adult age 
The results presented in Figure 2A show that plasma Fgf21 levels of the C- and MF-exposed 
animals were higher than that of the CR-exposed animals at all ages. Noticeably, plasma Fgf21 levels 
were particularly high at 6 month of age in the C and CR diet groups. Next, to examine a specific diet- or 
age-related effect on plasma Fgf21 levels, the correlation with IHTG content was carried out separately 
by diet and age. The CR diet group displayed low IHTG and plasma Fgf21 concentration, while the C 
and MF groups showed some variation, but overall we did not observe significant correlation in any 
of the different diet groups (Fig. 2B). On the other hand, the comparison by age indicated that, except 
for the 6-month-old mice, the correlations at different ages were comparable (Fig. 2C). Some of the 
young mice, independent of their diet types, exhibited high plasma Fgf21 concentrations despite their 
low IHTG levels. This observation implies that the plasma Fgf21 concentration reflects the hepatic fat 
accumulation at middle-age (12 months) and old age (24 and 28 months), which results in an overall 
correlation coefficient of 0.52 (p <0.0001), but performs differently at younger age (Fig. 2D). 
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Plasma Fgf21 levels reflected liver Fgf21 expression 
The gene expression levels of Fgf21 in the liver were obtained from the microarray data and 
revealed that, similar to the plasma Fgf21 levels, the C- and MF-exposed animals displayed higher 
expression levels of Fgf21 (Fig. 3A). Notably, the higher levels of plasma Fgf21 at the earliest time 
point of 6 months were also reflected in the Fgf21 liver expression level. The results presented in 
Figure 3B show that the plasma Fgf21 levels significantly correlated to hepatic Fgf21 expression 
levels obtained by microarray analysis (r = 0.63, p <0.0001). This result was confirmed by Q-PCR 
analysis (r = 0.71, p <0.0001, Supplementary Fig. S2A). These observations indicate that the 
plasma Fgf21 concentration reflects the Fgf21 mRNA levels in liver tissue. In addition, we examined 
whether plasma Fgf21 increased with body or liver weight. Correlation analyses confirmed that 
plasma Fgf21 had significant positive correlation with body and liver weights (Supplementary Fig. 
S2B and C). As Fgf21 has been reported to be expressed abundantly, not only in the liver, but also 
in other tissue types, we also examined whether the plasma Fgf21 concentrations reflect the Fgf21 
expression levels in epidydimal white adipose tissue (eWAT), tibialis anterior muscle and colon 
tissue. The results presented in Figure 3C, D, and E show that plasma Fgf21 levels was strongly 
associated with the liver expression, compared to the other tissues. The expression levels of Fgf21 
in the muscle and colon were extremely low (Fig. 3D and E). The correlation of plasma Fgf21 and 
expression in eWAT was significant, however, the levels of expression in the eWAT were much lower 
compared to those in the liver tissue (Fig. 3C). 
To examine whether plasma Fgf21 in mice indicates hepatic fat accumulation as observed in 
humans, the mice were divided into two groups: those that either developed or did not develop 
NAFLD according to the IHTG criterion of higher or lower than 50 mg TG per gram liver from Kleiner’s 
scoring [22]. This resulted in 53 animals without NAFLD, which largely consisted of young or CR-fed 
animals, and 36 animals with NAFLD, which mostly consisted of older animals or under the C or MF 
dietary regimen. The average IHTG contents of the animals with and without NAFLD were 111.1 and 
22.2 mg TG per gram liver, respectively. The characteristics of animals with and without NAFLD are 
summarized in Supplementary Table S3, showing that the animals with NAFLD had a significantly 
heavier body weight, larger epididymal fat depot, enlarged liver, and lower liver 4-HP content. The 
levels of fasting plasma insulin and the liver injury marker alanine aminotransferase (ALT) were 
elevated in the group of animals with NAFLD. 
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Figure 2. Plasma Fgf21 reflected the hepatic fat accumulation at middle and old age, but not at mature 
adult age. (A) Different plasma Fgf21 levels induced by the dietary interventions at the age of 6, 12, 24, and 28 
months. Correlation of IHTG and plasma Fgf21 for different dietary interventions (B) and ages (C). (D) Plasma Fgf21 
was positively correlated with IHTG levels at older ages, while the young 6-month-old mice had elevated plasma 
Fgf21, despite their low IHTG levels (in red symbols). r values were calculated with Pearson’s correlations and their 
significance are indicated in the parentheses. 
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Figure 3. Plasma Fgf21 levels were strongly reflected by the expression of Fgf21 in the liver. (A) Different 
expression levels of Fgf21 in the liver induced by the dietary interventions and age. (B) Significant positive correlation 
between plasma Fgf21 and Fgf21 expression in the liver. The association between plasma and expression levels of 
Fgf21 was also compared in other tissue types, (C) epidydimal white adipose tissue (eWAT), (D) muscle, and (E) colon 
tissue. r values were calculated with Pearson’s correlations and their significance are indicated in the parentheses.
Subsequently, AUROC analysis was performed using optimal cut-off points determined by 
the Youden Index (plasma Fgf21 >222.0 pg/ml). The results summarized in Table 1 show that the 
sensitivity was remarkably high at 91.4%, while the specificity was low (57.1%). This resulted in an 
AUROC of 0.77 (Supplementary Fig. S3A) and an accuracy of 71.4% (positive predictive value/
PPV of 60.4% and negative predictive value/NPV of 90.3%). Since plasma Fgf21 appears to perform 
differently at the age of 6 months and a previous study of obese children indicated that plasma Fgf21 
did not provide additional value in predicting NAFLD [33], we also tested the Fgf21 performance in 
older animals only. When the 6 months old animals were excluded, the AUROC and specificity of 
Fgf21 were improved to 0.84 (Supplementary Fig. S3B) and 73.5%, while the sensitivity remained 
high (88.6%). In addition, the accuracy was improved to 81.2% (PPV of 77.5% and NPV of 86.2%). 
Diagnosis using more markers commonly yield a better outcome, so we applied combinations of 
plasma Fgf21 with other plasma or trait markers for NAFLD, i.e. plasma ALT, plasma CK-18 and 
body weight. The performance accuracy described in Table 2 revealed that the plasma Fgf21 was 
best combined with plasma ALT (accuracy of 88.4%) or body weight (87.0%), while the combination 
with plasma CK-18 (81.2%) did not improve the performance of Fgf21. 
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Table 1. Overall performance of plasma Fgf21 levels for the diagnosis of NAFLD
AUROC Sensitivity Specificity PPV NPV Accuracy 
All time points 
0.77 (0.67 - 0.87) 91.4% 57.1% 60.4% 90.3% 71.4% 
      
Without 6 months old 
0.84 (0.74 - 0.94) 88.6% 73.5% 77.5% 86.2% 81.2% 
 
Table 2. NAFLD diagnosis performance of plasma Fgf21 in combination with other markers
Fgf21 in combination 
with 
Sensitivity Specificity PPV NPV Accuracy 
Plasma ALT 80.0% 97.1% 96.6% 82.5% 88.4% 
Plasma CK-18 82.9% 79.4% 80.6% 81.8% 81.2% 
Body weight 80.0% 94.1% 93.3% 82.1% 87.0% 
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Gene module strongly correlated with plasma Fgf21 level were 
steatosis- and cancer-related genes 
To explore the molecular mechanism underlying the involvement of Fgf21 in NAFLD development, 
microarray analysis was performed on mRNA isolated from the livers of the 12, 24, and 28-month old 
animals. In the search for the molecular processes underlying the association of plasma Fgf21 with 
NAFLD, the microarray data were analysed by a two-step approach: 1) gene co-expression network 
analysis using WGCNA [19] and 2) functional pathways and up-stream regulator analysis were 
determined by applying Ingenuity pathway analysis (IPA) on the co-expression network. 
The WGCNA results presented in Figure 4A, show that 5 modules were created from the hepatic 
transcriptome data and that 3 of them significantly correlated with plasma Fgf21 (p <0.05; module 
grey denotes background genes outside of modules). The module displaying the most significant 
correlation with plasma Fgf21 was MEturquoise (r = -0.61). Interestingly, cluster differentiation 36 
(Cd36), a fatty acid transporter gene involved in steatosis development, was identified as the top 
regulated gene in this module. A correlation analysis between plasma Fgf21 and Cd36 expression 
levels showed a positive significant association (Fig. 4B). Intriguingly, β-Klotho gene (Klb), a co-
receptor component that is required for Fgf21 metabolic activity [34], was included in this module. 
The expression of Klb decreased with the increase of plasma Fgf21 (Fig. 4C). In addition to plasma 
Fgf21, strong inverse correlations with Klb expression were also observed for body weight and 
IHTG (Supplementary Fig. S4A). We also examined plasma Fgf21 correlation with the liver gene 
expression levels of the 4 members of the Fgf receptor family and observed a significant negative 
correlation with Fgfr2 and Fgfr4 expression, similarly to Klb (Supplementary Fig. S4B).  
Next, we investigated which biological processes are represented by the genes in the 
MEturquoise module, by using IPA. Figure 4D shows the liver-specific functions with p-value <0.01 
and the 5 most significant regulators identified by IPA, which were ranked by p-value. Predicted 
activation/inhibition z-scores are displayed when available. The liver-specific functions associated 
with this module included hepatic steatosis and cholestasis, but the most significant function was 
the hepatocellular carcinoma (HCC). A number of genes related to HCC functions were identified 
in this module, including collagen type I, alpha 2 (Col1a2), matrix metallopeptidase 14 (Mmp14), 
frizzled-related protein (Frzb), dickkopf WNT signalling pathway inhibitor 3 (Dkk3), glutamate-
ammonia ligase (Glul), and cyclin D1 (Ccnd1). The functions of these genes include extracellular 
matrix formation/angiogenesis (Col1a2 and Mmp14), inhibitors of Wnt signalling (Frzb and Dkk3), 
and regulation of Wnt target genes (Glul and Ccnd1). The expression levels of these genes were 
significantly correlated with plasma Fgf21 levels (Fig. 4E), demonstrating that plasma Fgf21 
level is associated with HCC-related signalling. Moreover, the identification of predicted upstream 
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regulators further confirmed the association of this module with hepatocellular carcinoma (Fig. 
4D): predicted inhibition of hepatocyte nuclear factor 4α and 1α (HNF4A and HNF1A), both are 
tumor suppressor regulators, while rapamycin-insensitive companion of mTOR (RICTOR) and 
mitogen-activated protein 4 kinase 4 (MAP4K4), factors involved in cancer development, were 
activated. X-box binding protein (XBP1) was also identified as one of the top upstream regulators.
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Figure 4. Liver biological processes associated with plasma Fgf21 level. (A) Heatmap depicting the correlation 
between gene modules (in rows) and phenotypes (in columns). The top values in each cell represents the correlation 
coefficient between the module and phenotype with the correlation p-value in parentheses. Red and green color 
represents positive and negative correlation, respectively. Correlation between plasma Fgf21 levels and hepatic 
expressions of Cd36 (B) and Klb (C). (D) Biological processes and regulators associated with MEturquoise, which is the 
most significant modules correlated with plasma Fgf21. Significant liver-specific functions and upstream regulators 
are reported in p-values and z-scores. Positive and negative z-score represent predicted activation and inhibition, 
respectively. (E) Correlation between plasma Fgf21 and expression levels of hepatocellular carcinoma-related genes 
within MEturqouise, which included genes related to extracellular matrix formation and angiogenesis (Col1a 2 and 
Mmp14), inhibition of Wnt signalling (Frzb and Dkk3), and downstream target of Wnt signalling (Glul and Ccnd1). r 
values were calculated with Pearson’s correlations and their significance are indicated in the parentheses. 
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The elevated plasma Fgf21 levels in young animals without 
accumulation of IHTG was related to the up-regulation of lipid 
metabolism by PPARα, PPARGC1α and PPARγ 
To elucidate the functions of the genes associated with the elevated Fgf21 plasma level at 
young age without accumulation of IHTG, WGCNA analysis was performed with the inclusion of 
the 6-month-old animals. For this purpose, we searched for a gene module that was significantly 
associated with plasma Fgf21, but not with IHTG, and we found that module MEgreen (1286 genes) 
fulfilled this criterion (Supplementary Fig. S5A). This module has a significant correlation with 
Fgf21 (r = 0.44, p <0.0001), but not with IHTG (r = 0.004, p = 1). To screen for the genes strongly 
correlated with the plasma Fgf21, we filtered for the genes with a correlation coefficient larger 
than 0.4. IPA of biological functions revealed that these genes play a role in lipid metabolism (top 
3 functions/regulators are listed in Supplementary Fig. S5B) and IPA identified peroxisome 
proliferator-activated receptor α (PPARα), peroxisome proliferator-activated receptor γ coactivator 
1-α (PPARGC1α), and PPARγ as the predicted upstream regulators.
NRF2 and PPARα targets, pathways differentially up-regulated by 
NAFLD, were linked to Fgf21
Next, to determine the relevance of Fgf21 in the NAFLD-related pathways, we first identified 
the pathways differentially regulated in the animals with NAFLD by performing GSEA. Then, we 
explored the differentially regulated pathways in NAFLD for their link to Fgf21. The gene expression 
data of 12, 24, and 28-month old animals were analysed with the exclusion of the CR group, since 
the latter group has a markedly different gene expression profile [20]. Forty-five animals were 
included in the microarray analysis (32 and 13 animals, with and without NAFLD, respectively). 
The GSEA results (based on FDR q value <0.01), presented in Table 3 and 4, revealed that 18 and 
12 pathways were up- and down-regulated in NAFLD, respectively (lists of pathways with FDR q 
value <0.05 is available in Supplementary Table S4 and S5). The up-regulated pathways were 
dominated by pathways related to oxidative stress (nuclear factor (erythroid-derived 2)-like 2 or 
NRF2 targets, glutathione metabolism), energy and lipid metabolism (PPARα targets, oxidative 
phosphorylation and electron transport chain and fatty acid metabolism). The down-regulated 
pathways included various complement cascades pathways. Interestingly, NRF2 and PPARα 
targets, the 2 most significantly enriched up-regulated pathways, contained genes that have been 
previously identified for their strong correlation with IHTG [35]: NAD(P)H dehydrogenase quinone 1 
(Nqo1), sulfiredoxin 1 (Srxn1), cell death-inducing DFFA-like effector a (Cidea) and c (Cidec). Genes 
in the core enrichment of NRF2 and PPARα targets are listed in Supplementary Table S6 and S7. 
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The gene expression levels of these genes were analysed for their correlation with IHTG, which 
revealed highly significant correlations (p<0.0001; Fig. 5A and B). Although not as strong, the 
expression levels of these genes were also significantly correlated with the plasma Fgf21 levels. 
Thus, the differentially regulated PPARα and NRF2 target genes were pointed out to be the link 
between plasma Fgf21 levels and IHTG content during NAFLD.  
Table 3. List of the significantly enriched up-regulated pathways in NAFLD
*) Normalised enrichment score (NES); a statistical test for gene set enrichment 
Enriched up-regulated pathways NES* FDR q-value 
NRF2 TARGETS 2.617 0.00000 
PPARA TARGETS 2.404 0.00000 
WP1248 OXIDATIVE PHOSPHORYLATION 2.328 0.00000 
WP295 ELECTRON TRANSPORT CHAIN 2.299 0.00068 
KEGG OXIDATIVE PHOSPHORYLATION 2.260 0.00081 
KEGG LYSOSOME 2.223 0.00090 
WP1269 FATTY ACID BETA OXIDATION 2.208 0.00097 
KEGG FATTY ACID ELONGATION 2.180 0.00135 
KEGG FATTY ACID DEGRADATION 2.146 0.00210 
MITOCHONDRIAL TRANSLATION 2.113 0.00337 
MITOCHONDRIAL TRANSLATION TERMINATION 2.102 0.00344 
MAPK TARGETS NUCLEAR EVENTS MEDIATED BY MAP KINASES  2.079 0.00418 
KEGG GLUTATHIONE METABOLISM 2.052 0.00625 
RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS BY 
CHEMIOSMOTIC COUPLING AND HEAT PRODUCTION BY 
UNCOUPLING PROTEINS  
2.048 0.00629 
SPHINGOLIPID METABOLISM 2.032 0.00775 
AQUAPORIN MEDIATED TRANSPORT 2.025 0.00786 
KEGG SYNAPTIC VESICLE CYCLE 2.020 0.00795 
MITOCHONDRIAL TRANSLATION INITIATION 2.003 0.00937 
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Table 4. List of the significantly enriched down-regulated pathways in NAFLD
Enriched down-regulated pathways NES FDR q-value 
WP449 COMPLEMENT AND COAGULATION CASCADES -2.496 0.00000 
KEGG COMPLEMENT AND COAGULATION CASCADES -2.496 0.00000 
KEGG SELENOCOMPOUND METABOLISM -2.229 0.00018 
FORMATION OF FIBRIN CLOT CLOTTING CASCADE  -2.272 0.00024 
WP200 COMPLEMENT ACTIVATION CLASSICAL PATHWAY -2.219 0.00028 
BIOC INTRINSICPATHWAY -2.081 0.00213 
COMMON PATHWAY -2.086 0.00226 
REGULATION OF COMPLEMENT CASCADE -2.066 0.00304 
COMPLEMENT CASCADE -2.023 0.00428 
AMINO ACID TRANSPORT ACROSS THE PLASMA MEMBRANE -1.995 0.00606 
WP460 BLOOD CLOTTING CASCADE -1.962 0.00857 
INTRINSIC PATHWAY -1.963 0.00928 
 
Notably, MAPK targets was also among the pathways enriched in the NAFLD-differentially 
regulated pathway (full list of genes in core enrichment of MAPK targets in Supplementary Table 
S8). This is in line with the finding of MAP4K4 activation in Figure 4D. The top MAPK target genes, 
protein phosphatase 2, regulatory subunit A, beta (Ppp2r1b) and dual specificity phosphatase 3 
(Dusp3), showed significant correlations to both IHTG content and plasma Fgf21 levels (Fig. 5C). 
Therefore, this signifies the association of plasma Fgf21 with liver cancer-related signalling.
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Figure 5. The differentially regulated pathways in NAFLD were reflected by plasma Fgf21 levels. Stress 
induced by NAFLD may activate NRF2, PPARα and MAPK, and the expression of their target genes. The expression 
levels of the NRF2 (A), PPARα (B) and MAPK (C) target genes were strongly correlated with IHTG and more modestly 
with plasma Fgf21 levels (in black and red color, respectively). r values were calculated with Pearson’s correlations and 
their significance are indicated in the parentheses.
Gene expression response to PPARα activation demonstrates its 
dysregulation in NAFLD
Based on the essential role of PPARα in lipid homeostasis, we further investigated whether the 
dysregulation of PPARα in NAFLD extends to an altered response when the system is challenged. 
To examine the response of PPARα, prior to each sacrifice the PPARα agonist Wy-14,643 (Wy) 
substance was administered to half of the mice of each intervention group, while the other half of 
the group received mock treatment. A number of PPARα target genes, including Fgf21[36, 37], were 
analysed by Q-PCR, namely monoacylglycerol O-acyltransferase 1 (Mogat1), G0/G1 switch 2 (G0s2), 
acyl-CoA thioesterase 3 (Acot3), hydroxymethyl glutary coenzyme A reductase (Hmgcr) (Fig. 6A-E). 
These genes were selected to represent different functions regulated by PPARα (lipogenesis: Mogat1; 
lipolysis: G0s2; fatty acid oxidation: Acot3; cholesterol metabolism: Hmgcr). As shown in Figure 
6A, Wy treatment led to induced hepatic Fgf21 expression and the 2-way ANOVA test indicated an 
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interaction between NAFLD and the Wy response. Intriguingly, animals with NAFLD exhibited an 
augmented response to the treatment. Similarly to Fgf21 expression, the induction of Mogat1 and 
Hmgcr expression levels were stronger in the animals with NAFLD (Fig. 6B and E). However, not 
all genes demonstrated the stochastic response to Wy treatment. G0s2 and Acot3 expression levels 
were similarly up-regulated regardless of the presence of NAFLD (Fig. 6C and D). The expression of 
Pparα itself was also examined and the results in Figure 6F show that the stimulation of PPARα did 
not differ between the animals with and without NAFLD. Although NAFLD presence did not alter the 
response to Wy treatment of all PPARα target genes, the expression profiles of Fgf21, Mogat1 and 
Hmgcr underscore the dysregulation PPARα signalling pathway in NAFLD.
Figure 6. The response to PPARα challenge test showed that the presence of NAFLD partially altered the 
response at the gene expression levels. (A) Fgf21; (B) Mogat1; (C) G0s2; (D) Acot3; (E) Hmgcr; and (F) Pparα. The 
effect of PPARα agonist and NAFLD, as well as any interaction between them, were analysed using two-way ANOVA.
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DISCUSSION 
In our mouse aging cohort, NAFLD development started at middle-age in Control (C)- and 
medium-fat (MF)-exposed mice, but not in the calorie restricted (CR)-fed animals, which stayed 
lean over time. The prevalence of NAFLD in the ad libitum C- and MF-fed groups increased during 
aging, which reflects weight gain and aging as risk factors for developing NAFLD[38]. In this study, 
we applied a long-term exposure to a less extreme diet compared to previous studies [17, 18] by 
using a 25E% medium-fat diet to mimic the slow onset of NAFLD in the human population, which did 
not induce severe NAFLD. We assessed this by analysing the liver fibrosis marker, 4-hydroxyproline 
content, and observed a lower prevalence of liver fibrosis, compared to liver steatosis or benign 
NAFLD. 
The analysis of plasma Fgf21 levels in the different intervention groups and ages suggests 
that there is an age-effect on plasma Fgf21 levels, although we did not observe a diet-dependent 
effect on plasma Fgf21 levels. We found that at the age of 6 months, some of the mice displayed a 
high level of plasma Fgf21 in the absence of elevated IHTG levels. A previous study in children has 
also revealed a lack of correlation between serum FGF21 and NAFLD parameters [39], moreover 
another study showed an inverse correlation between FGF21 and hepatic damage [40]. The addition 
of serum FGF21 in a NAFLD diagnostic model for children and adolescent also failed to improve 
the diagnostic performance [33]. An age of 6 months in mice is equivalent to mature adult age (~30 
years old in human) [41] and does not correspond to a developmental period in childhood. However, 
both mice and human data support either an absence of correlation or different correlation between 
plasma Fgf21 and NAFLD in younger age groups. Overall, our results reveal that, with the exception 
of the 6-month-old animals, plasma Fgf21 levels significantly correlated with IHTG content and 
performed well as a plasma marker for NAFLD diagnosis. This is in agreement with the results of 
previous studies in humans [10, 11]. 
The pathogenesis of NAFLD is attributed to a multi-hit process that includes lipotoxicity, 
oxidative stress and endoplasmic reticulum (ER) stress. Liver fat accumulation involves excess 
fatty acid supply to the liver, which triggers fatty acid oxidation and, consequently, oxidative stress 
from microsomal enzymes and ER stress. We found that NRF2 and PPARα targets were the most 
significantly enriched up-regulated pathways in the animals with NAFLD. NRF2 acts as a protective 
measure against oxidative stress, by producing antioxidant proteins. Meanwhile, PPARα activation 
is crucial for maintaining the homeostasis of fatty acid metabolism by increasing mitochondrial 
β-oxidation, thereby reducing the potential for fatty acid-induced lipotoxicity [42]. In addition, the 
WGCNA followed by pathway analysis pointed XBP1 out as one of the predicted upstream regulators 
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of Fgf21. The elevated expression of FGF21 has been described as a counteractive mechanism for 
ER stress, by modulating lipid metabolism [43-45]. Therefore, the up-regulation of Fgf21 in NAFLD 
appears to be a simultaneous protection against lipotoxicity, oxidative stress and ER stress in 
NAFLD.
Intriguingly, we found that plasma Fgf21 levels at young age were related to fatty acid oxidation 
(L-carnitine shuttle and β-oxidation), which also corresponds to PPARα activation. While this seems 
to be contradictory with the idea of PPARα activation as a protective measure for fatty liver, both 
mouse and human studies have reported that the increased mitochondrial activity and β-oxidation 
do not necessarily reflect an efficient electron transport chain [46-48]. The authors found that the 
electron transport chain in subjects with hepatic steatosis and/or obesity is inefficient [46-48]. 
Therefore, it is worthwhile noting that, despite the up-regulated fatty acid oxidation in both young 
animals without NAFLD and old animals with NAFLD, the up-regulation in old animals with NAFLD 
measurement might lead to perturbing consequences, such as hepatic oxidative stress. 
The in vivo PPARα challenge performed in this study provides a novel insight into the ability 
of maintaining metabolic homeostasis. A dynamic measurement by using system perturbation or 
challenge tests are likely more valuable to define metabolic health or resilience, compared to more 
static measurements [49]. By performing the PPARα agonist treatment, we demonstrate that the 
PPARα response at the transcriptional level is partially altered in the presence of NAFLD. It appears 
that liver fat is the burden of the liver’s plasticity of lipid metabolism. A similar notion was reported 
by Hyotylainen and co-workers, showing that high liver fat markedly hampers the ability of the liver 
to adaptively regulate metabolism to meet the excessive demands on basic liver functions. As a 
consequence, individuals with NAFLD may be more vulnerable to various metabolic stressors on 
the liver [50]. This underlines that, although hepatic steatosis is considered benign (first hit), when 
the metabolic system faces a challenge (second/multiple hits), the ability to maintain or regain 
homeostasis might have been compromised.   
Furthermore, we revealed the association between plasma Fgf21 and transcriptional changes 
related to hepatocellular carcinoma (HCC) development. The predicted regulators (HNF1A, HNF4A, 
RICTOR, MAP4K4), functional pathways and genes (Wnt target genes Ccnd1 and Glul) associated 
with plasma Fgf21 suggest dysregulations of metabolic and proliferative pathways [51, 52], which 
are characteristics of a benign hepatocellular tumor. Although these dysregulations alone were 
not sufficient to induce carcinogenesis, it likely increases the susceptibility to HCC development. 
In line with this hypothesis, a pre-malignant stage in NAFLD has been shown to denote stress, 
inflammation and even apoptosis, which pre-condition and initiate pro-oncogenic signals [53]. This 
is supported by the evidence that both liver expression and circulating levels of FGF21 are increased 
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in patients with hepatitis, cirrhosis and hepatocarcinoma [54]. Therefore, the population would 
likely benefit from the use of plasma Fgf21 as a biomarker of an early stage of NAFLD. 
Although the association between plasma Fgf21 and HCC-related function is not as strong 
as its performance in reflecting the benign NAFLD stage, plasma Fgf21 might be beneficial in 
improving the performance of biomarkers for advanced stages of NAFLD. This has been suggested 
in the study of a NASH biomarker, that for the purpose of defining the stages of NASH, plasma 
CK-18 performs better than FGF21, but adding FGF21 to the CK-18 model significantly improved 
the performance [14]. We evaluated the combined analysis of plasma Fgf21 and CK-18 to detect 
NAFLD in our study, but it did not result in a higher accuracy compared to merely Fgf21 analysis. 
A plausible explanation for this observation is that our mice cohort modelled a rather mild NAFLD 
development, so that the addition of plasma CK-18, which represents advanced stages of NAFLD, 
did not effectively improve the analysis. 
In this study, we discovered that the expression level of Klb, a critical co-receptor of the FGF 
receptors, was negatively correlated with plasma Fgf21, IHTG and body weight. In addition, the 
liver expression levels of the FGF receptors Fgfr2 and Fgfr4 showed similar patterns, although the 
declining expression levels were not as strong as observed for Klb. FGFR2 and FGFR4 proteins, 
along with FGFR1, have been shown to form a transmembrane complex with β-klotho to mediate 
the effects of FGF21 in adipocytes [55]. Although the type of FGF receptor that forms a complex 
with β-klotho protein in the liver is still unclear, this observation underlines the growing notion 
that metabolic system might develop a resistance to mediate the beneficial effect of Fgf21. The 
Fgf21 resistance due to its co-receptor alteration is an essential issue to be addressed during the 
further development of FGF21 as a novel pharmacological agent for metabolic diseases [56]. Both 
human and mice studies have reported increased FGF21 gene expression or circulating protein 
levels with obesity and/or metabolic syndrome [57-59]. One of these studies also demonstrated 
that the diet-induced obese mice with an elevated endogenous level of Fgf21 responded poorly 
to acute exogenous Fgf21 administration [59]. Since Klb plays a critical role in mediating Fgf21’s 
metabolic activity [34, 60], the declining Klb expression that occurs over a long-term obesity and/
or hepatic steatosis development might result in Fgf21 resistance. Therefore, in order to assess 
the possibility of resistance to FGF21 treatment, the consequence of the down-regulation of critical 
FGF21 receptors/co-receptors in the liver on sensitivity to endo- and exogenous FGF21 warrants 
further investigation. It is worthwhile noting that, in the acute induction of obesity in mouse model, 
Klb expression was not altered in the obese state [59]. 
Taken together, in this study, we demonstrate that plasma Fgf21 levels strongly reflects liver 
fat accumulation, confirming its potential as NAFLD marker. However, this association is age-
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dependent and does not apply at the age of 6 months in the C57BL/6J mice. The molecular link 
between plasma Fgf21 and IHTG levels was associated with dysregulation of both metabolic and 
cancer-related pathways. The up-regulated Fgf21 levels in NAFLD appears to be a measure to 
maintain homeostasis against the adverse effects in NAFLD, e.g. lipotoxicity, oxidative stress 
and endoplasmic reticulum stress. The elevated plasma Fgf21 is also associated with declining 
expression of Klb, its crucial co-receptor, which suggests a resistance to Fgf21. Therefore, 
although liver fat accumulation is a benign stage of NAFLD, the liver is likely more vulnerable to 
metabolic stressors and progress to end-stage liver disease. The in vivo PPARα challenge further 
demonstrates the dysregulation of PPARα signalling in the presence of NAFLD, which results in 
a stochastically increasing hepatic expression of Fgf21. In conclusion, Fgf21 plasma levels reflect 
liver fat accumulation and dysregulation of metabolic pathways at a transcriptional level in the liver 
of C57BL/6J mice. 
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SUPPLEMENTARY FIGURES
Supplementary Table S1. Composition of the experimental diet. The CR diet was adjusted for 
the vitamins and minerals amount to ensure a homologous intake between both groups.
Supplementary Table S2. List of primer sequence used in Q-PCR analysis
Supplementary Table S3. Characteristics of animals with/without NAFLD 
Data are mean ± s.e.m.; p-values are t-test between animals with and without NAFLD
 AIN-93W AIN-93W-CR AIN-93W-MF 
Energy (kcal/g) 3.85 3.77 4.25 
Energy from fat (%) 9 10 25 
Energy from protein (%) 15 15 13 
Energy from carbohydrates (%) 76 75 61 
Mineral mix AIN-93M (g%) 35 50 35 
Vitamin mix AIN-93M (g%) 10 14 10 
Choline bitartrate (g%) 2.5 3.5 2.5 
 
Gene name Forward primer (5’ → 3’) Reverse primer (5’ → 3’) 
Fgf21 GTG-TCA-AAG-CCT-CTA-GGT-TTC-TT GGT-ACA-CAT-TGT-AAC-CGT-CCT- C 
Mogat1 TCC-CGT-TGT-TCC-GAG-AAT-ATC-T TGC-TCA-GCA-CAT-GAG-ACA-AAC 
G0s2 AGT-GCT-GCC-TCT-CTT-CCC-AC TTT-CCA-TCT-GAG-CTC-TGG-GC 
Acot3 TCC-AAC-ATC-GGC-GGA-AAC-TTA ACG-GGA-ATC-AAG-CTC-TTC-TGG 
Hmgcr AGC-TTG-CCC-GAA-TTG-TAT-GTG TCT-GTT-GTG-AAC-CAT-GTG-ACT-TC 
Ppar TAT-TCG-GCT-GAA-GCT-GGT-GTA-C CTG-GCA-TTT-GTT-CCG-GTT-CT 
Rplp0 ATG-GGT-ACA-AGC-GCG-TCC-TG GCC-TTG-ACC-TTT-TCA-GTA-AG 
 
 Without NAFLD 
(n = 53) 
NAFLD 
(n = 36) 
p-value 
Body weight (g)  28.9  0.9 44.5  1.2 <0.0001 
eWAT weight (g) 0.46  0.05 1.44  0.59 <0.0001 
Relative eWAT weight (%) 1.43  0.11 3.19  0.17 <0.0001 
Liver weight (g) 1.02  0.04 1.71  0.07 <0.0001 
Relative liver weight (%) 3.50  0.09 3.86  0.15 0.0341 
Fasting plasma insulin (ng/ml) 0.627  0.093 1.767  0.283 <0.0001 
Plasma ALT (U/l) 6.82  0.72 11.17  1.03 0.0006 
IHTG (mg/g liver) 22.2  1.7 111.1  6.2 <0.0001 
Liver hydroxyproline (g/mg liver) 0.140  0.008 0.192  0.015 0.0013 
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Supplementary Table S4. List of the significantly enriched up-regulated pathways in NAFLD 
(FDR q-value <0.05)
Enriched up-regulated pathways NES FDR q-
value 
NRF2 TARGETS 2.617 0.00000 
PPARA TARGETS 2.404 0.00000 
WP1248 OXIDATIVE PHOSPHORYLATION 2.328 0.00000 
WP295 ELECTRON TRANSPORT CHAIN 2.299 0.00068 
KEGG OXIDATIVE PHOSPHORYLATION 2.260 0.00081 
KEGG LYSOSOME 2.223 0.00090 
WP1269 FATTY ACID BETA OXIDATION 2.208 0.00097 
KEGG FATTY ACID ELONGATION 2.180 0.00135 
KEGG FATTY ACID DEGRADATION 2.146 0.00210 
MITOCHONDRIAL TRANSLATION 2.113 0.00337 
MITOCHONDRIAL TRANSLATION TERMINATION 2.102 0.00344 
MAPK TARGETS NUCLEAR EVENTS MEDIATED BY MAP KINASES  2.079 0.00418 
KEGG GLUTATHIONE METABOLISM 2.052 0.00625 
RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS BY CHEMIOSMOTIC 
COUPLING AND HEAT PRODUCTION BY UNCOUPLING PROTEINS  
2.048 0.00629 
SPHINGOLIPID METABOLISM 2.032 0.00775 
AQUAPORIN MEDIATED TRANSPORT 2.025 0.00786 
KEGG SYNAPTIC VESICLE CYCLE 2.020 0.00795 
MITOCHONDRIAL TRANSLATION INITIATION 2.003 0.00937 
MEMBRANE TRAFFICKING 1.991 0.01022 
MITOCHONDRIAL TRANSLATION ELONGATION 1.984 0.01085 
BIOC MPRPATHWAY 1.975 0.01157 
REGULATION OF ACTIN DYNAMICS FOR PHAGOCYTIC CUP FORMATION 1.962 0.01232 
IRON UPTAKE AND TRANSPORT 1.963 0.01280 
MHC CLASS II ANTIGEN PRESENTATION 1.964 0.01319 
TRANSFERRIN ENDOCYTOSIS AND RECYCLING 1.943 0.01459 
RESPIRATORY ELECTRON TRANSPORT 1.945 0.01479 
APOPTOTIC EXECUTION PHASE 1.928 0.01634 
KEGG PPAR SIGNALING PATHWAY 1.884 0.01960 
PHAGOSOMAL MATURATION EARLY ENDOSOMAL STAGE  1.910 0.01961 
WP2316 PPAR SIGNALING PATHWAY 1.887 0.01962 
KEGG SPHINGOLIPID METABOLISM 1.887 0.02005 
PROSTACYCLIN SIGNALLING THROUGH PROSTACYCLIN RECEPTOR 1.889 0.02012 
CAM PATHWAY 1.890 0.02023 
KEGG VASOPRESSIN REGULATED WATER REABSORPTION 1.895 0.02026 
VASOPRESSIN REGULATES RENAL WATER HOMEOSTASIS VIA AQUAPORINS 1.877 0.02040 
LYSOSOME VESICLE BIOGENESIS 1.896 0.02043 
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Enriched up-regulated pathways NES FDR q-
value 
CALMODULIN INDUCED EVENTS 1.892 0.02051 
BIOC CHREBPPATHWAY 1.898 0.02056 
CA DEPENDENT EVENTS 1.900 0.02085 
THE CITRIC ACID TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT 1.900 0.02152 
WP401 MITOCHONDRIAL LC FATTY ACID BETA OXIDATION 1.870 0.02157 
MITOTIC PROPHASE 1.859 0.02232 
SYNTHESIS AND INTERCONVERSION OF NUCLEOTIDE DI AND 
TRIPHOSPHATES 
1.860 0.02243 
TRANSLOCATION OF GLUT4 TO THE PLASMA MEMBRANE 1.864 0.02248 
DARPP 32 EVENTS 1.855 0.02260 
NUCLEAR EVENTS KINASE AND TRANSCRIPTION FACTOR ACTIVATION  1.850 0.02261 
LATENT INFECTION OF HOMO SAPIENS WITH MYCOBACTERIUM 
TUBERCULOSIS 
1.851 0.02286 
KEGG BIOSYNTHESIS OF UNSATURATED FATTY ACIDS 1.860 0.02289 
INSULIN RECEPTOR RECYCLING 1.842 0.02434 
KEGG AMINO SUGAR AND NUCLEOTIDE SUGAR METABOLISM 1.842 0.02471 
GLUCAGON TYPE LIGAND RECEPTORS 1.833 0.02616 
KEGG COLLECTING DUCT ACID SECRETION 1.828 0.02650 
GLYCEROPHOSPHOLIPID BIOSYNTHESIS 1.822 0.02679 
KEGG OOCYTE MEIOSIS 1.829 0.02688 
APOPTOTIC CLEAVAGE OF CELLULAR PROTEINS 1.823 0.02724 
CITRIC ACID CYCLE TCA CYCLE  1.813 0.02917 
GLYCOSPHINGOLIPID METABOLISM 1.794 0.03413 
INTRINSIC PATHWAY FOR APOPTOSIS 1.790 0.03454 
KEGG ALCOHOLISM 1.779 0.03656 
BIOC BIOPEPTIDESPATHWAY 1.780 0.03688 
TRANS GOLGI NETWORK VESICLE BUDDING 1.781 0.03706 
WP2087 MIRNA REGULATION OF DNA DAMAGE RESPONSE 1.782 0.03737 
FATTY ACID TRIACYLGLYCEROL AND KETONE BODY METABOLISM 1.774 0.03805 
G ALPHA Z SIGNALLING EVENTS 1.768 0.03839 
WP317 GLYCOGEN METABOLISM 1.769 0.03877 
KEGG PARKINSON S DISEASE 1.769 0.03938 
METABOLISM OF NUCLEOTIDES 1.763 0.03947 
ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 12 1.759 0.04059 
CLATHRIN DERIVED VESICLE BUDDING 1.752 0.04113 
BIOC CREBPATHWAY 1.755 0.04113 
KEGG DOPAMINERGIC SYNAPSE 1.750 0.04146 
ACTIVATION OF BAD AND TRANSLOCATION TO MITOCHONDRIA 1.752 0.04172 
Supplementary Table S4. (Continued)
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Supplementary Table S5. List of the significantly enriched down-regulated pathways in NAFLD 
(FDR q-value <0.05)
Enriched up-regulated pathways NES FDR q-
value 
KEGG TIGHT JUNCTION 1.746 0.04235 
KEGG RETINOL METABOLISM 1.736 0.04585 
SEMA3A PAK DEPENDENT AXON REPULSION 1.726 0.04880 
POST CHAPERONIN TUBULIN FOLDING PATHWAY 1.727 0.04916 
 
Supplementary Table S4. (Continued)
Enriched down-regulated pathways NES FDR q-
value 
WP449 COMPLEMENT AND COAGULATION CASCADES -2.496 0.00000 
KEGG COMPLEMENT AND COAGULATION CASCADES -2.496 0.00000 
KEGG SELENOCOMPOUND METABOLISM -2.229 0.00018 
FORMATION OF FIBRIN CLOT CLOTTING CASCADE  -2.272 0.00024 
WP200 COMPLEMENT ACTIVATION CLASSICAL PATHWAY -2.219 0.00028 
BIOC INTRINSICPATHWAY -2.081 0.00213 
COMMON PATHWAY -2.086 0.00226 
REGULATION OF COMPLEMENT CASCADE -2.066 0.00304 
COMPLEMENT CASCADE -2.023 0.00428 
AMINO ACID TRANSPORT ACROSS THE PLASMA MEMBRANE -1.995 0.00606 
WP460 BLOOD CLOTTING CASCADE -1.962 0.00857 
INTRINSIC PATHWAY -1.963 0.00928 
GLUTAMATE NEUROTRANSMITTER RELEASE CYCLE -1.930 0.01245 
BMAL1 CLOCK NPAS2 ACTIVATES CIRCADIAN GENE EXPRESSION -1.832 0.04132 
SYNTHESIS OF BILE ACIDS AND BILE SALTS VIA 7ALPHA 
HYDROXYCHOLESTEROL 
-1.821 0.04408 
WP310 MRNA PROCESSING -1.806 0.04612 
KEGG PROTEIN EXPORT -1.806 0.04900 
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Supplementary Table S6. The list of genes in core enrichment of NRF2 targets 
 Genes Rank in list 
genegenest 1 NQO1 24 
2 UGDH 36 
3 SRXN1 44 
4 GPX1 60 
5 ABCB1A 99 
6 ALDH1A7 112 
7 SULT1C2 128 
8 GCLC 141 
9 FTH1 151 
10 EPHX1 164 
11 GSTM3 287 
12 GSTM4 332 
13 ALDH3A2 344 
14 PGD 347 
15 SQSTM1 387 
16 ALDH1A1 508 
17 CES1G 689 
18 GSTM1 730 
19 GSTM5 767 
20 CBR3 818 
21 ABCC4 864 
22 TKT 899 
23 ALDH9A1 910 
24 BLVRB 1076 
25 GSTM2 1115 
26 GPX3 1527 
27 GSS 1726 
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Supplementary Table S7. The list of genes in core enrichment of PPARα targets 
 Genes Rank in list  Genes Rank in list 
1 CIDEA 0 42 HMGCL 1074 
2 UGT1A9 1 43 ACADM 1096 
3 CIDEC 2 44 ACOT9 1144 
4 MOGAT1 9 45 ELOVL5 1147 
5 PLIN4 27 46 PCTP 1178 
6 CD36 35 47 CYP3A11 1220 
7 ECH1 38 48 EHHADH 1251 
8 CPT1B 55 49 HSD17B10 1307 
9 AQP7 56 50 ACAT1 1309 
10 SLC27A4 73 51 ACAA1B 1397 
11 ACOT2 75 52 SLC25A20 1458 
12 CYP4A14 86 53 ECI1 1490 
13 PEX11A 110 54 ACOT5 1501 
14 PLIN2 139 55 ACOT8 1507 
15 VLDLR 173 56 ACACB 1521 
16 CRAT 244 57 CPT2 1543 
17 CYP4A10 306 58 GPAM 1592 
18 ALDH3A2 344 59 AGPAT3 1671 
19 AGXT2 360 60 HADH 1683 
20 ELOVL7 410 61 ABCD2 1809 
21 LIPA 428 62 CYP4A12A 1826 
22 HADHA 449 63 ACOT1 1989 
23 ACAD9 509 64 UCP3 2131 
24 IL1RN 525 65 ACSM3 2132 
25 FABP2 541 66 SCD2 2139 
26 ODC1 549 67 PLTP 2292 
27 SLC25A10 634 68 OAT 2367 
28 CROT 687 69 CPT1A 2517 
29 CES1G 689 70 ACOT7 2553 
30 FGF21 699 71 ACOX1 2576 
31 PDK4 713 72 CYP2J6 2601 
32 LIPE 716 73 GPD2 2629 
33 ACOT3 738 74 ACADL 2813 
34 GYK 776 75 HSD17B4 2842 
35 ALDH9A1 910 76 MGLL 2994 
36 ACOT4 916 77 ETFDH 2997 
37 ACAD10 928 78 ACOT10 3011 
38 RAB9 1033 79 ABCB4 3036 
39 DECR2 1050 80 UCP2 3040 
40 DECR1 1055 81 ACAA1A 3110 
41 TXNIP 1065    
 
134
5
Fgf21  ref lects  l i ver  fat  accumulat ion  and  dysregulat ion  of  s ignal l ing  pathways  in  the  l i ver
Supplementary Table S8. The list of genes in core enrichment of MAPK targets 
 Genes Rank in list 
1 PPP2R1B 12 
2 DUSP3 115 
3 MAPK3 621 
4 JUN 1001 
5 MAPK9 1066 
6 MAPKAPK2 1214 
7 RPS6KA1 1407 
8 MAPK8 1570 
9 MAPK10 2011 
10 PPP2R1A 2102 
11 PPP2CA 2797 
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Supplementary Figure S1
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Supplementary Figure S1. Study design scheme. The male C57BL/6J mice arrived at 7 weeks old and were 
acclimatized for 2 weeks. The dietary intervention was started at the age of 9 weeks and the mice were culled at 6, 12, 
24 and 28 months, in order to cover different life stages.
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Supplementary Figure S2
Supplementary Figure S2. (A) Validating the microarray data, plasma Fgf21 levels were positively correlated with 
hepatic Fgf21 expressions, which was obtained through Q-PCR technique. (B) Plasma Fgf21 levels were positively 
correlated with body weight. (C) Plasma Fgf21 levels were positively correlated with liver weight. r value and its 
significance were calculated with Pearson’s correlation.
Supplementary Figure S3
 
Supplementary Figure S3. (A) ROC analysis of plasma Fgf21 predicting animals with and without NAFLD. In this 
analysis, all animals from 4 age time points were included. (B) ROC analysis of plasma Fgf21 predicting animals with 
and without NAFLD at middle and old age. The 6 month-old mice were excluded in this analysis.
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Supplementary Figure S4
Supplementary Figure S4. (A) Body weight and intrahepatic triglyceride (IHTG) were inversely correlated with Klb 
expression levels. (B) Correlations between the plasma Fgf21 and gene expression levels of Fgfr1, Fgfr2, Fgfr3, and 
Fgfr4. r values and their significance (in parentheses) were calculated with Pearson’s correlation. 
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Supplementary Figure S5
 
 
Supplementary Figure S5. (A) Heat map depicting the correlation between gene modules (in rows) and phenotypes 
(in columns). To investigate the functions of the genes associated with the elevated Fgf21 plasma level at young 
age without accumulation of IHTG, this analysis was performed with the inclusion of the 6 month old animals. In 
this analysis, the variable deepSplit setting in WGCNA was fine-tuned to obtain a module with a strong correlation 
with plasma Fgf21 levels, but not with IHTG content. The top values in each cell represents the correlation coefficient 
between the module and phenotype with the correlation p-value in parentheses. Red and green color represents 
positive and negative correlation, respectively. (B) Biological processes, pathways and regulators associated with 
MEgreen (in Supplementary Figure S5A). Significant liver-specific functions and canonical pathways are reported in 
p-values. Significant upstream regulators are reported in predicted activation z-score. Positive and negative z-score 
represent predicted activation and inhibition, respectively.
IPA results Biological processes/regulators p-value/ z-score
Liver-specific 
functions
Liver steatosis                                                     
Hepatocellular peroxisome proliferation             
Liver damage                                                      
2.39x10-1 – 4.18x10-3
4.28x10-2 – 1.36x10-8
5.51x10-1 – 1.15x10-3
Canonical 
pathways
Mitochondrial L-carnitine shuttle pathway                                                                     
Fatty acid β-oxidation I                                                          
Stearate biosynthesis I (animals)                                                                                            
8.09x10-7
1.11x10-6
2.29x10-6
Upstream 
regulators
PPARα
PPARGC1α
PPARGγ
5.905
3.349
3.313
A
B
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Significance of this study
The study presented in this thesis adds to our understanding the important impacts of different 
diets have on genotype-phenotype relationships, which translate into different health states. We 
investigated the effects of different dietary regimen on the phenotypes of genetically identical mice, 
particularly of an intermittent (INT) diet, which alternates weekly between the ad libitum medium-
fat (MF) and calorie restriction (CR) diet. The research largely focused on the liver as the central 
organ in metabolic regulation and aging markedly alters its morphology, physiology and capacity 
to function. This is reflected by the high prevalence of non-alcoholic fatty liver disease (NAFLD) in 
the elderly population. We found that the repetitive bouts of CR diet within the INT dietary regimen 
protected the liver from developing advanced stages of NAFLD, which was induced by exposure to 
the MF diet (chapter 2 and 3). We further examined the potential of the INT diet as a treatment to 
counteract the effects of a long-term continuous MF diet and revealed that, important metabolic 
features (glucose clearance, liver health and survival) were successfully improved, despite 
the development of hepatic steatosis (chapter 3). By switching the diets at a defined time point 
during the study (chapter 3 and 4), we demonstrated that, even at middle and old age, the liver is 
still a highly flexible organ that rapidly adapts its transcriptional program to the different dietary 
challenges. In the last chapter, we explored the diet-induced development of NAFLD during aging. 
We also demonstrated that the strong link between the diet-induced NAFLD and fibroblast growth 
factor (Fgf21) denoted a dysregulation of PPARα signalling pathway during the development of the 
liver disease (chapter 5). 
Intermittent calorie intake as a novel healthy dietary regimen? 
The key physiological profile of INT-exposed animals during aging is summarized in Figure 1, 
whereby the degree of similarity of INT-exposed animals at middle and old age, compared to the 
continuous CR and MF diets is depicted. At both 12 and 24 months of age, the body weights of INT-
exposed animals were between those of CR- and MF-fed animals, as might be expected from the 
overall energy intake. With aging, plasma insulin and IL-6 of animals in the INT diet group became 
more comparable with the profiles of the CR group. Furthermore, unlike in the continuous MF-
exposed animals, NAFLD in the INT diet group did not progress to severe pathology, as indicated 
by the liver 4-hydroxyproline content and plasma ALT levels that are similar to those of CR group. 
In contrast, intrahepatic triglyceride (IHTG) substantially elevated during aging (see also Figure 
2), reaching a level similar to that of the MF group at the age of 24 months. It is important to note 
that these measurements were performed consistently during the ad libitum MF feeding week and 
to draw a more definitive conclusion, ideally, measurements during the restricted feeding week 
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should have been included. Despite this limitation, the data still strongly suggests that there was 
an age-related alteration in the INT diet group that led to the development of hepatic steatosis. At 
the gene expression levels (chapter 3), although the transcriptomic profile of the INT-exposed mice 
at the middle age time point resembles that of the MF group, at the old age of 24 months the gene 
expression profile of INT shifts toward the profile of CR group. Thus, weekly intermittent calorie 
restriction largely reversed the long-term health effects caused by the lipogenic MF diet. 
Figure 1. Feature similarity of the INT diet group at 12 and 24 months in comparison to the CR and MF groups. The bar 
represents the difference between the CR and MF groups, which was set as 100% for each timepoint. Then, the position 
of the INT-exposed group within the 100% scale was determined and represented by the line and pointer.
Figure 2. The intrahepatic triglyceride (IHTG) content of the INT-exposed animals at different time points. Dashed line 
indicate the commonly applied threshold to define NAFLD, 5% or 50 mg triglyceride per g liver [1].
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We hypothesized that the INT dietary regimen might achieve its beneficial effects in counteracting 
the adverse effects of the MF diet through the repeated exposure to metabolic challenges during 
the restricted feeding week, i.e. stress from energy deficiency and time-restricted feeding [2-4]. 
The compelling weekly fluctuation of ~15% body weight indicates that metabolism was strongly 
challenged in this dietary regimen. At the final sacrifice (28 months) we had the opportunity to include 
an extra group of INT-exposed animals culled during the restricted feeding week. By comparing the 
physiological features measured following  ad libitum MF and restricted feeding week, we confirm 
that the weekly alternating regimen induced strong physiological changes (Figure 3). In addition 
to the body weight difference, there was a pronounced alteration in the visceral white adipose 
tissue (WAT) weight, but not in the epidydimal WAT. This is an intriguing observation regarding the 
partitioning of fat deposition, suggesting that during the weekly fluctuation of energy availability, the 
visceral fat depot was more flexible than the more stable epidydimal one. Visceral WAT dysfunction 
is thought to be implicated in obesity and insulin resistance and likely plays a role in NAFLD [5]. It 
has been suggested that the proximity of visceral WAT to the portal vein may allow visceral WAT to 
exert more direct metabolic effects on the liver [6]. 
Figure 3. Physiological alterations in the ad libitum MF and restricted feeding week of the INT dietary regimen, which 
was measured at the age of 28 months. Error bars represent standard deviation. *) p <0.05; **) p <0.01
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Liver weights measurements also showed a difference between the ad libitum and restricted 
feeding week (Figure 3). However, despite the difference in liver weight, the analysis of liver 
triglyceride content revealed that IHTG was not significantly altered. Possible explanations are 1) 
IHTG content is expressed as a concentration, which denotes that the absolute amount of IHTG 
would still be substantially higher in the MF week, 2) at a very old age, the redistribution of IHTG in 
the CR week (that we hypothesized in chapter 2) was not effective anymore, or 3) it is possible that 
the fluctuation occurred on other liver constituents, such as glycogen. This intriguing observation 
merits a further research, since this will bring insight on how dietary intervention affect lipid 
deposition in different organs over the course of time: does the fat storage partitioning and/or fuel 
utilization following a metabolic challenge alter during aging? To investigate this, multiple age time 
point comparison for both ad libitum MF and restricted feeding week have to be used/performed. 
The daily activity measurement revealed an interesting finding that the INT-exposed animals 
showed a spontaneous increase of daily activity to a level comparable to that of the CR group 
(chapter 3). Although this was thought to occur only in the restricted feeding week due to foraging 
activity when hungry, unexpectedly we found the same enhanced level of activity in the ad libitum 
feeding week. The increased activity level will most likely contribute substantially to the overall 
health advantages of the INT diet over the MF diet, in addition to the diet effect itself. Therefore, this 
study provides novel insights of 1) the INT diet-induced effects on increasing physical activity and 2) 
the importance of performing behaviour or physical activity measurements animal studies exploring 
novel dietary intervention. In human studies, dietary intervention and physical activity modification 
are two independent variables; physical activity in human has to be modified intentionally. 
Due to the complexity and extensiveness of this mice aging study, we were not yet able to 
explore all interesting and promising aspects of the INT-induced alterations. We have not yet 
investigated the status of signalling pathways and transcriptional effectors responding to energy 
stress, such as the reduced insulin/insulin-like growth factor (IGF-1) signalling, the target of 
rapamycin (TOR) signalling repression, and AMP-activated protein kinase (AMPK) activation [7]. 
The cycles of CR and ad libitum MF feeding in INT dietary regimen can also be expected to cause 
fluctuations of various intermediate metabolites, such as acetyl-CoA, uridine diphosphate-glucose, 
α-ketoglutarate, nicotinamide adenine dinucleotide (NAD+), flavin adenine dinucleotide [8]. These 
metabolites are utilized by chromatin-modifying enzymes and other transcriptional regulators 
[8,9], which may significantly affect chromatin activity. Therefore, the challenge imposed by INT 
dietary regimen would also likely induce some features of ‘chromatin exercise’ [10], affecting post-
translational modifications of histones and DNA and, in the long run, maintain chromatin flexibility.
The INT regimen imposes the effects from both calorie and feeding time restriction. When 
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the mice received their daily rations during the restricted feeding week, they ate immediately and 
stayed fasted until the next feeding time. Time-restricted feeding without reduction in calorie intake 
has been shown to be beneficial for health by improving nutrient sensing pathways and preventing 
from developing metabolic disorders induced by high-fat diet [11]. This brings about the question 
of, between the calorie reduction and the time-restricted feeding in the INT dietary regimen, which 
one has the compelling effect mediating the beneficial effects of INT dietary regimen? To investigate 
this, a comparison with an isocaloric pair-fed group would be required. When the eating pattern is 
kept constant, time restriction factor can be excluded and this allows to examine which factor is 
essential in mediating the beneficial effects of INT diet. 
The alternating dietary pattern between CR and MF diet is also expected to have an immediate 
effect on the gut microbiota composition. Studies have reported microbiome alterations, e.g. the 
increased proportion of Firmicutes to Bacteroidetes, in obese subjects [12-14] and diet-induced 
mice [15, 16]. Although not a direct measurement, urine metabolomics analysis that was performed 
on the 28-month-old animals provided indications that microbiota composition changed rapidly in 
response to the weekly alternating dietary regimen. Urine samples of the INT-exposed animals 
were collected for both the restricted and ad libitum feeding week. Metabolites that are related to 
microbial activity are p-cresol and trimethylamine (TMA). The levels of p-cresol and TMA showed 
to fluctuate according to the feeding week. However, while the fluctuation pattern of p-cresol was 
similar to the continuous CR or MF diet, the elevated level of TMA in the ad libitum MF feeding 
week was significantly different from the continuous MF diet group (Figure 4). P-cresol is derived 
from tyrosine in reactions involving gut bacteria, i.e. some species of Clostridia [17] and TMA is 
a product of bacterial degradation from choline in distal intestine [18]. Thus, this analysis of the 
urine metabolite provides an indication that microbiota composition could be altered rapidly 
within a week of alternating diet. It would be interesting to investigate further how the microbiota 
population in the different parts of the small intestine and the colon adjust to the INT diet and what 
are the systemic and liver-specific metabolic consequences. 
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Figure 4. The levels of p-cresol and trimethylamine (TMA) measured in the mice urine samples at the age of 27 
months, by using 1H-NMR measurement technique [19]. Urine samples collection covered both feeding weeks in the 
INT dietary regimen. 
The type of control diet used in this study is a semisynthetic diet, which is rich in easily digestible 
carbohydrates (76E% carbohydrate, composed of 62% corn starch, 14% maltodextrin, 14% sucrose 
and 10% dextrose). We have used these diets already for many years [20] in most of our animal 
studies because of the well-defined composition compared to ill-defined chow diets that are still 
widely used. We observed that also control mice (low-fat) developed overweight and a number 
of their physiological profiles, i.e. IHTG content, were comparable to those of MF-exposed mice. 
Benoit et al. (2013) compared chow-low fat diet (LFD) and semisynthetic-LFD to semisynthetic-
high fat diet (HFD) and discovered that conclusions on body weight gain, insulin sensitivity and 
adipose tissue inflammation were dependent on the type of the LFD control [21]. Microbiota 
analysis of small intestines collected from the current study revealed that diet rich in easy digestible 
carbohydrates increased the ratio of Firmicutes to Bacteroidetes, compared to chow diet containing 
more dietary fibres (M. Müller, personal communication). Therefore, a better comparison may be 
obtained by using a purified diet that more closely resembles the composition of chow diet, but 
without its fluctuation in composition. Sucrose and digestible starch-rich diets have been linked 
to increased de novo lipogenesis (DNL) and related changes in lipid metabolism that contribute 
to liver fat accumulation [22, 23]. Fatty liver is a result from an interplay of lipid accumulation 
(DNL, lipolysis, and dietary lipids) and removal (lipoprotein secretion and fatty acid oxidation) [24]. 
Carbohydrate excess has double takes on this interplay: 1) direct effect of increased DNL in order to 
store the excess carbohydrate as triglycerides, 2) an intermediate in DNL, malonyl-CoA, acts as an 
inhibitor of carnitine palmitoyl transferase-1, which results in β-oxidation restriction  [25].
To conclude, although the health features of INT diet were not as superior as those of the 
continuous CR diet, we found that the INT dietary regimen provided a remarkable protection against 
the severe health outcomes of the long-term MF diet consumption. The repeated exposure to 
metabolic challenges during the restricted feeding period likely contributed to the significant health 
improvements of INT dietary regimen. 
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Development of hepatic steatosis in the INT-exposed mice at old 
age: a loss of plasticity? 
In chapter 2 we proposed that, due to exposure to the INT regimen, liver fat can be effectively 
reduced during the restricted-feeding week. This is due to the IHTG content of INT-fed animals that 
strongly differed from those of MF diet group, even when the measurement was performed after 
their MF feeding week. However, to our surprise at older age this effect was less pronounced (see 
Figure 2). This suggests that the metabolic capacity required for the modulation of liver fat content 
by catabolism and redistribution at old age might be impaired. A number of studies, which have 
reported dysregulation of fat metabolism during aging, indicated a similar notion. Houtkooper and 
co-workers reported the dysregulation of fat metabolism at old age indicated by the lipidomic profiles 
[26]. Furthermore, it has been demonstrated in the liver that, although the mitochondrial activity did 
not decrease, the function/efficacy of the electron transport chain decreases with aging. Therefore, 
the increased mitochondrial activity and β-oxidation do not necessarily reflect an efficient electron 
transport chain [27-29]. The authors also found that the electron transport chain in animals with fatty 
liver is inefficient. Therefore, it is worthwhile noting that, despite the up-regulated fatty acid oxidation 
in both young animals without NAFLD and old animals with NAFLD, the up-regulation in old animals 
with NAFLD measurement might lead to perturbing consequences, such as hepatic oxidative stress.
In terms of loss of liver plasticity and function during aging, it would be interesting to zoom in to 
how exactly the plasticity/function was lost between the age of 12 and 24 months, in order to learn 
when exactly the shift of metabolic health occurs and why. We proposed that the shift might occur 
in two different ways. Inspired by a review article by Muoio [30], we use the mitochondrial energy 
selection as an example of metabolic plasticity. Figure 5A and B depict how energy homeostasis is 
maintained by switching between fuels suitable with the energy status. In the energy surplus condition, 
carbohydrate is the main source for energy combustion, while during a state of energy stress, lipid 
metabolism is activated and fatty acid oxidation provides energy to most types of tissues. The loss 
of plasticity during aging that we observed here could manifest in two ways. The first possibility 
involves a “hit”, which impact will impair the homeostasis (Figure 5A). Such a hit could be a damaging 
environmental stimuli, a set point or a threshold. As an example, when the liver fat content exceeds a 
threshold for a certain lipid species, it results on lipotoxicity, which impairs the lipid homeostasis [31]. 
In the second model involves a gradual loss of homeostasis (Figure 5B), which could be illustrated by 
the progressive decreasing levels of growth hormone and IGF-1 with age [32, 33]. 
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6Figure 5. A conceptual model of the loss of metabolic plasticity during aging. In healthy, metabolically flexible state, in a high energy availability condition, carbohydrate (glucose) is the oxidative fuel used, while, in low energy availability, 
such as in post-absorptive state or fasting, fat oxidation will be the predominant fuel. In between the two states, a 
mixture between fat and carbohydrate is utilized. When plasticity is lost, the capacity to switch freely between oxidative 
fuels depending on the nutritional context is lost, represented by persistent oxidation of a mixture of carbon fuels [30]. 
In the “hit” model (A), plasticity is impaired following damaging environmental stimuli, a set point or a threshold. On 
the other hand, in the gradual loss model (B), plasticity is progressively impaired. The decreasing plasticity results in 
increasing metabolic disturbance. The model is an adaptation from Muoio [30].
- + - + - -+
fa
t
m
ix
ed
Energy availability
Plasticity
Metabolic disturbance
CH
O
B
- + - + - -+
fa
t
m
ix
ed
Energy availability
CH
O
A
150
6
Discuss ion
Another factor that possibly contributes to the liver fat accumulation is the microbiota 
composition. Microbiota composition changes during aging [34-36], and the changes may favour 
the fat accumulation, for example by increasing the capacity to harvest energy from the diet. This 
highlights the importance of investigating how multiple tissues/organs are interconnected in 
relation to the observed metabolic disturbance.
PPARα challenge as a readout of metabolic plasticity
We initially explored the possibility of utilizing PPARα challenge experiment as a readout to 
measure plasticity of lipid metabolism. We expected that, due to the metabolic challenge it imposes, 
the INT dietary regimen would result in a better plasticity at an old age. A treatment of PPARα 
agonist, Wy-14,643, on a subset of mice from each diet group was performed in every sacrifice 
time point. However, we discover that there was no significant difference in the regulation of PPARα 
target genes between animals exposed to different dietary interventions or age time points. Figure 
6 displays an example of PPARα target gene response to Wy-14,643 treatment at the age of 24 
months. However, when the PPARα response was distinguished between animals with/without 
NAFLD (chapter 5), a clear difference in PPARα targets’ expression levels was observed, particularly 
for Fgf21, Hmgcr and Mogat1 expression levels. It appears that liver fat is the burden of the liver’s 
plasticity of lipid metabolism. A similar notion was reported by Hyotylainen and co-workers, that 
high liver fat markedly hampers the ability of the liver to adaptively regulate metabolism to meet 
the excessive demands on basic liver functions, and therefore, individuals with NAFLD may be 
more vulnerable to various metabolic stressors on the liver [37]. Our mice cohort exhibited a large 
inter-individual variation in the development of NAFLD, particularly in the ad libitum control- and 
MF-fed groups. Therefore, here hepatic steatosis appears to be a stronger determinant for PPARα 
metabolic plasticity.
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Figure 6. The gene expression levels of PPARα target genes, Pdk4 (left) and Ehhadh (right), when treated with either 
mock or PPARα agonist Wy-14,643. Gene expression was measured at the age of 24 months and normalized to a 
housekeeping gene. Colors denote the type of dietary intervention (black = Control, red = MF, green = INT, blue = CR). 
For each diet group, the measurements of mock- and Wy-14,643-treated animals were performed, which are denoted 
by C and WY in the graph, respectively. Error bars represent standard deviation. 
Such dynamic measurements by using system perturbation or challenge tests are likely more 
valuable to define metabolic health or resilience, compared to more static measurements [38], e.g. 
oral glucose tolerance test depicts glucose homeostasis better than one time point measurement 
of plasma glucose or insulin. Therefore, it is worthwhile to find other challenge tests that are more 
appropriate to measure the homeostasis capacity, for instance AMPK-α2 activation test by using 
AICAR or β-guanidinopropionic acid [39]. The differential response to the two compounds have 
been shown to be age-related in muscle [39, 40]. In the current study, the mock and Wy-14,643 
treatments of the PPARα challenge were performed from another set of mice within the same diet/
age groups. Considering the heterogeneity of C57BL/6J mice, ideally both treatments should refer 
to the same mice. This could be performed in experiments by using primary hepatocytes, which 
would also provide more liver-specific effects, instead of a complex in vivo responses. 
Liver plasticity induced by the diet switches 
In chapter 3, the obesity-counteracting effect of the INT diet was investigated. Part of the mice 
that had been exposed to the MF diet till 12 months of age were transferred to the INT diet until 
sacrifice at the age of 24 months. The switch to INT diet successfully improved glucose clearance, 
survival and liver health, although failed to improve IHTG levels. In relation to the proposed models 
describing how plasticity/function is lost, it is inciting to speculate that the MF-induced irreversible 
gene(s) might play a role as a set point in the proposed “hit” model (Figure 5A). The persistently 
regulated lipid metabolism and/or storage genes, i.e. Pparα, Cd36, Cidea, Cidec, Cyp7b1, might “set” 
the homeostasis to be either inefficient in transporting and oxidizing fatty acid or susceptible for fat 
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accumulation. 
From this experiment we also learn that, despite the health improvement of INT diet, the risk 
imposed by the first 12 months of MF diet exposure for development of liver dysfunction persists. 
This implies that irreversible and potentially serious health risk imposed by Western-style diets 
may start since early age and an intermittent CR can be a practical way to avoid the health risk. 
Ubiquitin-conjugating enzyme 2c (Ube2c; Figure 7) is an example of hepatocellular carcinoma gene 
[41, 42] which expression elevated already at 6 month of age in the continuous MF diet, but INT diet 
appears to reverse this effect. Overexpression of Ube2c leads to loss of genomic stability, since the 
cells neglect the mitotic spindle checkpoint signals [43]. 
Figure 7. Gene expression levels of Ube2c, a hepatocellular carcinoma-related gene, showing that, starting as early 
as 6 months of age, the expression levels of the MF diet group were elevated. However, no elevation was observed in 
the INT and other diet groups.
The second diet switch experiment, although focused on the converse direction from healthy 
CR diet to the less healthy MF diet, similarly demonstrated the plasticity of metabolism in adapting 
to the diet switch. This experiment particularly observed that the robust metabolic network that 
includes multiple regulators contributing its plasticity in coping with the challenge of MF diet, as 
displayed by the dynamic of Cd36 and Cav1 expressions. At the epigenetic level, the diet switch also 
revealed the plasticity of DNA methylation status. 
Relevance to aging and NAFLD development in human population
Muoio (2014) and Mattson (2014) proposed that the challenge on metabolic flexibility and 
not leaving the metabolic state at a chronic overnutrition status all the time, are the keys to 
the health improvement [4, 30]. Chronic overnutrition leads to a state of metabolic confusion, 
wherein excessive carbon supply and heightened substrate competition give rise to a set of 
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muted and/or conflicting signals [30]. The results obtained from this extensive animal study 
have shown that the INT dietary regimen largely protected the liver from developing advanced 
stages of NAFLD. Many variants of this dietary regimen have been explored in both animal 
models and humans, and, in general, they show promising health improvements. For example, 
intermittent calorie restriction in humans has been reported to increase insulin sensitivity, 
even more than daily CR that achieves similar weight loss [44, 45]. Therefore, a repetitive 
exposure to metabolic stress could be an effective intervention for health improvement. This 
also implies that, in addition to intervening the food intake that tackles the nutrient surplus, 
another possibility is the modification on the physical activity intermittently, for example in the 
“exercise snacking” regimen [46]. Recent studies have established a strong positive association 
between exercise training and metabolic flexibility [47, 48]. Or more recently, a nutritional 
strategy that incorporates both diet and exercise management has been shown to improve 
metabolic health in older adults [49].
The choice between calorie restriction and fasting as the intervening metabolic challenge is 
still debated. Fasting imposes greater health risks, especially to subjects who are frail and old, and 
patients with diabetes receiving insulin or insulin-like drugs. Thus, the lack of medical supervision 
in subjects undergoing intermittent fasting or alternate-day fasting regimen might result in severe 
adverse effects. The effect of fasting could be similarly induced in CR, although the less severe 
intervention of CR means a longer time required to achieve the effect. The application of fasting 
mimicking diet (FMD), for instance, similarly induce ~15% body weight fluctuation as we found in 
our INT regimen. In FMD regimen, this effect on body weight was induced by 4 days of fasting at 
40E% restriction [50].  
Another notable implication of this finding is the importance of a long-term investigation on 
the effects of a novel dietary regimen. To our knowledge, only this study and that of Brandhorst et 
al. (2015) investigate the effects of FMD in a long period that extends to old age (16-30 months) [50]. 
Most of other animal studies applied the novel diets for only 4-20 weeks [51-53]. Another study of 
intermittent fasting (IF) regimen has a longer term of 32 weeks, in addition to the comparison of 
short period of 4 weeks in the same study [54]. While in the Brandhorst study the health markers 
measured did not show major adverse effect of FMD [50], the study on IF dietary regimen provided 
a similar notion to our study that, in the long run, IF impairs redox balance and glucose tolerance, 
but did not do so in the short-term [54].
Another dietary strategy that shows promising health beneficial effects is protein restriction. 
Protein restriction, which could also be derived from the restriction of a certain amino acid, 
demonstrated similar effects to CR [55, 56], but without any calorie reduction. One of the 
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signalling pathways associated with aging, mTOR, is specifically activated by amino acids, which 
is the rationale of how protein restriction leads to healthy aging by avoiding mTOR activation. As 
there are more pathways involved in aging, e.g. insulin/IGF-1 signalling, protein restriction may 
not encompass all beneficial effects of CR. Furthermore, protein restriction is not compatible at 
all ages. Older adults may be protected from losing muscle mass by consuming more protein 
[57, 58]. 
The last alternative to intervene with aging is pharmacological treatment. A number of 
pharmacological agents for this purpose has been discovered. Compounds derived from plant 
foods include resveratrol, epicathechin, curcumin and sulforaphane, while the pharmacological 
alternatives cover rapamycin, rimonabant, metformin and AICAR [59, 60]. The application of these 
agents, however, does not completely mimic the effects of CR. Each compound has specific signalling 
target(s), for example AMPK is the target of AICAR, and AMPK activation in not responsible for all 
the benefits achieved by CR.  
It should be noted that sex dimorphism is an important aspect in response to dietary 
intervention and aging. Female rats has been shown to display an extreme response to 40E% 
CR in comparison to the male counterparts [61]. The females became emaciated, ceased 
menstrual cycling, underwent endocrine masculinization, exhibited changes on behaviour and 
activity profile. The 40E% restricted male mice maintained a higher body weight than the females 
and did not change their activity levels as significantly as the females. However, the male and 
female exhibited similar metabolic responses of circulating lipids (cholesterols/ triglycerides) 
and energy-regulating hormones (insulin, leptin, adiponectin, ghrelin) to the CR [61]. In human, 
the metabolic responses have been studied in a different approach. General responses to energy 
stress, such as increases in plasma fatty acid and ketones, and decrease in plasma glucose, do 
not differ between genders, however gender-related differences on lipid metabolism appeared in 
a short term CR [62]. Male subjects showed greater propensity to take up and store fatty acid in 
the liver, compared to the female subjects [62]. The age-related hormonal alteration, i.e. estrogen 
level pre- and post-menopause [63], also has a large impact on metabolic health, and therefore 
investigating the diet-induced phenotypic plasticity on female mice would require a separate 
study dedicated for this purpose.
Final Conclusion and Future Perspectives
Faced with the fast-growing aging population in a nutrition superfluous environment, 
researchers in the field of nutrition and health sciences continually strive to find new strategies 
to support healthy aging. In this thesis we studied the intermittent CR diet as a novel dietary 
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regimen for healthy aging and we found that it provided a remarkable protection against the severe 
health outcomes of the long-term medium-fat diet consumption. We demonstrated that this diet 
improves life quality by reducing the burden of chronic disease, especially those concerning the 
liver, providing support for the use of INT diet to promote healthy aging. We demonstrated that 
the liver is a highly flexible organ metabolically and dietary pattern shapes its metabolic plasticity. 
These health improvements puts forward the INT diet as a potential health strategy in combating 
metabolic adverse effects of our modern diet. Moreover, it is intuitively likely that people will find 
this diet easier to comply to, compared to a continuous CR regimen. Therefore, the intermittent CR 
represents an attractive area for further investigation.
Currently, it is too early to conclude that the INT dietary regimen (or modulation of the energy 
intake) would provide the same beneficial effects and is safe to be applied in the human population. 
However, this study is a proof-of-concept of intervening with a chronic overnutrition status with a 
metabolic challenge of energy stress. Further investigation on this novel dietary regimen is needed 
to allow this regimen to be safely applied in humans. To mention the two most important subjects, 
the first is to investigate the holistic consequences of this regimen on different organs/tissues and 
also at different molecular levels, i.e. epigenome and microbiome. The second is to determine 
the extent of the metabolic challenge that is beneficial in humans. This includes the degree and 
duration of CR, diet quality and modification on physical activity. These are especially crucial, since 
it is possible that a certain degree of calorie restriction simultaneously benefit some organs/tissue 
but harm others [64]. The type of test can be used to quantify metabolic health merits further 
investigation, since we showed here that PPARα challenge exhibited quite a robust response and 
might not be sensitive enough to reveal the weak point in the metabolic health network. 
In sum, the take home message from this study is that the metabolic health during aging 
is highly modifiable by dietary pattern and the novel intermittent calorie restriction diet provides 
a remarkable protection against the severe health outcomes of the long-term medium-fat diet, 
which poses adverse health effects. This diet improves life quality by reducing the burden of chronic 
disease, and therefore, represents an attractive area for further investigation.
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Increasing life expectancy in the past decades has led to the emergence of age-related chronic 
diseases and disabilities. A deeper understanding in the molecular events of the aging process 
is essential to provide evidence-based guidance how lifestyle interventions will be more efficient 
in delaying age-related disease phenotypes. Calorie restriction (CR) is by far the best nutritional 
strategy to achieve longevity in animal models. Although potentially also effective for humans, 
most people experience this rigorous diet as not feasible. To search for a practicable alternative we 
explored, using a C57BL/6J mice cohort, the effects of intermittent (INT) diet, a weekly alternating 
diet regimen between 40E% CR and ad libitum medium-fat feeding. We hypothesized that the 
weekly fluctuating energy availability provides beneficial challenges to the body.
In this thesis we focused on the effects induced by the INT diet on the liver, the central metabolic 
organ in the body. Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease that 
develops with age and is considered as the hepatic phenotype of the metabolic syndrome. NAFLD is 
a disease that develops slowly over the years; its prevalence has been shown to increase at old age 
(>60 years). In chapter 2 we investigated whether the INT dietary regimen was able to reverse the 
unfavourable effects of a medium-fat (25%E fat; MF) diet on the liver and its implication on NAFLD 
development. We showed that, at the age of 12 months, the INT diet prevented NAFLD development. 
INT-exposed animals retained healthy physiological features as displayed by continuous exposure 
to CR; maintenance of glucose tolerance, normal insulin levels and low plasma alanine and 
aspartate aminotransferases. Furthermore, they did not exhibit signs of hepatic steatosis and 
fibrosis, indicated by the reduced hepatic TG levels and morphological observations. The results 
presented in chapter 3 show that, at the age of 24 months, INT-fed mice displayed normal plasma 
ALT levels, no liver inflammation or fibrosis. These mice, however, display mild steatosis with IHTG 
levels significantly lower than the MF-exposed mice. To summarize, long-term exposure to a MF 
diet seriously impaired metabolic homeostasis and was a risk factor for NAFLD development. 
Applying every-other-week 40E% CR largely reversed the adverse health effects induced by the MF 
diet. Although the livers of the INT-exposed mice were still protected for the advanced stages of 
NAFLD, it is noteworthy that, in the long run, liver fat accumulation still occurred.
The second part of chapter 3 describes the obesity-counteracting effects of the INT diet. Part 
of the mice that had been exposed to the MF diet till 12 months of age was switched to the INT diet 
until the age of 24 months. The switch to the INT diet successfully improved glucose clearance, 
survival and liver health, but failed to improve IHTG levels. Within the diet switch experiment, 
we also investigated the plasticity of adaptive response to the switch by means of transcriptome 
analysis. Most of the genes differentially expressed between the INT- and MF-exposed mice (~95% 
of 2,667 genes) switched to the INT-expression profile. There was only a small subset of 148 genes 
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which expression levels persistently remained similar to the MF diet-induced expression levels, 
instead of adapting to INT’s expression profile. Pathway analysis pointed out that this subset of 
148 genes contains genes involved in lipid and xenobiotic metabolism, with PXR as the strongest 
upstream regulator. This suggests that MF-induced deregulated PXR activity persistently affects 
lipid and xenobiotic metabolism in the liver of the old diet switch mice. Therefore, we suggested 
that, despite the strong improvement of overall and liver-specific phenotypes, these persistently 
regulated genes might have potentially adverse effects on health.
The adaptive response to the diet switch at an old age was further investigated in chapter 4, 
but then in the reverse order: switching from a healthy to an unhealthy diet. Our results showed that, 
despite the long-term exposure to CR regimen, mice in the CR-MF group displayed hyperphagia, 
rapid weight gain, and hepatic steatosis. However, no hepatic fibrosis/injury or alteration in CR-
improved survival was observed in the diet switch group. The liver transcriptomic profile of CR-
MF group largely shifted to a profile similar to the MF-fed animals but leaving ~22% of the 1578 
differentially regulated genes between the CR and MF diet groups comparable with the expression 
of the life-long CR group. Therefore, although the diet switch was performed at an old age, the CR-
MF-exposed mice were still able to rapidly gain weight to similar level as life-long MF mice with the 
same age, but without developing severe liver pathologies. 
In chapter 5, the data from the different dietary interventions and age time points were 
combined to further explore the molecular mechanisms underlying the NAFLD development. 
Hereby, we focussed our analysis on the association with Fgf21, an emerging non-invasive 
biomarker for NAFLD. We demonstrated that plasma Fgf21 levels strongly reflected liver fat 
accumulation, confirming its potential as NAFLD marker. Transcriptomics analysis of the liver was 
performed and revealed that the link between plasma Fgf21 and IHTG levels was associated with 
differentially regulated PPARα and NRF2 targets during NAFLD. This suggested that the elevated 
Fgf21 levels in NAFLD was a measure to maintain homeostasis against the adverse effects of 
lipotoxicity, oxidative stress and endoplasmic reticulum stress in NAFLD. The PPARα challenge 
test, which was performed by administrating PPARα agonist Wy-14,643 to the mice, confirmed the 
dysregulation of PPARα signalling in NAFLD, including the hepatic expression of Fgf21.
To conclude, the results presented in this thesis adds to our understanding the effects of 
different diets have on genotype-phenotype relationships, which translate into different health 
states and are essential for identifying healthy aging strategies. We investigated the role of different 
dietary regimen on the phenotypes of genetically identical mice, particularly on an intermittent 
(INT) diet, which alternates weekly between the ad libitum medium-fat (MF) and calorie restriction 
(CR) diet. We found that the INT dietary regimen provided a remarkable protection against the 
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Summary
severe health outcomes of the long-term medium-fat diet consumption, which may improve life 
quality by reducing the burden of chronic disease. Although it is too early to conclude that the INT 
dietary regimen (or modulation of the energy intake) is beneficial and safe to be applied in human 
population, this study is a proof-of-concept of intervening a chronic overnutrition status with a 
metabolic challenge of energy stress. Further investigation of this novel dietary regimen is needed 
to allow it to be safely applied in humans. By switching the diets at a defined time point during the 
study, we demonstrated that, even at middle and old age, the liver is still a highly flexible organ that 
rapidly adapts its transcriptional program to the different dietary challenges. We also demonstrated 
that the strong link between the diet-induced NAFLD and Fgf21 denoted a dysregulation of PPARα 
signalling pathway during the development of the liver disease. 
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